
International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 79

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–117) and Recommended (1–78) International Nonproprietary Names can be found in *Cumulative List No. 17, 2017* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 79

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–117) et recommandées (1–78) dans la *Liste récapitulative No. 17, 2017* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 79

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–117) y Recomendadas (1–78) se encuentran reunidas en *Cumulative List No. 17, 2017* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:
Recommended INN

DCI Recommandée

DCI Recomendada

*Chemical name or description; Molecular formula;
Graphic formula*

*Nom chimique ou description; Formule brute; Formule
développée*

*Nombre químico o descripción; Fórmula molecular;
Fórmula desarrollada*

adafosbuvirum

adafosbuvir

propan-2-yl *N*-[(*P*^{5'}*S*)-4'-fluoro-2'-*C*-methyl-*P*-*O*-phenyl-5'-uridylyl]-*L*-alaninate


adafosbuvir

N-[(*P*^{5'}*S*)-4'-fluoro-2'-*C*-méthyl-*P*-*O*-phényl-5'-uridylyl]-*L*-alaninate de propan-2-yle

adafosbuvir

N-[(*P*^{5'}*S*)-4'-fluoro-2'-*C*-metil-*P*-*O*-fenil-5'-uridilil]-*L*-alaninato de propan-2-ilo

C₂₂H₂₉FN₃O₁₀P



adarigilinum

adarigiline

(4-hydroxypiperidin-1-yl){5-[4-methyl-5-(trifluoromethyl)-1,2-oxazol-3-yl]thiophen-2-yl}methanone


adarigiline

(4-hydroxypipéridin-1-yl){5-[4-méthyl-5-(trifluorométhyl)-1,2-oxazol-3-yl]thiophén-2-yl}méthanone

adarigilina

(4-hidroxiopiperidin-1-il){5-[4-metil-5-(trifluorometil)-1,2-oxazol-3-il]tiofeno-2-il}metanona

C₁₅H₁₅F₃N₂O₃S



adavosertibum

adavosertib


1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-(prop-2-en-1-yl)-1,2-dihydro-3*H*-pyrazolo[3,4-*d*]pyrimidin-3-one

adavosertib

1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-méthylpipérazin-1-yl)anilino]-2-(prop-2-én-1-yl)-1,2-dihydro-3*H*-pyrazolo[3,4-*d*]pyrimidin-3-one

adavosertib

1-[6-(2-hidroxiopropan-2-il)piridin-2-il]-6-[4-(4-metilpiperazin-1-il)anilino]-2-(prop-2-en-1-il)-1,2-dihidro-3*H*-pirazolo[3,4-*d*]pirimidin-3-ona

C₂₇H₃₂N₈O₂**adimlecleucelum**

adimlecleucel

Human culture enriched allogenic Cytomegalovirus-specific cytotoxic T cells (CMV-CTL) for cell-based therapy. Cells are isolated from blood of CMV seropositive healthy human donors. CMV-CTLs exhibit human leukocyte antigen (HLA)-restricted cytotoxic activity against CMV+ cells in allogeneic hematopoietic cell or solid organ transplant patients with CMV infection.

adimlecleucel

Lymphocytes T cytotoxiques spécifiques du cytomégalo virus (CMV-CTL), allogéniques, humains, enrichis en culture pour thérapie cellulaire. Les cellules sont isolées à partir du sang de donneurs humains sains séropositifs au CMV. Les CMV-CTL montrent une activité cytotoxique restreinte à l'antigène leucocytaire humain (HLA) contre les cellules CMV+ chez des patients transplantés avec des cellules hématopoïétiques allogéniques ou avec un organe solide, et souffrants d'une infection à CMV.

adimlecleucel

Linfocitos T citotóxicos específicos del virus de Citomegalovirus (CMV-CTL), alogénicos, humanos, enriquecidos en cultivo para terapia celular. Las células están asiladas a partir de sangre de donantes humanos sanos seropositivo para CMV. Los CMV-CTLs muestran actividad citotóxica restringida por HLA contra células CMV+ en pacientes trasplantados con células hematopoyéticas alogénicas u órgano sólido con infección por CMV.

alirinetidum

alirinetide

L-phenylalanyl-L-seryl-L-arginyl-L-tyrosyl-L-alanyl-L-arginine

alirinéide

L-phénylalanyl-L-séryl-L-arginyl-L-tyrosyl-L-alanyl-L-arginine

alirinetida

L-fenilalanil-L-seril-L-arginil-L-tirosil-L-alanil-L-arginina

 $C_{36}H_{54}N_{12}O_9$

H-Phe-Ser-Arg-Tyr-Ala-Arg-OH

alobresibum


alobresib

[2-cyclopropyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)-1*H*-benzimidazol-4-yl]di(pyridin-2-yl)methanol

alobrésib

[2-cyclopropyl-6-(3,5-diméthyl-1,2-oxazol-4-yl)-1*H*-benzimidazol-4-yl]di(pyridin-2-yl)méthanol

alobresib

[2-ciclopropil-6-(3,5-dimetil-1,2-oxazol-4-il)-1*H*-benzimidazol-4-il]di(piridin-2-il)metanol $C_{26}H_{23}N_5O_2$ **arfolitixorinum**


arfolitixorin

N-{4-[(6a*R*)-3-amino-1-oxo-1,2,5,6,6a,7-hexahydroimidazo[1,5-*f*]pteridin-8(9*H*)-yl]benzoyl}-L-glutamic acid

arfolitixorine

acide *N*-{4-[(6a*R*)-3-amino-1-oxo-1,2,5,6,6a,7-hexahydroimidazo[1,5-*f*]ptéridin-8(9*H*)-yl]benzoyl}-L-glutamique

arfolitixorina

ácido *N*-{4-[(6a*R*)-3-amino-1-oxo-1,2,5,6,6a,7-hexahidroimidazo[1,5-*f*]pteridin-8(9*H*)-il]benzoil}-L-glutámico $C_{20}H_{23}N_7O_6$ 

asivatrepum

asivatrep


(2*E*)-*N*-{[(1*R*)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide

asivatrep

(2*E*)-*N*-{[(1*R*)-1-[3,5-difluoro-4-(méthanesulfonamido)phényl]éthyl]-3-[2-propyl-6-(trifluorométhyl)pyridin-3-yl]prop-2-énamide

asivatrep

(2*E*)-*N*-{[(1*R*)-1-[3,5-difluoro-4-(metanosulfonamido)fenil]etil]-3-[2-propil-6-(trifluorometil)piridin-3-il]prop-2-enamida

C₂₁H₂₂F₅N₃O₃S**atabecestatum**

atabecestat


N-{3-[(4*S*)-2-amino-4-methyl-4*H*-1,3-thiazin-4-yl]-4-fluorophenyl}-5-cyanopyridine-2-carboxamide

atabécestat

N-{3-[(4*S*)-2-amino-4-méthyl-4*H*-1,3-thiazin-4-yl]-4-fluorophényl}-5-cyanopyridine-2-carboxamide

atabecestat

N-{3-[(4*S*)-2-amino-4-metil-4*H*-1,3-tiazin-4-il]-4-fluorofenil}-5-cianopiridina-2-carboxamida

C₁₈H₁₄FN₅OS**atidortoxumabum #**

atidortoxumab

immunoglobulin G1-kappa, anti-[*Staphylococcus aureus* alpha toxin (AT, alpha-hemolysin, alpha-HL, hly, hla) and bi-component leukocidins (HlgAB, HlgCB, LukED, and LukSF (Panton-Valentine leukocidin, PVL)), *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-448) [*Homo sapiens* VH (IGHV4-38-2*01 (92.90%) - (IGHD) -IGHJ6*03) [9.7.12] (1-119) - *Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), hinge (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (95.80%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (228-228":231-231")-bisdisulfide

atidortoxumab

immunoglobuline G1-kappa, anti-[*Staphylococcus aureus* toxine alpha (AT, hémolysine alpha, HL-alpha, hly, hla) et leucocidines à deux composants (HlgAB, HlgCB, LukED, LukSF (leucocidine de Pantón-Valentine, PVL)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-448) [*Homo sapiens* VH (IGHV4-38-2*01 (92.90%) -(IGHD) -IGHJ6*03) [9.7.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), charnière (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfure avec la chaîne légère (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (95.80%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (228-228":231-231")-bisdisulfure

atidortoxumab

inmunoglobulina G1-kappa, anti-[*Staphylococcus aureus* toxina alfa (AT, hemolisina alfa, HL-alfa, hly, hla) y leucocidinas con dos componentes (HlgAB, HlgCB, LukED, LukSF (Pantón-Valentine leucocidina, PVL)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma1 (1-448) [*Homo sapiens* VH (IGHV4-38-2*01 (92.90%) -(IGHD) -IGHJ6*03) [9.7.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), bisagra (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfuro con la cadena ligera (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (95.80%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLQESGPG	LVRPSETLSL	TCAVSGYSIS	SGMGWGWIQ	PPGKGLEWIG	50
SIDQRGSTYY	NPSLKSRTVI	SVDTSKNQFS	LKLSSTAAAD	TAVYYCARD	100
GHAVDMDVMG	KGTTVTVSSA	STKGPSVFPL	APSSKSTSGG	TAALGCLVKD	150
YFPEPVTVSW	NSGALTSGVH	TFPAVLQSSG	LYSLSSVTV	PSSSLGTQTY	200
ICNVNHKPSN	TKVDKKVEPK	SCDKTHCTCP	CPAPELLGGP	SVFLFPKPK	250
DTLMISRTP	VTCVVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREEQYN	300
TYRVVSVLTV	LHQDNLNGKE	YKCKVSNKAL	PAPIEKTISK	AKGQPREPQV	350
YTLPPSRDEL	TKNQVSLTCL	VKGFPYSDIA	VEWESNGQPE	NNYKTPPVVL	400
DSGDSFFLYS	KLTVDKSRWQ	QGNVFSCSVM	HEALHNHYTQ	KSLSLSPG	448

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS	VSASVGDRTV	ITCRASQGIS	RWLAWYQQKP	GKAPKLLIYA	50
ASSLQSGVPS	RFGSGSGTD	FTLTISLQFP	EDFATYYCQ	GYVFPPLTFGG	100
GTKVEIKRTV	AAPSVFIFFP	SDEQLKSGTA	SVVCLNNFY	PREAKVQWKV	150
DNALQSGNSQ	ESVTEQDSKD	STYLSSTLT	LSKADYEKKH	VYACEVTHQG	200
LSPFVTKSFN	RGEC				214

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	146-202	263-323	369-427
	22"-96"	146"-202"	263"-323"	369"-427"

Intra-L (C23-C104)	23'-88'	134'-194'
	23"-88"	134"-194"

Inter-H-L (h 5-CL 126) 222-214' 222"-214"

Inter-H-H (h 11, h 14) 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

299, 299"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires

complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

G0F 46%, G1F 39.9%

avadomidum


avadomide

rac-(3*R*)-3-(5-amino-2-methyl-4-oxoquinazolin-3(4*H*)-yl)piperidine-2,6-dione

avadomide

rac-(3*R*)-3-(5-amino-2-méthyl-4-oxoquinazolin-3(4*H*)-yl)pipéridine-2,6-dione

avadomida

rac-(3*R*)-3-(5-amino-2-metil-4-oxoquinazolin-3(4*H*)-il)piperidina-2,6-dionaC₁₄H₁₄N₄O₃and enantiomer
et énantiomère
y enantiómero**avalglucosidasum alfa #**

avalglucosidase alfa

mutated human acid α -glucosidase produced in Chinese hamster ovary (CHO) cells, glycoform alfa, conjugated to a synthetic branched hexasaccharide containing two terminal mannose-6-phosphate (M6P), via aminooxy linkers;

[His¹⁴³>Arg,Arg¹⁶⁷>His,Val⁷²⁴>Ile]prepro-lysosomal α -glucosidase (EC=3.2.1.20) (human) (57-952)-peptide, expressed in CHO cells, glycoform alfa, with 5~9 sialyl end groups of glycan residues being oxidized and chemically modified to 5-acetamido-3,5,7-trideoxy-7-[(*E*)-(2-oxo-2-{2-[4-({O-(6-O-phosphono- α -D-mannopyranosyl)-(1 $\rightarrow$ 2)-O- α -D-mannopyranosyl-(1 $\rightarrow$ 6)-O- α -D-mannopyranosyl-(1 $\rightarrow$ 6)-O-[O-(6-O-phosphono- α -D-mannopyranosyl)-(1 $\rightarrow$ 2)-O- α -D-mannopyranosyl-(1 $\rightarrow$ 3)]- β -D-mannopyranosyl]oxy)butanoyl]hydrazinyl]ethoxy)imino]- β -L-*arabino*-2-heptulo-2,6-pyranosylonic acid groups

avalglucosidase alfa

α -glucosidase acide humaine modifiée, produite dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa, liée à un hexasaccharide de synthèse dont les résidus terminaux sont deux mannose-6-phosphates via un groupe aminoxy;

[His¹⁴³>Arg,Arg¹⁶⁷>His,Val⁷²⁴>Ile]prépro- α -glucosidase lysosomale (EC=3.2.1.20) (humaine) (57-952)-peptide, exprimé dans des cellules CHO, glycoforme alfa: 5~9 résidus sialyl terminaux sont oxydés et chimiquement modifiés en acide 5-acétamido-3,5,7-tridésoxy-7-[(*E*)-(2-oxo-2-{2-[4-({O-(6-O-phosphono- α -D-mannopyranosyl)-(1 $\rightarrow$ 2)-O- α -D-mannopyranosyl-(1 $\rightarrow$ 6)-O- α -D-mannopyranosyl-(1 $\rightarrow$ 6)-O-[O-(6-O-phosphono- α -D-mannopyranosyl)-(1 $\rightarrow$ 2)-O- α -D-mannopyranosyl-(1 $\rightarrow$ 3)]- β -D-mannopyranosyl]oxy)butanoyl]hydrazinyl]éthoxy)imino]- β -L-*arabino*-2-heptulo-2,6-pyranosylonique

avalglucosidasa alfa

α -glucosidasa ácida humana modificada, producida en las células ováricas de hamster chino (CHO), glicoforma alfa, conjugada con un glicano hexasacárido sintético que contiene dos manosa-6-fosfatos (M6Ps) terminales, vía un grupo aminoxi;

[His¹⁴³>Arg,Arg¹⁶⁷>His,Val⁷²⁴>Ile]prepro- α -glucosidasa lisosomal (EC=3.2.1.20) (humana) (57-952)-péptido, expresada en las células CHO, glicoforma alfa: con los 5~9 restos sialil terminales están oxidados y químicamente modificados en ácido 5-acetamido-3,5,7-tridesoxi-7-[(E)-(2-oxo-2-{2-[4-({O-(6-O-fosfono- α -D-manopiranosil)-(1 $\rightarrow$ 2)-O- α -D-manopiranosil-(1 $\rightarrow$ 6)-O- α -D-manopiranosil-(1 $\rightarrow$ 6)-O-[O-(6-O-fosfono- α -D-manopiranosil)-(1 $\rightarrow$ 2)-O- α -D-manopiranosil-(1 $\rightarrow$ 3)]- β -D-manopiranosil]oxi)butanoil]hidrazinil]etoxi)imino]- β -L-arabino-2-heptulo-2,6-piranosilónico

Sequence / Séquence / Secuencia

```

QQGASRPGPR DAQAHGGRPR AVPTQCDVFP NSRFDCAFDK AITQECCAR 50
GCCYIPAKQG LQGAQMGPWF CFFPPSYPSY KLENLSSEM GYTATLTRTT 100
PTFFPKDILT LRLDVMMETE NRLHFTIKDP ANRRYEVPLE TPRVHSRAP 150
PLYSVEFSEE PFGVIVHRQL DGRVLLNTTV APLFFADQFL QLSTSLPSQY 200
ITGLAEHLSP LMLSTSWTRI TLWNRDLAPT PGANLYGSHF FYLALEDGGS 250
AHGVFLLNSN AMDVVLQPSF ALSWRSTGGI LDVYIFLGPE PKSVVQQYLD 300
VVGYPFMPFY WGLGFHLCRW GYSSTAITRQ VVENMTRAHF PLDVQWMDLD 350
YMDERRDTF NKDGFDFPA MVQELHQGR RYMMIVDPAI SSSGPAGSYR 400
PYDEGLRRGV FITNETGQPL IGKVPWGSTA FPDFTNPATL AWWEDMVAEF 450
HDQVPFDGMW IDMNPSNFI RGSDEGCPNN ELENPPYVPG VVGTLQAAT 500
ICASSHQFLS THYNLHNLG LTEATASHRA LVKARGTRPF VISRSTFAGH 550
GRYAGHWTGD VSSWEQLAS SVPEILQFNL LGVPLVGADV CGFLGNTSEE 600
LCVRWTQLGA FYPFMRNHSN LSLPQEPYS FSEPAQQAMR KALTRLRYALL 650
PHLYTLFHQA HVAGETVARP LFLEFPKDS TWTVDHQLLW GEALLITPVL 700
QAGKAETVGY FPLGTWYDLQ TVPIEALGSL PPPAAPREP AIHSEGWVT 750
LPAPLDTINV HLRAGYIIPL QGFPLTTTES RQPPMALAVA LTKGGEARGE 800
LFWDGDESLE VLERGAYTQV IFLARNNTIV NELVRVTSEG AGLQLQKVT 850
LGVATAPQQV LSNQVPVSNF TSPDTKVLD ICVSLMGEQ FLVSWC 896

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
26-53 36-52 47-71 477-502 591-602 882-896

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-84 Asn-177 Asn-334 Asn-414 Asn-596 Asn-826 Asn-869

Methionine S-oxide / S-Oxide de méthionine / S-Óxido de metionina (~50 %)
Met-66 Met-90 Met-116 Met-117

avapritinibum
avapritinib



(1S)-1-(4-fluorophenyl)-1-(2-{4-[6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl}pyrimidin-5-yl)ethan-1-amine

avapritinib

(1S)-1-(4-fluorophényl)-1-(2-{4-[6-(1-méthyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pipérazin-1-yl}pyrimidin-5-yl)éthan-1-amine

avapritinib

(1S)-1-(4-fluorofenil)-1-(2-{4-[6-(1-metil-1H-pirazol-4-il)pirrolo[2,1-f][1,2,4]triazin-4-il]piperazin-1-il}pirimidin-5-il)etan-1-amina



axicabtagenum ciloleucelum #
axicabtagene ciloleucel

human culture expanded genetically modified autologous T cells for cell-based gene therapy. Cells are derived from isolated blood of the patient and are transduced with non-replicative retroviral vector encoding the FMC63 anti-CD19 single chain variable fragment (scFv) CD28/CD3zeta chimeric antigen receptor (FMC63-28Z CAR). Cells exhibit anti-tumoral activity in patients with CD19-expressing B cell malignancies.

axicabtagène ciloleucel

Lymphocytes T humains autologues en culture d'expansion et modifiés génétiquement pour thérapie génique avec cellules. Les cellules sont dérivées du sang prélevé chez le patient et sont transduites avec un vecteur rétroviral non-répliquant codant pour le récepteur de l'antigène chimérique FMC63 anti-CD-19 fragment de la chaîne simple de la région variable de l'anticorps (scFv) CD28/CD3zêta (FMC63-28Z CAR). Les cellules montrent une activité anti-tumorale chez les patients présentant des lymphocytes B malins exprimant le CD19.

axicabtagén ciloleucel

Linfocitos T autólogos, humanos, expandidos en cultivo y modificados genéticamente, para terapia génica con células. Las células se derivan a partir de sangre aislada del paciente y están transducidas con un vector retroviral no replicativo que codifica para el receptor de antígenos quimérico FMC63 anti-CD19 fragmento de cadena simple de la región variable del anticuerpo (scFv) CD28/CD3zeta (FMC63-28Z CAR). Las células muestran actividad anti-tumoral en pacientes con malignidades de linfocitos B que expresan CD19.

beinaglutidum
beinaglutide

human glucagon-like peptide-1 (7-36)-peptide (GLP-1-(7-36))

béinaglutide

peptide 1 semblable au glucagon humain (7-36) (GLP-1-(7-36))

beinaglutida

péptido tipo 1 similar al glucagón humano (7-36) (GLP-1-(7-36))



HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR 30

bemarituzumabum #

bemarituzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* FGFR2 (fibroblast growth factor receptor 2, keratinocyte growth factor receptor, KGFR, bacteria-expressed kinase, BEK, craniofacial dysostosis I, CFDI, Jackson-Weiss syndrome, JWS, CD332) isoform b (FGFR2b)], humanized monoclonal antibody;
gamma1 heavy chain (1-444) [humanized VH (*Homo sapiens* IGHV1-46*01 (80.60%) -(IGHD) -IGHJ4*01) [8.8.7] (1-114) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (211) (115-212), hinge (213-227), CH2 (228-337), CH3 E12 (353), M14 (355) (338-442), CHS (443-444)) (115-444)], (217-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-33*01 (85.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (223-223":226-226")-bisdisulfide

b marituzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* FGFR2 (r cepteur 2 du facteur de croissance des fibroblastes, r cepteur du facteur de croissance des k ratinocytes, KGFR, kinase exprim e dans des bact ries, BEK, dysostose craniofaciale I, CFDI, syndrome de Jackson-Weiss, JWS, CD332) isoforme b (FGFR2b)], anticorps monoclonal humanis ;
cha ne lourde gamma1 (1-444) [VH humanis  (*Homo sapiens* IGHV1-46*01 (80.60%) -(IGHD) -IGHJ4*01) [8.8.7] (1-114) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (211) (115-212), charni re (213-227), CH2 (228-337), CH3 E12 (353), M14 (355) (338-442), CHS (443-444)) (115-444)], (217-214')-disulfure avec la cha ne l g re (1'-214') [V-KAPPA humanis  (*Homo sapiens* IGKV1-33*01 (85.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dim re (223-223":226-226")-bisdisulfure

bemarituzumab

immunoglobulina G1-kappa, anti-[*Homo sapiens* FGFR2 (receptor 2 del factor de crecimiento de fibroblastos, receptor del factor de crecimiento de keratinocitos, KGFR, kinasa expresada en bacterias, BEK, disostosa craneofacial I, CFDI, s ndrome de Jackson-Weiss, JWS, CD332) isoforma b (FGFR2b)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-444) [VH humanizado (*Homo sapiens* IGHV1-46*01 (80.60%) -(IGHD) -IGHJ4*01) [8.8.7] (1-114) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (211) (115-212), bisagra (213-227), CH2 (228-337), CH3 E12 (353), M14 (355) (338-442), CHS (443-444)) (115-444)], (217-214')-disulfuro con la cadena ligera (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-33*01 (85.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; d mero (223-223":226-226")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGSSVKV SKKASGYIFT TYNVHWVRQA PGQGLEWIGS 50
 IYPDNGDTSY NQNFKGRATI TADKSTSTAY MELSSLRSRD TAVYYCARGD 100
 FAYWQGQTLV TVSSASTKGF SVFPLAPSSK STSGGTAAALG CLVKDYFPEP 150
 VTVSWNSGAL TSGVHTFPFAV LQSSGLYSLS SVVTVPSSSL CTQTYICNVN 200
 HKPSNTKVDK RVEPKSCDKT HTCPCCPAPE LLGGPSVFLF PPKPKDTIMI 250
 SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV 300
 SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKARGQP REPQVYTLPP 350
 SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS 400
 FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTKQSLSL SPGR 444

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS LSASVGDRTV ITCKASQGVV NDVAWYQQKPK GKAPKLLIYS 50
 ASYRYTGVPS RFSGSGSGTD FTFTISSLPQ EDIATYYCQQ HSTTPYTFGQ 100
 GTKLEIKRTV AAPSVFIIPP SDEQLKSGTA SVVCLLNFFY PREAKVQWKV 150
 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKKH VYACEVTHQG 200
 LSSPVTKSFN RGEC 214

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 141-197 258-318 364-422
 22"-96" 141"-197" 258"-318" 364"-422"

Intra-L (C23-C104) 23'-88" 134'-194"
 23'''-88''' 134'''-194'''

Inter-H-L (h 5-CL 126) 217-214' 217"-214"

Inter-H-H (h 11, h 14) 223-223" 226-226"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

294, 294"

Afucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
 complexes afucosylés / glicanos de tipo CHO biantenarijos complejos afucosilados

bemcentinibum

bemcentinib


1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-*N*³-[(7*S*)-7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulen-2-yl]-1*H*-1,2,4-triazole-3,5-diamine

bemcentinib

1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-*N*³-[(7*S*)-7-(pyrrolidin-1-yl)-6,7,8,9-tétrahydro-5*H*-benzo[7]annulén-2-yl]-1*H*-1,2,4-triazole-3,5-diamine

bemcentinib

1-(6,7-dihidro-5*H*-benzo[6,7]ciclohepta[1,2-*c*]piridazin-3-il)-*N*³-[(7*S*)-7-(pirrolidin-1-il)-6,7,8,9-tetrahidro-5*H*-benzo[7]anulen-2-il]-1*H*-1,2,4-triazol-3,5-diamina

C₃₀H₃₄N₈**berdazimerum natricum**

berdazimer sodium




polysodium poly[{{[3-(methylamino)propyl]silasesquioxane}-co-{{[3-(1-methyl-2-nitroso-2-oxidohydrazin-1-yl)propyl]silasesquioxane}}-co-silicate (1:3:6 x)], partially hydrolysed (Si : OH ~ 10 : 5)

berdazimère sodique

poly[[[3-(méthylamino)propyl]silasesquioxane]-co-[[3-(1-méthyl-2-nitroso-2-oxidohydrazin-1-yl)propyl]silasesquioxane]-co-silicate (1:3:6 x)]
 polysodique, partiellement hydrolysé (Si : OH ~ 10 : 5)

berdazimero de sodio

poli[[[3-(metilamino)propil]silasesquioxano]-co-[[3-(1-metil-2-nitroso-2-oxidohidrazin-1-il)propil]silasesquioxano]-co-silicato (1:3:6 x)] polisódico, parcialmente hidrolizado (Si : OH ~ 10 : 5)



berlimatoxumabum #
 berlimateoxumab

immunoglobulin G1-kappa, anti-[*Staphylococcus aureus* LukGH (LukAB) bi-component leukocidin], *Homo sapiens* monoclonal antibody;
 gamma1 heavy chain (1-448) [*Homo sapiens* VH (IGHV4-39*01 (94.90%) -(IGHD) -IGHJ6*04) [10.7.11] (1-119) - *Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), hinge (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (94.70%) -IGKJ4*01) [6.3.9] (1'-107') - *Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (228-228":231-231")-bisdisulfide

berlimatoxumab

immunoglobuline G1-kappa, anti-[*Staphylococcus aureus* LukGH (Luk AB) leucocidine à deux composants], *Homo sapiens* anticorps monoclonal;
 chaîne lourde gamma1 (1-448) [*Homo sapiens* VH (IGHV4-39*01 (94.90%) -(IGHD) -IGHJ6*04) [10.7.11] (1-119) - *Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (CH1 (120-217), charnière (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfure avec la chaîne légère (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (94.70%) -IGKJ4*01) [6.3.9] (1'-107') - *Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (228-228":231-231")-bisdisulfure

berlimatoxumab

inmunoglobulina G1-kappa, anti-[*Staphylococcus aureus* LukGH (Luk AB) leucocidina con dos componentes], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma1 (1-448) [*Homo sapiens* VH (IGHV4-39*01 (94.90%) -(IGHD) -IGHJ6*04) [10.7.11] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (CH1 (120-217), bisagra(218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfuro con la cadena ligera (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (94.70%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
ELQLQESGPG LVKPSETLSL TCTVSGGSIS SGSYYWDWIR QPPKGLEWI 50
GNIYKSGSTY YNPSLKSRTV ISVDTSKNQF SLKLSSTVTA DTAVVYCAR 100
RGMHYMDVWG KGTTVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAPVLQSSG LYSLSSTVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGSP SVFLFPPKPK 250
DTLMISRTPV VTCVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRIVSVLTV LHQDNLNGKE YKCKVSNKAL PAPIETISK AKQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDSGFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPG 448
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGRVT ITCRASQIN SYLNWYQQKP GKAPKLLIYA 50
ASSLQSGVPS RFGSGSGTD FTLTISSLPQ EDFATYYCQQ QFDPPPTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYEKKH VYACEVTHQG 200
LSSPVTKSFN RGEK 214
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-97 146-202 263-323 369-427
22"-97" 146"-202" 263"-323" 369"-427"

Intra-L (C23-C104) 23'-88' 134'-194'
23"-88" 134"-194"

Inter-H-L (h 5-CL 126) 222-214' 222"-214"

Inter-H-H (h 11, h 14) 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

299, 299"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires

complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

G0F 42.5%, G1F 39.8%

berzosertibum

berzosertib

3-(3-{4-[(methylamino)methyl]phenyl}-1,2-oxazol-5-yl)-5-[4-(propane-2-sulfonyl)phenyl]pyrazin-2-amine


berzosertib

3-(3-{4-[(méthylamino)méthyl]phényl}-1,2-oxazol-5-yl)-5-[4-(propane-2-sulfonyl)phényl]pyrazin-2-amine

berzosertib

3-(3-{4-[(metilamino)metil]fenil}-1,2-oxazol-5-il)-5-[4-(propano-2-sulfonyl)fenil]pirazin-2-amina

C₂₄H₂₅N₅O₃S




brexanolonum

brexanolone 3α-hydroxy-5α-pregnan-20-one

brexanolone 3α-hydroxy-5α-prègnan-20-one

brexanolona 3α-hidroxi-5α-pregnano-20-ona

 $C_{21}H_{34}O_2$ **camidanlumabum #**

camidanlumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-445) [*Homo sapiens* VH (IGHV1-69*02 (94.90%) -(IGHD) -IGHJ4*01) [8.8.8] (1-115) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (212) (116-213), hinge (214-228), CH2 (229-338), CH3 E12 (354), M14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214'))]; dimer (224-224'':227-227'')-bisdisulfide

camidanlumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* IL2RA (sous-unité alpha du récepteur de l'interleukine 2, IL-2RA, TAC, p55, CD25)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-445) [*Homo sapiens* VH (IGHV1-69*02 (94.90%) -(IGHD) -IGHJ4*01) [8.8.8] (1-115) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (212) (116-213), charnière (214-228), CH2 (229-338), CH3 E12 (354), M14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfure avec la chaîne légère (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214'))]; dimère (224-224'':227-227'')-bisdisulfure

camidanlumab

immunoglobulina G1-kappa, anti-[*Homo sapiens* IL2RA (subunidad alfa del receptor de la interleukina 2, IL-2RA, TAC, p55, CD25)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma1 (1-445) [*Homo sapiens* VH (IGHV1-69*02 (94.90%) -(IGHD) -IGHJ4*01) [8.8.8] (1-115) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (212) (116-213), bisagra (214-228), CH2 (229-338), CH3 E12 (354), M14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfuro con la cadena ligera

(1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]]; dímero (224-224":227-227")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGGTFS RYIINWVRQA PGQGLEWMGR 50
IIPILGVENY AQKFQGRVTI TADKSTSTAY MELSSLRSED TAVYYCARKD 100
WFDYWGQGTLL VTVSSASTKG PSVFPLAPSS KSTSGGTAAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTQTYICNV 200
NHKPSNTKVD KRVEPKSCDK THTCPPCPAP ELLGGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV 300
VSVLTIVLHGD WLNKGKEYCK VSNKALPAP EKTISKAKGQ PREPQVYTL 350
PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
SFFLYSKLTV DKSRWQQGNV FSCSVMEAL HNHYTQKSL LSPGK 445
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SYLAWYQQK QAPRLLIYG 50
ASSRATGIPD RFGSGSGSDT FTLTISRLEP EDFAVYYCQ YGSSPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKKH VYACEVTHQG 200
LSSPVTKSFN RGEK 214
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22"-96" 142"-198" 259"-319" 365"-423"
22"-96" 142"-198" 259"-319" 365"-423"

Intra-L (C23-C104) 23"-88" 134"-194"
23"-88" 134"-194"

Inter-H-L (h 5-CL 126) 218"-214" 218"-214"

Inter-H-H (h 11, h 14) 224"-224" 227"-227"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

295, 295"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

camidanlumabum tesirinum #

camidanlumab tesirine

immunoglobulin G1-kappa, anti-[*Homo sapiens* IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25)], *Homo sapiens* monoclonal antibody conjugated to the pyrrolbenzodiazepine (PBD) dimer SCX; gamma1 heavy chain (1-445) [*Homo sapiens* VH (IGHV1-69*02 (94.90%) -(IGHD) -IGHJ4*01) [8.8.8] (1-115) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (212) (116-213), hinge (214-228), CH2 (229-338), CH3 E12 (354), M14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]]; dimer (224-224":227-227")-bisdisulfide; conjugated, on an average of 2 cysteines, to the pyrrolbenzodiazepine (PBD) dimer SCX, via a cleavable (valine-alanine dipeptide as cathepsine B cleavage site) maleimide type linker containing a spacer PEG (n=8)

For the *tesirine* part, please refer to the prop.INN List 113, published in the *WHO Drug Information*, Vol.29, No.2, 2015.

camidanlumab tésirine

immunoglobuline G1-kappa, anti-[*Homo sapiens* IL2RA (sous-unité alpha du récepteur de l'interleukine 2, IL-2RA, TAC, p55, CD25)], *Homo sapiens* anticorps monoclonal conjugué au dimère de pyrrolbenzodiazépine (PDB) SCX;

camidanlumab tesirina

chaîne lourde gamma1 (1-445) [*Homo sapiens* VH (IGHV1-69*02 (94.90%) -(IGHD) -IGHJ4*01) [8.8.8] (1-115) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (212) (116-213), charnière (214-228), CH2 (229-338), CH3 E12 (354), M14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfure avec la chaîne légère (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (224-224'':227-227'')-bisdisulfure; conjugué, sur 2 cystéines en moyenne, au dimère de pyrrolobenzodiazépine (PBD) SCX, via un linker clivable (dipeptide valine-alanine clivable par la cathepsine B) de type maléimide et comprenant un espaceur PEG (n=8).

Pour la partie *tesirina*, veuillez vous référer à la Liste 113 des DCI prop, publiée dans le *WHO Drug Information*, Vol.29, No.2, 2015.

inmunoglobulina G1-kappa, anti-[*Homo sapiens* IL2RA (subunidad alfa del receptor de la interleukina 2, IL-2RA, TAC, p55, CD25)], *Homo sapiens* anticuerpo monoclonal conjugado con el dímero de pirrolobenzodiazepina (PDB) SCX; cadena pesada gamma1 (1-445) [*Homo sapiens* VH (IGHV1-69*02 (94.90%) -(IGHD) -IGHJ4*01) [8.8.8] (1-115) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (212) (116-213), bisagra (214-228), CH2 (229-338), CH3 E12 (354), M14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfuro con la cadena ligera (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (224-224'':227-227'')-bisdisulfuro; conjugado, en una media de 2 cisteínas, al dímero de pirrolobenzodiazepina (PBD) SCX, mediante un espaciador escindible (dipéptido valina-alanina escindible por la catepsina B) de tipo maleimida que comprende un espaciador PEG (n=8)

Para la fracción *tesirina* se puede referir a la Lista 113 de DCI prop., publicada en el *WHO Drug Information*, Vol.29, No.2, 2015.

Heavy chain / Chaîne lourde / Cadena pesada

```

QVQLVQSGAE VKKPGSSVKV SCKASGGTFS RYIINWVRQA PGQGLEWMGR 50
IPILGVENY AQKFGGRVTI TADKSTSTAY MELSSLRSED TAVYYCARKD 100
WFDYWGQGTI VTSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTQTYICNV 200
NHKPSNTKVD KRVEPKSCDK THTCPPCPAP ELLGGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYR 300
VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTL 350
PSREMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPFVLDSDG 400
SFFLYSKLTV DKSRRWQGNV FSCSVMEAL HNHYTQKSL SLPKGK 445

```

Light chain / Chaîne légère / Cadena ligera

```

EIVLTQSPGT LSLSPGERAT LSCRASQSVS SYLAWYQQKFP GQAPRLLIYG 50
ASSRATGIPD RFSGSGSGTD FTLTISRLEP EDFAVYYCQQ YGSSPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKKH VYACEVTHQG 200
LSPFVTKSFN RGEK 214

```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 142-198 259-319 365-423
22"-96" 142"-198" 259"-319" 365"-423"

Intra-L (C23-C104) 23'-88" 134'-194"
23'''-88''' 134'''-194'''

Inter-H-L (h 5-CL 126) * 218-214' 218"-214"

Inter-H-H (h 11, h 14) * 224-224' 227-227"

*One or two of the inter-chain disulfide bridges are not present, an average of 2 cysteinyl being conjugated each via a thioether bond to a drug linker.

*Un ou deux des ponts disulfures inter-chaînes ne sont pas présents, 2 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.

*Faltan uno o dos puentes disulfuro inter-catenarios, una media de 2 cisteinil están conjugados con sendos enlaces tioéther, a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

295, 295*

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados

canerpaturevum #

canerpaturev

Replication-competent, spontaneously occurring mutant of Herpes Simplex Virus type 1 (HSV-1) with a number of deletions and insertions in the genome, resulting in the lack of functional expression of UL43, UL49.5, UL55 and UL56.

canerpaturev

mutant spontané de Virus Herpes Simplex type 1 (HSV-1) capable de se répliquer, avec un nombre de délétions et d'insertions dans le génome, résultant en l'absence de l'expression fonctionnelle des gènes UL43, UL49.5, UL55 et UL56.

canerpaturev

Virus Herpes Simplex tipo 1 (HSV-1) competente de replicación, mutado espontáneamente, con un número de deleciones e inserciones en el genoma que dan como resultado la ausencia de expresión funcional de los genes UL43, UL49.5, UL55 y UL56.

capivasertibum

capivasertib


4-amino-*N*-[(1*S*)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(1*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)piperidine-4-carboxamide

capivasertib

4-amino-*N*-[(1*S*)-1-(4-chlorophényl)-3-hydroxypropyl]-1-(1*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)pipéridine-4-carboxamide

capivasertib

4-amino-*N*-[(1*S*)-1-(4-chlorofenil)-3-hidroxiopropil]-1-(1*H*-pirrolo[2,3-*d*]pirimidin-4-il)piperidina-4-carboxamida

$$\text{C}_{21}\text{H}_{25}\text{ClN}_6\text{O}_2$$
**cobomarsenum**

cobomarsen


all-P-ambo-5-methyl-2'-*O*,4'-*C*-methylene-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-methylene-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanlylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-methylene-*P*-thiouridylyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-methylene-*P*-thiouridylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-*O*,4'-*C*-methylene-*P*-thioguanlylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-*O*,4'-*C*-methylene-*P*-thioadenylyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-methylene-*P*-thiouridylyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-methylene-*P*-thiouridylyl-(3'→5')-2'-*O*,4'-*C*-methyleadenosine

cobomarsen

tout-P-ambo-5-méthyl-2'-O,4'-C-méthylène-P-thiocytidylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-5-méthyl-2'-O,4'-C-méthylène-P-thiocytidylyl-(3'→5')-2'-désoxy-P-thioguanilyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-5-méthyl-2'-O,4'-C-méthylène-P-thiouridylyl-(3'→5')-5-méthyl-2'-O,4'-C-méthylène-P-thiouridylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-2'-O,4'-C-méthylène-P-thioguanilyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-2'-O,4'-C-méthylène-P-thioadénylyl-(3'→5')-5-méthyl-2'-O,4'-C-méthylène-P-thiouridylyl-(3'→5')-5-méthyl-2'-O,4'-C-méthylène-P-thiouridylyl-(3'→5')-5-méthyl-2'-O,4'-C-méthylène-P-thiouridylyl-(3'→5')-2'-O,4'-C-méthylèneadénosine

cobomarsén

todo-P-ambo-5-metil-2'-O,4'-C-metileno-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-5-metil-2'-O,4'-C-metileno-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-5-metil-2'-O,4'-C-metileno-P-tiouridilil-(3'→5')-5-metil-2'-O,4'-C-metileno-P-tiouridilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-O,4'-C-metileno-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-O,4'-C-metileno-P-tioadenilil-(3'→5')-5-metil-2'-O,4'-C-metileno-P-tiouridilil-(3'→5')-5-metil-2'-O,4'-C-metileno-P-tiouridilil-(3'→5')-2'-O,4'-C-metileneadenosina

C₁₄₈H₁₇₇N₅₂O₇₇P₁₃S₁₃(3'-5')(P-thio)(m⁵C-dA-m⁵C-dG-dA-m⁵U-m⁵U-dA-G-dC-A-m⁵U-m⁵U-A)

dX : 2'-deoxy-X / dX : 2'-désoxy-X / dX: 2'-desoxi-X

cofetuzumabum #
cofetuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* PTK7 (protein tyrosine kinase 7, colon carcinoma kinase 4, CCK4) extracellular domain], humanized monoclonal antibody; gamma1 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV1-3*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.12] (1-119) - *Homo sapiens* IGHG1*01, G1m17.1 (CH1 K120 (216) (120-217), hinge (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K>del (448)) (120-448)], (222-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV3-11*01 (83.80%) -IGKJ4*01) [10.3.9] (1'-111') - *Homo sapiens* IGKC*01, Km3 A45.1 (157), V101 (195) (112'-218')]; dimer (228-228":231-231")-bisdisulfide

cofétuzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* PTK7 (protéine tyrosine kinase 7, kinase du cancer du côlon, CCK4) domaine extracellulaire], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-448) [VH humanisé (*Homo sapiens* IGHV1-3*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), charnière (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K>del (448)) (120-448)], (222-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV3-11*01 (83.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 A45.1 (157), V101 (195) (112'-218')]; dimère (228-228":231-231")-bisdisulfure

cofetuzumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* PTK7 (proteína tirosina kinasa 7, kinasa del cáncer de colon, CCK4) dominio extracelular], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-448) [VH humanizado (*Homo sapiens* IGHV1-3*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), bisagra (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K>del (448)) (120-448)], (222-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (*Homo sapiens* IGKV3-11*01 (83.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 A45.1 (157), V101 (195) (112'-218')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGPE VKKPGASVKV SCKASGYTFT DYAVHWVRQA PGKRLIEWIGV 50
ISTYNDITYN NQDFKGRVTM TRDTSASTAY MELSLRSED TAVYYCARGN 100
SYFYALDYWG QGTSTVTSSA STKGPSVFPPL APSSKSTSGG TAALGCLVKD 150
YFPEPTVTSW NSGALTSGVH TFPFVLQSSG LYSLSVTVV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDNLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTTPVL 400
SDSGSFFLYS KLTVDKSRWQ QGNVFSCSVN HEALHNHYTQ KSLSLSPG 448
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASESD SYGKSFMHMY QKPGQAPRL 50
LIYRASNLGS GIPARFSGSG SGTDFLTIS SLEPEDFAVY YCQSNEDPW 100
TFGGGTKLEI KRTVAAPSVF IFPPSDEQLK SGTSVVCCL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSL STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC 218
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 146-202 263-323 369-427

22"-96" 146"-202" 263"-323" 369"-427"

Intra-L (C23-C104) 23'-92' 138'-198'

23"-92" 138"-198"

Inter-H-L (h 5-CL 126) 222-218' 222"-218"

Inter-H-H (h 11, h 14) 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

299, 299"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados.

cofetuzumabum pelidotinum #

cofetuzumab pelidotin

immunoglobulin G1-kappa, anti-[*Homo sapiens* PTK7 (protein tyrosine kinase 7, colon carcinoma kinase 4, CCK4) extracellular domain], humanized monoclonal antibody, conjugated to auristatin-0101; gamma1 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV1-3*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), hinge (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K>del (448)) (120-448)], (222-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV3-11*01 (83.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 A45.1 (157), V101 (195) (112'-218')]; dimer (228-228":231-231")-bisdisulfide; conjugated, on an average of 4 cysteinyl, to auristatin-0101 (Aur0101), via a cleavable maleimidocaproyl-valyl-citrullinyl-*p*-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker

cofétuzumab pélidotine

immunoglobuline G1-kappa, anti-[*Homo sapiens* PTK7 (protéine tyrosine kinase 7, kinase du cancer du côlon, CCK4) domaine extracellulaire], anticorps monoclonal humanisé, conjugué à l'auristatine-0101; chaîne lourde gamma1 (1-448) [VH humanisé (*Homo sapiens* IGHV1-3*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), charnière (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K>del (448)) (120-448)], (222-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV3-11*01 (83.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 A45.1 (157), V101 (195) (112'-218')]; dimère (228-228":231-231")-bisdisulfure; conjugué, sur 4 cystéinyl en moyenne, à l'auristatine-0101 (Aur0101), via un linker clivable de type maléimidocaproyl-valyl-citrullinyl-*p*-aminobenzyloxycarbonyl (mc-val-cit-PABC)

cofetuzumab pelidotina

immunoglobulina G1-kappa, anti-[*Homo sapiens* PTK7 (proteína tirosina kinasa 7, kinasa de cáncer de colon, CCK4) dominio extracelular], anticuerpo monoclonal humanizado, conjugado con la auristatina-0101; cadena pesada gamma1 (1-448) [VH humanizado (*Homo sapiens* IGHV1-3*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), bisagra (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K>del (448)) (120-448)], (222-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (*Homo sapiens* IGKV3-11*01 (83.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 A45.1 (157), V101 (195) (112'-218')]; dímero (228-228":231-231")-bisdisulfuro; conjugado, en una media de 3 a 4 restos cisteinil, con la auristatina-0101 (Aur0101), mediante un conector escindible de tipo maléimidocaproyl-valil-citrulinil-*p*-aminobenziloxycarbonil (mc-val-cit-PABC)

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGPE VVKPGASVKV SCASGYTFT DYAVHWVRQA PGKRLIEWIGV 50
 ISTYNDYTYN NQDFKGRVTM TRDTSASTAY MELSRLESED TAVVYCARGN 100
 SYFYALDYWG QGTSTVTSSA STKGPSVFPL APSKSTSGG TAALGCLVKD 150
 YFPEPVTVSW NSGALTSVGH TFPVQLQSSG LYSLSVTVV PSSSLGTQTY 200
 ICNVNHKFSN TKVDKKVEPK SCDKTHCTCP CPAPELLGGP SVFLFPPKPK 250
 DTLMIKRTPE VTCVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
 TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIETISK AKGQPREPQV 350
 YTLPPSRDEL TKNQVSLTCL VKGFYFSDIA VEWESNGQPE NNYKTTTPPV 400
 DSDGSFFLYS KLTVDKSRWQ QGNVFSQSVN HEALHNHYTQ KSLSLSPG 448

Light chain / Chaîne légère / Cadena ligera

EIVLTQSPAT LSISLGERAT LSCRASESDV SYGKSFHMY QOKPQOAPRL 50
 LIYRASNLIS GIPARFSGSG SGTDTFLTIS SLEPEFVAV YCQNSNEDPW 100
 TFGGGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCIL NNFVPREAKV 150
 QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
 THQGLSSPVT KSFNRGEC 218

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro


Intra-H (C23-C104) 22-96 146-202 263-323 369-427
 22"-96" 146"-202" 263"-323" 369"-427"

Intra-L (C23-C104) 23-92' 138'-198'
 23'''-92''' 138'''-198'''

Inter-H-L (h 5-CL 126) * 222-218" 222"-218"

Inter-H-H (h 11, h 14) * 228-228" 231-231"

Modified residues / résidus modifiés / restos modificados



N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH12 N84.4:

299, 299"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
 complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados.

crenigacestatum
 crenigacestat


4,4,4-trifluoro-N-[(2S)-1-[[[(7S)-5-(2-hydroxyethyl)-6-oxo-6,7-dihydro-5H-pyrido[3,2-a][3]benzoxazepin-7-yl]amino]-1-oxopropan-2-yl]butanamide

crénigacestat

4,4,4-trifluoro-N-[(2S)-1-[[[(7S)-5-(2-hydroxyéthyl)-6-oxo-6,7-dihydro-5H-pyrido[3,2-a][3]benzoxazépin-7-yl]amino]-1-oxopropan-2-yl]butanamide

crenigacestat

4,4,4-trifluoro-N-[(2S)-1-[[[(7S)-5-(2-hidroxietyl)-6-oxo-6,7-dihidro-5H-pirido[3,2-a][3]benzoxazepin-7-il]amino]-1-oxopropan-2-il]butanamida

C₂₂H₂₃F₃N₄O₄

danvatirsenum

danvatirsén




all-P-ambo-2'-O,4'-C-[(1S)-ethane-1,1-diyl]-5-methyl-P-thiocytidylyl-(3'→5')-2'-O,4'-C-[(1S)-ethane-1,1-diyl]-5-methyl-P-thiouridylyl-(3'→5')-2'-O,4'-C-[(1S)-ethane-1,1-diyl]-P-thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanynylyl-(3'→5')-2'-deoxy-P-thioguanynylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanynylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-O,4'-C-[(1S)-ethane-1,1-diyl]-P-thioadenylyl-(3'→5')-2'-O,4'-C-[(1S)-ethane-1,1-diyl]-P-thioguanynylyl-(3'→5')-2'-O,4'-C-[(1S)-ethane-1,1-diyl]-5-methylcytidine

danvatirsén

tout-P-ambo-2'-O,4'-C-[(1S)-éthane-1,1-diyl]-5-méthyl-P-thiocytidylyl-(3'→5')-2'-O,4'-C-[(1S)-éthane-1,1-diyl]-5-méthyl-P-thiouridylyl-(3'→5')-2'-O,4'-C-[(1S)-éthane-1,1-diyl]-P-thioadénylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-désoxy-P-thioguanynylyl-(3'→5')-2'-désoxy-P-thioguanynylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-désoxy-P-thioguanynylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-désoxy-5-méthyl-P-thiocytidylyl-(3'→5')-2'-O,4'-C-[(1S)-éthane-1,1-diyl]-P-thioadénylyl-(3'→5')-2'-O,4'-C-[(1S)-éthane-1,1-diyl]-P-thioguanynylyl-(3'→5')-2'-O,4'-C-[(1S)-éthane-1,1-diyl]-5-méthylcytidine

danvatirsén

todo-P-ambo-2'-O,4'-C-[(1S)-etano-1,1-diil]-5-metil-P-tiocitidilil-(3'→5')-2'-O,4'-C-[(1S)-etano-1,1-diil]-5-metil-P-tiouridilil-(3'→5')-2'-O,4'-C-[(1S)-etano-1,1-diil]-P-tioadenilil-(3'→5')-P-tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-O,4'-C-[(1S)-etano-1,1-diil]-P-tioadenilil-(3'→5')-2'-O,4'-C-[(1S)-etano-1,1-diil]-P-tioguanilil-(3'→5')-2'-O,4'-C-[(1S)-etano-1,1-diil]-5-metilcitidina



dX : 2'-deoxy-X / dX : 2'-désoxy-X

darvadstrocelum

darvadstrocel

Human culture expanded allogeneic adipose stromal progenitor cells (eASC) for cell-based therapy. Cells are derived from isolated adipose tissue of healthy living donors. eASC express cell surface markers CD29, CD73, CD90 and CD105 and are capable to express factors such as vascular endothelial growth factor (VEGF), transforming growth factor-beta 1 (TGF- β 1), interleukin-6 (IL-6), matrix metalloproteinase inhibitor-1 (TIMP-1), and interferon-gamma (IFN- γ) inducible indoleamine 2,3-dioxygenase (IDO).

darvadstrocel

Cellules progénitrices humaines allogéniques du stroma adipeux (eASC), en culture d'expansion, pour thérapie à base de cellules. Les cellules sont dérivées d'un tissu adipeux isolé à partir de donneurs vivants sains. Les eASC expriment les marqueurs de surface CD29, CD73, CD90 et CD105 et sont capables d'exprimer les facteurs comme le facteur de croissance de l'endothélium vasculaire (VEGF), le facteur de croissance transformant beta 1 (TGF- β 1), l'interleukine 6 (IL-6), l'inhibiteur tissulaire des métalloprotéases 1 (TIMP-1) et l'indoléamine 2,3-dioxygénase (IDO) induite par l'interféron gamma (IFN- γ).

darvadstrocel

Células progenitoras del estroma adiposo alogénicas, humanas, expandidas en cultivo (eASC) para terapia celular. Las células se derivan a partir tejido adiposo aislado de donantes sanos vivos. Las eASC expresan los marcadores de superficie CD29, CD73, CD90 y CD105, y pueden expresar factores como el factor de crecimiento del endotelio vascular (VEGF), factor transformador del crecimiento beta 1 (TGF- β 1), interleukina 6 (IL-6), inhibidor de metaloproteína de la matriz 1 (TIMP-1), e indoleamina 2,3- dioxigenasa (IDO) inducible por interferón gamma (IFN- γ) .

davamotecanum pegadexamerum

davamotecan pegadexamer



α -acetyl- ω -{[(2*RS*)-2-hydroxypropyl]amino}poly[({bis}[(4*S*)-4-ethyl-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-4-yl] S,S'-(6',6'^{IV}-dideoxycyclomaltoheptaose-6',6'^{IV}-diyl)bis(L-cysteinylglycinate))-N^{2,1},N^{2,1'}-diyl](1-oxopropane-1,3-diyl)poly(oxyethylene)oxy(3-oxopropane-1,3-diyl)]

davamotécan pégadexamère

α -acétyl- ω -{[(2*RS*)-2-hydroxypropyl]amino}poly[({bis}[(4*S*)-4-éthyl-3,14-dioxo-3,4,12,14-tétrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-4-yl] S,S'-(6',6'^{IV}-didésoxycyclomaltoheptaose-6',6'^{IV}-diyl)bis(L-cystéinylglycinate))-N^{2,1},N^{2,1'}-diyl](1-oxopropane-1,3-diyl)poly(oxyéthylène)oxy(3-oxopropane-1,3-diyl)]

davamotecán pegadexámero

α -acetil- ω -{[(2*RS*)-2-hidroxipropil]amino}poli[({bis}[(4*S*)-4-etil-3,14-dioxo-3,4,12,14-tetrahidro-1*H*-pirano[3',4':6,7]indolizino[1,2-*b*]quinolin-4-il] S,S'-(6',6'^{IV}-didesoxiciclomaltoheptaosa-6',6'^{IV}-diil)bis(L-cisteinilglicinato))-N^{2,1},N^{2,1'}-diil](1-oxopropano-1,3-diil)poli(oxietileno)oxi(3-oxopropano-1,3-diil)]

**delgocitinibum**

delgocitinib



3-[(3*S*,4*R*)-3-méthyl-6-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile

delgocitinib

3-[(3*S*,4*R*)-3-méthyl-6-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile

delgocitinib

3-[(3*S*,4*R*)-3-méthyl-6-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile

**demiplatinum pegraglumerum**

demiplatin pegraglumer




{[α-{3-[α-*N*-hydropoly(L-glutamyl-κO⁵)_m-ω-amino]propyl}-ω-méthoxypoly(oxyéthane-1,2-diyl)_n]polyato}poly[*cis*-(*SP*-4)-aquadiammineplatine(II)/*cis*-(*SP*-4)-diammineplatine(II) (x:y)], with *m* ~ 40, *n* ~ 268, *x* ~ 8, (*m*+*x*)/2 = 24

demiplatine péraglumère

{[α-{3-[α-*N*-hydropoly(L-glutamyl-κO⁵)_m-ω-amino]propyl}-ω-méthoxypoly(oxyéthane-1,2-diyl)_n]polyato}poly[*cis*-(*SP*-4)-aquadiammineplatine(II)/*cis*-(*SP*-4)-diammineplatine(II) (x:y)], avec *m* ~ 40, *n* ~ 268, *x* ~ 8, (*m*+*x*)/2 = 24

demplatino pegraglúmero

{[α-3-[α-*N*-hidropoli(L-glutamyl-κO⁵)_m-ω-amino]propil]-ω-metoxipoli(oxietano-1,2-diil)_n]poliato}poli[*cis*-(*SP*-4)-aquadiammineplatino(II)/*cis*-(*SP*-4)-diammineplatino(II) (x:y)], con $m \sim 40$, $n \sim 268$, $x \sim 8$, $(m+x)/2 = 24$

**desidustatum**

desidustat



N-[1-(cyclopropylmethoxy)-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonyl]glycine

désidustat

N-[1-(cyclopropylméthoxy)-4-hydroxy-2-oxo-1,2-dihydroquinoléine-3-carbonyl]glycine

desidustat

N-[1-(ciclopropilmetoxi)-4-hidroxi-2-oxo-1,2-dihidroquinoleína-3-carbonil]glicina

**desmetramadolum**

desmetramadol



rac-3-[(1*R*,2*R*)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]phenol

desmétramadol

rac-3-[(1*R*,2*R*)-2-[(diméthylamino)méthyl]-1-hydroxycyclohexyl]phénol

desmetramadol

rac-3-[(1*R*,2*R*)-2-[(dimetilamino)metil]-1-hidroxiciclohexil]fenol



and enantiomer
et énantiomère
y enantiómero

efepoetinum alfa #
efepoetin alfa

human erythropoietin (epoetin alfa) fused to a hybrid human immunoglobulin (Ig), consisting of the Fc fragment of the IgG4 fused to the hinge and amino-terminus of the IgD heavy chain isotype 2, produced in Chinese hamster ovary (CHO) cells, glycoform alfa;

[human erythropoietin (EPO) (1-166)]-[immunoglobulin heavy chain delta (IGHD) isoform 2 constant region (133-170)-peptide (C-terminal hinge region and N-terminal CH2 domain) (167-204)]-[immunoglobulin heavy chain gamma 4 (IGHG4) constant region (121-327)-peptide (CH2 and CH3 domains) (205-411)]-fusion protein, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

éfépoétine alfa

érythropoïétine humaine (époétine alfa) fusionnée à une immunoglobuline (Ig) humaine hybride, consistant en un fragment Fc de l'IgG4 fusionné à la région charnière et à la chaîne lourde isotype 2 de l'IgD sur la partie N-terminale, produite par des cellules ovariennes de hamster chinois (CHO), glycoforme alfa;

[érythropoïétine humaine (EPO) (1-166)]-[région constante de la chaîne lourde delta de l'immunoglobuline (IGHD) isoforme 2 (133-170)-peptide (région charnière C-terminale et domaine CH2 N-terminal) (167-204)]-[région constante de la chaîne lourde de l'immunoglobuline gamma 4 (IGHG4) (121-327)-peptide (domaines CH2 et CH3) (205-411)]- protéine de fusion, produite par des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

efepoetina alfa

eritropoyetina humana (epoetina alfa) fusionada con una inmunoglobulina (Ig) humana híbrida, consistente en un fragmento Fc de la IgG4 fusionada con la región bisagra y con la cadena pesada isótopo 2 de la IgD sobre la parte N-terminal, producida por las células ováricas de hamster chino (CHO), glicofoma alfa;

[eritropoyetina humana (EPO) (1-166)]-[región constante de la cadena pesada delta de la inmunoglobulina (IGHD) isoforma 2 (133-170)-péptido (región bisagra C-terminal y dominio CH2 N-terminal) (167-204)]-[región constante de la cadena pesada de la inmunoglobulina gamma 4 (IGHG4) (121-327)-péptido (dominios CH2 y CH3) (205-411)]- proteína de fusión, producida por las células ováricas de hamster chinos (CHO), glicofoma alfa

Monomer sequence / Séquence du monomère / Secuencia del monómero

```
APRLICDSR VLERYLLEAK EAENITTGCA EHCSLNNIT VPDTKVNFYA 50
WKRMEVGQQA VEVWQGLALL SEAVLRGQAL LVNSSQFPWE LQLHVDKAVS 100
GLRSLTLLR ALGAQKEAIS PPDAASAAPL RTITADTFRK LFRVYSNFLR 150
GKLKLYTGEA CRTGDRRNTG RGGEKKKEK EKEEQEERET RTPECPSTQ 200
PLGVFLFPPK PKDTLMISRT PEVTCVVVDV SQEDPEVQFN WYVDGVEVHN 250
AKTKPREEQF NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK GLPSSIEKTI 300
SKAKGQPREP QVYTLPPSQE EMTKNQVSLT CLVKGFFPSD IAVEWESNGQ 350
PENNYKTPP VLDSDGSFFL YSRLTVDKSR WQEGNVFSCS VMHEALHNHY 400
TQKSLSLSLG K 411
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-chain disulfide bridges: 7-161 29-33 225-285 331-389
7-161' 29'-33' 225'-285' 331'-389'

Inter-chain disulfide bridges: 195-195'

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-24 Asn-38 Asn-83 Asn-261

Glycosylation sites (O) / Sites de glycosylation (O) / Posiciones de glicosilación (O)
Ser-126

efizonerimodum alfa #

efizonerimod alfa

modified human immunoglobulin G4 Fc fragment fused to tumor necrosis factor receptor-associated factor TRAF2 (human C-C domain fragment) and to the CD252 antigen (human extracellular domain fragment), hexamer, produced in Chinese hamster ovary (CHO) cells, glycoform alfa;

modified human immunoglobulin G4 Fc fragment (1-229) [*Homo sapiens*IGHG4*01 del-CH1, [10-proline (S>P)]hinge] fusion protein with human TNF receptor-associated factor2 (TRAF2)-(310-349)-peptide (230-269) fusion protein with des-(1-50)-human tumor necrosis factor ligand superfamily member4 (TNFSF4, also known as CD252 or OX40L) (270-402), produced in Chinese hamster ovary (CHO) cells, non-covalent trimer of (8-8',11-11')-bisdisulfide dimers, glycoform alfa

éfizonérimod alfa

fragment Fc modifié de l'immunoglobuline G4 humaine, fusionné au facteur associé au récepteur du facteur de nécrose tumorale TRAF2 (fragment du domaine C-C humain) et à l'antigène CD252 (fragment du domaine extracellulaire humain), hexamère, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa;

fragment Fc modifié de l'immunoglobuline G4 humaine (1-229)[*Homo sapiens*IGHG4*01 del-CH1, [10-proline (S>P)]charnière] protéine de fusion avec le facteur 2 associé au récepteur du TNF humain (TRAF2)-(310-349)-peptide (230-269) protéine de fusion avec le des-(1-50)-membre 4 de la superfamille des ligands du facteur de nécrose tumorale humain (TNFSF4, CD252, OX40L) (270-402), produit dans des cellules ovariennes de hamster chinois (CHO), trimère non-covalent de dimères (8-8',11-11')-bisdisulfure, glycoforme alfa

efizonerimod alfa

fragmento Fc modificado de la inmunoglobulina G4 humana, fusionada con el factor asociado al receptor del factor de necrosis tumoral TRAF2 (fragmento del dominio C-C humano) y al antígeno CD252 (fragmento del dominio extracelular humano), hexámero, producido en las células ováricas de hámsters chinos (CHO), glicofoma alfa;

fragmento Fc modificado de la inmunoglobulina G4 humana (1-229)[*Homo sapiens*IGHG4*01 del-CH1, [10-prolina (S>P)]bisagra] proteína de fusión con el factor 2 asociado al receptor del TNF humano (TRAF2)-(310-349)-péptido (230-269) proteína de fusión con el des-(1-50)- miembro 4 de la superfamilia de los ligandos del factor de necrosis tumoral humano (TNFSF4, CD252, OX40L) (270-402), producido en las células ováricas de hámster chino (CHO), trímero no-covalente de dímeros (8-8',11-11')-bisdisulfuro, glicofoma alfa

Monomer sequence / Séquence du monomère / Secuencia del monómero

```
ESKYGPFCPP CPAEFLGGP SVLFPPKPK DTLMSRTPE VTCVVVDVSQ 50
EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE 100
YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL 150
VKGFPSPDIA VEWESNGQPE NNYKTPPVVL DSDGSFFLYS RLTVDKSRWQ 200
EGNVFSCSVM HEALHNHYTQ KSLSLSLGKD QDKIEALSSK VQQLERSIGL 250
KDLAMADLEQ KVLEMEASTQ VSHRYPRIQS IKVQFTEYKK EKGFIILTSQK 300
EDEIMKVQNN SVIINCDFGY LISLKGYSQ EVNISLHYQK DEEPLFQLKK 350
VRSVNSIMVA SLTYKDKVYL NVTTDNTSLD DFHVNGLI LIHQNPGEFC 400
VL 402
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
8-8' 11-11' 43-103 149-207 316-400

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-79 Asn-309 Asn-333 Asn-371 Asn-376

eflenograstimum alfa #

eflenograstim alfa

human granulocyte-colony stimulating factor (G-CSF) fused to a hybrid human immunoglobulin consisting of the Fc fragment of the IgG4 fused to the hinge region and amino-terminus of the IgD heavy chain isotype 2, produced in Chinese hamster ovary (CHO) cells, glycoform alfa;

[human granulocyte-colony stimulating factor (G-CSF) short isoform (1-174)]-[immunoglobulin heavy chain delta (IGHD) constant region isoform 2 (133-170)-peptide (C-terminal hinge and N-terminal CH2 domains) (175-212)]-[immunoglobulin heavy chain gamma 4 (IGHG4) constant region (121-327)-peptide (CH2 and CH3 domains) (213-419)]-fusion protein, (203-203')-disulfide dimer, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

éflénograstim alfa

facteur stimulant les colonies de granulocytes humain (G-CSF) fusionné à une immunoglobuline (Ig) humaine hybride, consistant en un fragment Fc de l'IgG4 fusionné à la région charnière et à la chaîne lourde isotype 2 de l'IgD sur la partie N-terminale, produite par des cellules ovariennes de hamsters chinois (CHO), glycoforme alfa;

[facteur stimulant les colonies de granulocytes humain (G-CSF) isoforme courte (1-174)]-[région constante de la chaîne lourde delta de l'immunoglobuline (IGHD) isoforme 2 (133-170)-peptide (région charnière C-terminale et domaine CH2 N-terminal) (175-212)]-[région constante de la chaîne lourde de l'immunoglobuline gamma 4 (IGHG4) (121-327)-peptide (domaines CH2 et CH3) (213-419)]-protéine de fusion, (203-203')-disulfide dimère, produite par des cellules ovariennes de hamsters chinois (CHO), glycoforme alfa

eflenograstim alfa

factor estimulante de las colonias de granulocitos humanos (G-CSF) fusionado con una inmunoglobulina (Ig) humana híbrida, consistente en un fragmento Fc de la IgG4 fusionado con la región bisagra y con la cadena pesada isótopo 2 de la IgD sobre la parte N-terminal, producido por las células ováricas de hamster chino (CHO), glicofoma alfa;

[factor estimulante de las colonias de granulocitos humanos (G-CSF) isoforma corta (1-174)]-[región constante de la cadena pesada delta de la inmunoglobulina (IGHD) isoforma 2 (133-170)-péptido (región bisagra C-terminal y dominio CH2 N-terminal) (175-212)]-[región constante de la cadena pesada de la inmunoglobulina gamma 4 (IGHG4) (121-327)-péptido (dominios CH2 y CH3) (213-419)]-proteína de fusión, (203-203')-disulfuro dímero, producido por las células ováricas de hamster chino (CHO), glicofoma alfa

Monomer sequence / Séquence du monomère / Secuencia del monómero

TPLGFASSLP QSFLLKCLEQ VRKIQQDGAA LQEKLCATYK LCHPEELVLL 50
 GHSLGIFWAP LSSCPSQALQ LAGCLSQLHS GLFLYQGLLQ ALEGISPELG 100
 PTLDTLQLDV ADFATTIWQQ MEELGMAPAL QPTQGAMPAP ASAFQRRAGG 150
 VLVASHLQSF LEVSYRVLRH LAQPRNTGRG GEEKKKEKEK EEQEERETKT 200
 PECPSHTQPL GVFLFPPKPK DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY 250
 VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL 300
 PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA 350
 VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFCSCVM 400
 HEALHNHYTQ KSLSLSLGG 419

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-chain disulfide bridges: 36-42 64-74 233-293 339-397
 36'-42' 64'-74' 233'-293' 339'-397'

Inter-chain disulfide bridges: 203-203'

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
 Asn-269

Glycosylation sites (O) / Sites de glycosylation (O) / Posiciones de glicosilación (O)
 Thr-133

elenbecestatum

elenbecestat


N-{3-[(4*a*S,5*R*,7*a*S)-2-amino-5-methyl-4*a*,5-dihydro-4*H*-furo[3,4-*d*][1,3]thiazin-7*a*(7*H*)-yl]-4-fluorophenyl}-5-(difluoromethyl)pyrazine-2-carboxamide

élenbécestat

N-{3-[(4*a*S,5*R*,7*a*S)-2-amino-5-méthyl-4*a*,5-dihydro-4*H*-furo[3,4-*d*][1,3]thiazin-7*a*(7*H*)-yl]-4-fluorophényl}-5-(difluorométhyl)pyrazine-2-carboxamide

elenbecestat

N-{3-[(4*a*S,5*R*,7*a*S)-2-amino-5-metil-4*a*,5-dihidro-4*H*-furo[3,4-*d*][1,3]tiazin-7*a*(7*H*)-il]-4-fluorofenil}-5-(difluorometil)pirazina-2-carboxamida

$$\text{C}_{19}\text{H}_{18}\text{F}_3\text{N}_5\text{O}_2\text{S}$$
**elsulfavirinum**

elsulfavirine


N-(4-{2-[4-bromo-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl]acetamido}-3-chlorobenzenesulfonyl)propanamide

elsulfavirine

N-(4-{2-[4-bromo-3-(3-chloro-5-cyanophénoxy)-2-fluorophényl]acétamido}-3-chlorobenzènesulfonyl)propanamide

elsulfavirina

N-(4-{2-[4-bromo-3-(3-cloro-5-cianofenoxi)-2-fluorofenil]acetamido}-3-clorobencenosulfonyl)propanamida



emiplacelum
emiplacel

human culture expanded allogenic adherent mesenchymal-like stromal cells for cell-based therapy. Cells are derived of maternal origin from isolated placentae of healthy donors following a cesarean section. Cells express cell surface markers CD29, CD73, and CD105 and exhibit immunomodulatory, pro-angiogenic and muscle regeneration effects.

émiplacel

cellules mésenchymales adhérentes humaines allogéniques semblables au stroma, en culture d'expansion, pour thérapie cellulaire. Les cellules d'origine maternelle sont obtenues à partir du placenta de donneuses saines et vivantes suivant une césarienne. Les cellules expriment les marqueurs de surface CD29, CD73, and CD105 et montrent des propriétés immunomodulatrices et des effets pro-angiogéniques.

emiplacel

células adherentes mesenquimales similares al estroma alogénicas, humanas, expandidas en cultivo para terapia celular. Las células de origen maternal se derivan a partir de la placenta de donantes sanos vivos tras una sección por cesárea. Las células expresan los marcadores de superficie CD29, CD73 y D105, y muestran efectos inmunomoduladores y angiogénicos

enarodustatum
enarodustat



N-[7-hydroxy-5-(2-phenylethyl)[1,2,4]triazolo[1,5-*a*]pyridine-8-carbonyl]glycine

énarodustat

N-[7-hydroxy-5-(2-phényléthyl)[1,2,4]triazolo[1,5-*a*]pyridine-8-carbonyl]glycine

enarodustat

N-[7-hidroxi-5-(2-feniletíl)[1,2,4]triazolo[1,5-*a*]piridina-8-carbonil]glicina



estetrolum


estetrol

estra-1,3,5(10)-triene-3,15 α ,16 α ,17 β -tetrol

estétrol

estra-1,3,5(10)-triène-3,15 α ,16 α ,17 β -tétrol

estetrol

estra-1,3,5(10)-trieno-3,15 α ,16 α ,17 β -tetrolC₁₈H₂₄N₄**exebacasum #**

exebacase

Streptococcus suis bacteriophage-derived lysin, produced in *Escherichia coli*;des-Met¹-phage lysin (endolysin, lysozyme, murein hydrolase, EC 3.2.1.17) of *Streptococcus suis* phage ϕ 891591 (PlySs2), produced in *Escherichia coli*

exébacase

lysine dérivée du bactériophage *Streptococcus suis*, produite par *Escherichia coli*;lysine du dès-Mét¹-phage *Streptococcus suis* ϕ 891591 (PlySs2) (endolysine, lysozyme, muréine hydrolase, EC 3.2.1.17), produite par *Escherichia coli*

exebacasa

lisina derivada del bacteriófago *Streptococcus suis*, producido por *Escherichia coli*;lisina del des-Met¹-fago *Streptococcus suis* ϕ 891591 (PlySs2) (endolisina, lisozima, mureína hidrolasa, EC 3.2.1.17), producida por *Escherichia coli*

Sequence / Séquence / Secuencia

```

TTVNEALNNV RAQVSGSVS GNGECYALAS WYERMISPD A TVGLGAGVGW 50
VSGAIGDTIS AKNIGSSYNW QANGWTVSTS GPFGAGQIVT LGATPGNPGY 100
HVVIVEAVDG DRLTILEQNY GKKRYPVRNY YSAASYRQQV VHYITPPGTV 150
AQSAPNLGAS RSYRETGTMT VTVDALNVRP APNTSGEIVA VYKRGESFDY 200
DTVIIDVNGY VVVS YIGGSG KRNYVATGAT KDGKRFNGAW GTFK 244

```

fenebrutinibum

fenebrutinib


(6²S)-2³-(hydroxymethyl)-1⁷,1⁷,3¹,6²-tetramethyl-1³,1⁴,1⁷,1⁸-tetrahydro-4-aza-1(2)-cyclopenta[4,5]pyrrolo[1,2-a]pyrazina-6(1,4)-piperazina-2(2,4),3(3,5),5(2,5)-tripyrindina-7(3)-oxetanaheptaphane-1¹(1⁶H),3⁶(3¹H)-dione

fénébrutinib

(6²S)-2³-(hydroxyméthyl)-1⁷,1⁷,3¹,6²-tétraméthyl-1³,1⁴,1⁷,1⁸-tétrahydro-4-aza-1(2)-cyclopenta[4,5]pyrrolo[1,2-a]pyrazina-6(1,4)-pipérazina-2(2,4),3(3,5),5(2,5)-tripyrindina-7(3)-oxétanaheptaphane-1¹(1⁶H),3⁶(3¹H)-dione

fenebrutinib

(6²*S*)-2³-(hidroximetil)-1⁷,1⁷,3¹,6²-tetrametil-1³,1⁴,1⁷,1⁸-tetrahidro-4-aza-1(2)-ciclopenta[4,5]pirrolo[1,2-*a*]pirazina-6(1,4)-piperazina-2(2,4),3(3,5),5(2,5)-tripiridina-7(3)-oxetanaheptafano-1¹(1⁶*H*),3⁶(3⁶*H*)-diona

C₃₇H₄₄N₈O₄**firibastatum**


firibastat

4,4'-disulfanediybis[(3*S*)-3-aminobutane-1-sulfonic] acid

firibastat

acide 4,4'-disulfanediybis[(3*S*)-3-aminobutane-1-sulfonique]

firibastat

ácido 4,4'-disulfanodiilbis[(3*S*)-3-aminobutano-1-sulfónico]C₈H₂₀N₂O₆S₄**foligluraxum**

foliglurax


N-[6-[3-(morpholin-4-yl)propyl]-2-(thieno[3,2-*c*]pyridin-6-yl)-4*H*-1-benzopyran-4-ylidene]hydroxylamine

foliglurax

N-[6-[3-(morpholin-4-yl)propyl]-2-(thieno[3,2-*c*]pyridin-6-yl)-4*H*-1-benzopyran-4-ylidene]hydroxylamine

foliglurax

N-[6-[3-(morfolin-4-il)propil]-2-(tieno[3,2-*c*]piridin-6-il)-4*H*-1-benzopiran-4-ilideno]hidroxilamina

C₂₃H₂₃N₃O₃S

fulacimstatum

fulacimstat


1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1*R*)-4-(trifluoromethyl)-2,3-dihydro-1*H*-inden-1-yl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid

fulacimstat

acide 1-(3-méthyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1*R*)-4-(trifluorométhyl)-2,3-dihydro-1*H*-indén-1-yl]-1,2,3,4-tétrahydropyrimidine-5-carboxylique

fulacimstat

ácido 1-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1*R*)-4-(trifluorometil)-2,3-dihidro-1*H*-inden-1-il]-1,2,3,4-tetrahidropirimidina-5-carboxílico

C₂₃H₁₆F₃N₃O₆**garvagliptinum**

garvagliptin


(2*R*,3*S*,5*R*)-2-(2,5-difluorophenyl)-5-[5-(methanesulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-*c*]pyrrol-2(1*H*)-yl]oxan-3-amine

garvagliptine

(2*R*,3*S*,5*R*)-2-(2,5-difluorophényl)-5-[5-(méthanesulfonyl)-3,4,5,6-tétrahydropyrrolo[3,4-*c*]pyrrol-2(1*H*)-yl]oxan-3-amine

garvagliptina

(2*R*,3*S*,5*R*)-2-(2,5-difluorofenil)-5-[5-(metanosulfonyl)-3,4,5,6-tetrahidropirrol[3,4-*c*]pirrol-2(1*H*)-il]oxan-3-amina

C₁₈H₂₃F₂N₃O₃S**gimsilumabum #**

gimsilumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CSF2 (colony stimulating factor 2 (granulocyte-macrophage), granulocyte-macrophage colony stimulating factor, GM-CSF)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-451) [*Homo sapiens* VH (IGHV3-74*03 (84.70%) - (IGHD) -IGHJ4*01, L123>P (116) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (218) (122-219), hinge (220-234), CH2 (235-344), CH3 D12 (360), L14 (362), M107>V (432) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (89.50%) -IGKJ2*01 [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (108'-214')]; dimer (230-230":233-233")-bisdisulfide

gimsilumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CSF2 (facteur 2 stimulant de colonies (granulocyte-macrophage), facteur stimulant des colonies de granulocytes et macrophages, GM-CSF)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-451) [*Homo sapiens* VH (IGHV3-74*03 (84.70%) -(IGHD) -IGHJ4*01, L123>P (116) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01 G1m17,1 (CH1 K120 (218) (CH1 (122-219), charnière (220-234), CH2 (235-344), CH3 D12 (360), L14 (362), M107>V (432) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfure avec la chaîne légère (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (89.50%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (108'-214')]; dimère (230-230":233-233")-bisdisulfure

gimsilumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CSF2 (factor 2 estimulante de colonias (granulocito-macrófago), factor estimulante de colonias de granulocitos y macrófagos, GM-CSF)], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma1 (1-451) [*Homo sapiens* VH (IGHV3-74*03 (84.70%) -(IGHD) -IGHJ4*01, L123>P (116) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01 G1m17,1 (CH1 K120 (218) (CH1 (122-219), bisagra (220-234), CH2 (235-344), CH3 D12 (360), L14 (362), M107>V (432) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfuro con la cadena ligera (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (89.50%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (108'-214')]; dímero (230-230":233-233")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS RHWMLRLQV PGKGPVWVSR 50
INGAGTSITY ADSVRGRFTI SRDNNNTLF LQMSLRADD TALYFCARAN 100
SVWFRGLFDY WQGGTPVTVS SASTKGPSVF PLAPSSKSTS GGTAAALGCLV 150
KDYFPEPFTV SWNSGALTSG VHTFPAVLQS SGLYSLSSV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKKEV PKSCDKTHTC PFCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVSVSL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQFPREP 350
QVYTLPPSRD ELTKNQVSLT CLVKGFPYPSD IAVEWESNGQ PENNYKTPPP 400
VLDSGGSFFL YSKLTVDKSR WQQGNVFCSS VVHEALHNNH YQKSLSLSPG 450
K 451
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPVT LSVSPGERVT LSCRASQSVS TNLAWYQQKL GQGPRLLIYG 50
ASTRATDIPA RFGSGGSETE FTLTISSLQS EDFAVYYCQQ YDKWPDFTGQ 100
GTKLEIKRTV AAPSVFIFFP SDEQLKSGTA SVVCLNNFY PREAKVQNKV 150
DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEK 214
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 148-204 265-325 371-429
22"-96" 148"-204" 265"-325" 371"-429"

Intra-L (C23-C104) 23'-88' 134'-194'
23'''-88''' 134'''-194'''

Inter-H-L (h 5-CL 126) 224-214' 224"-214"
Inter-H-H (h 11, h 14) 230-230" 233-233"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H VH N84

76, 76"

H CH2 N84.4:

301, 301"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados

ianalumabum #

ianalumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* TNFRSF13C (tumor necrosis factor receptor (TNFR) superfamily member 13C, BAFFR, BAFF-R, BR3, B cell activating factor receptor, CD268)], *Homo sapiens* monoclonal antibody;
 gamma1 heavy chain (1-454) [*Homo sapiens* VH (IGHV6-1*01 (96.00%) -(IGHD) -IGHJ5*01) [10.9.14] (1-124) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), hinge (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3D-11*01 (86.80%) -IGKJ1*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01, Km3 A45.1 (154), V101 (192) (109'-215')]; dimer (233-233":236-236")-bisdisulfide

ianalumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* TNFRSF13C (membre 13C de la super famille du récepteur du facteur de nécrose tumorale (TNFR), BAFFR, BAFF-R, BR3, récepteur du facteur d'activation des lymphocytes B], *Homo sapiens* anticorps monoclonal;
 chaîne lourde gamma1 (1-454) [*Homo sapiens* VH (IGHV6-1*01 (96.00%) -(IGHD) -IGHJ5*01) [10.9.14] (1-124) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), charnière (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfure avec la chaîne légère (1'-215') [*Homo sapiens* V-KAPPA (IGKV3D-11*01 (86.80%) -IGKJ1*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01, Km3 A45.1 (154), V101 (192) (109'-215')]; dimère (233-233":236-236")-bisdisulfure

ianalumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* TNFRSF13C (miembro 13C de la super familia del receptor del factor de necrosis tumoral (TNFR), BAFFR, BAFF-R, BR3, receptor del factor de activación de los linfocitos B], *Homo sapiens* anticuerpo monoclonal;
 cadena pesada gamma1 (1-454) [*Homo sapiens* VH (IGHV6-1*01 (96.00%) -(IGHD) -IGHJ5*01) [10.9.14] (1-124) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), bisagra (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfuro con la cadena ligera (1'-215') [*Homo sapiens* V-KAPPA (IGKV3D-11*01 (86.80%) -IGKJ1*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01, Km3 A45.1 (154), V101 (192) (109'-215')]; dímero (233-233":236-236")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLQQSGPG LVKPSQTLSTL TCAISGDSVS SNSAAWGWR QSPGRGLEWL 50
 GRIYYRSKWY NSYAVSVKSR ITINPDTSKN QFSLQLNSVT PEDTAVYYCA 100
 RYQWVPKIGV FDSWGQGLTV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
 CLVKDYFPEP VTSWNSGAL TSGVHTFPAV LQSSGLYSLS SVTVVPSSSL 200
 GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HTCPCPCAPE LLGGPSVFLF 250
 PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300
 EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350
 REPQVYTLPP SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400
 TTPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450
 SPGK 454

Light chain / Chaîne légère / Cadena ligera

DIVLTQSPAT LSLSPGERAT LSCRASQFIL PEYLSWYQQK PGQAPRLLIY 50
 GSSSRATGVP ARFSGSGSGT DFTLTISSE PEDFAVYYCQ QFYSSPLTFG 100
 QGTKEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNPF YPREAKVQWK 150
 VDNALQSGNS QESVTEQDSK DSTYLSSTL TSLKADYERH KVAACEVTHQ 200
 GLSSPVTKSF NRGE 215

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22"-99 151"-207 268"-328 374"-432
 22"-99" 151"-207" 268"-328" 374"-432"

Intra-L (C23-C104) 23"-89" 135"-195"
 23"-89" 135"-195"

Inter-H-L (h 5-CL 126) 227"-215" 227"-215"

Inter-H-H (h 11, h 14) 233"-233" 236"-236"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

304, 304"

Afucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires

complexes afucosylés / glicanos de tipo CHO biantenaricos complejos afucosilados

N-terminal glutamine cyclization

H VH Q1: 1, 1"

C-terminal lysine clipping

H CHS K2: 454, 454"

iberdomidum

iberdomide


(3S)-3-[4-({4-[(morpholin-4-yl)methyl]phenyl}methoxy)-
 1-oxo-1,3-dihydro-2H-isoindol-2-yl]piperidine-2,6-dione

iberdomide

(3S)-3-[4-({4-[(morpholin-4-yl)méthyl]phényl}méthoxy)-
 1-oxo-1,3-dihydro-2H-isoindol-2-yl]pipéridine-2,6-dione

iberdomida

(3S)-3-[4-({4-[(morfolin-4-il)metil]fenil}metoxi)-1-oxo-
 1,3-dihidro-2H-isoindol-2-il]piperidina-2,6-diona

C₂₅H₂₇N₃O₅**imlifidasum #**

imlifidase

human immunoglobulin G-degrading cysteine protease
 from *Streptococcus pyogenes* (IdeS, residues 30-339),
 produced in *Escherichia coli*;
 L-methionyl-immunoglobulin G-degrading protease
 (*Streptococcus pyogenes*) (IdeS) pro-protein (30-339)-
 peptide, produced by *Escherichia coli*

imlifidase	cystéine protéase de <i>Streptococcus pyogenes</i> dégradant l'immunoglobuline G humaine (IdeS, résidus 30-339), produite par <i>Escherichia coli</i> ; L-méthionyl-protéase dégradant l'immunoglobuline G (<i>Streptococcus pyogenes</i>) (IdeS) pro-protéine (30-339)-peptide, produite par <i>Escherichia coli</i>
imlifidasa	cisteína proteasa de <i>Streptococcus pyogenes</i> que degrada a la inmunoglobulina G humana (IdeS, residuos 30-339), producida por <i>Escherichia coli</i> ; L-metionil-proteasa que degrada la inmunoglobulina G (<i>Streptococcus pyogenes</i>) (IdeS) pro-proteína (30-339)-péptido, producido por <i>Escherichia coli</i>
Sequence / Séquence / Secuencia MDSFSANQEI RYSEVTPYHV TSVWTKGVTP PANFTQGEDV FHAPYVANQG 50 WYDITKTFNG KDDLCCGAAT AGNMLHWWFD QNKDQIKRYL EEHPEKQKIN 100 FNGEQMFDVK EAIDTKNHQL DSKLFEYFKE KAFPYLSTKH LGVFPPDHVID 150 MFINGYRLSL TNHGPVPVKE GSKDPRGGIF DAVFTRGDQS KLLTSRHDFFK 200 EKNLKEISDL IKKELTEGKA LGLSHTYANV RINHVINLWG ADFDSNGNLK 250 AIYVTDSDSN ASIGMKKYFV GVNAGKVAI SAKEIKEDNI GAQVLGLFTL 300 STGQDSWNQT N 311	
istiratumabum # istiratumab	immunoglobulin G1-kappa anti-[<i>Homo sapiens</i> IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221)], each heavy chain being fused to a scFv anti-[<i>Homo sapiens</i> ERBB3 (receptor tyrosine-protein kinase erbB-3, HER3)], <i>Homo sapiens</i> monoclonal antibody, bispecific tetravalent; gamma1 heavy chain anti-IGFR1 fused to a scFv anti-ERBB3 (1-720) [<i>Homo sapiens</i> gamma1 heavy chain {(Homo sapiens VH (IGHV3-23*01 (90.80%) -(IGHD) -IGHJ4*01 L123>T (117)) [8.8.15] (1-122) -Homo sapiens IGHG1*03v,G1m3>G1m17, nG1m1 (CH1 R120>K (219) (123-220), hinge (221-235), CH2 (236-345), CH3 E12 (361), M14 (363) (346-450), CHS K2>del (451)) (123-451)) (1-451)-15-mer tris(tetraglycyl-seryl) linker (452-466) -scFv {(Homo sapiens VH (IGHV3-9*01 (92.90%) -(IGHD) -IGHJ4*01) [8.8.15] (467-588) -23-mer alanyl-seryl-threonyl-tetrakis(tetraglycyl-seryl) linker (589-611) -Homo sapiens V-LAMBDA (IGLV3-19*01 (94.80%) -IGLJ3*02 L124>V (716)) [6.3.11] (612-719) -glycyl (720)) (467-720)), (225-214')-disulfide with kappa light chain anti-IGFR1 (1'-214') [<i>Homo sapiens</i> V-KAPPA(IGKV1-12*01 (90.50%) -IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (231-231'':234-234'')-bisdisulfide
istiratumab	immunoglobuline G1-kappa anti-[<i>Homo sapiens</i> IGF1R (récepteur du facteur de croissance 1 analogue à l'insuline, IGF1-R, IGF-1R, CD221)], chaque chaîne lourde étant fusionnée à un scFv anti-[<i>Homo sapiens</i> ERBB3 (récepteur à activité tyrosine kinase erbB-3, HER3)], <i>Homo sapiens</i> anticorps monoclonal, bispécifique tétravalent; chaîne lourde gamma1 anti-IGFR1 fusionnée à un

istiratumab

scFv anti-ERBB3 (1-720) [chaîne lourde gamma1 *Homo sapiens* {(Homo sapiens VH (IGHV3-23*01 (90.80%) -(IGHD) -IGHJ4*01 L123>T (117))[8.8.15] (1-122) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (219)(123-220), charnière (221-235), CH2 (236-345), CH3 E12 (361), M14 (363) (346-450), CHS K2>del (451))(123-451))(1-451) -15-mer tris(tétraglycyl-séryl) linker (452-466)-scFv {(Homo sapiens VH (IGHV3-9*01 (92.90%) -(IGHD) -IGHJ4-01) [8.8.15](467-588) -23-mer alanyl-séryl-thréonyl-tétrakis(tétraglycyl-séryl) linker (589-611) -Homo sapiens V-LAMBDA (IGLV3-19*01 (94.80%) -IGLJ3*02 L124>V (716)) [6.3.11] (612-719) -glycyl (720))(467-720)), (225-214')-disulfure avec la chaîne légère kappa anti-IGFR1 (1'-214') [Homo sapiens V-KAPPA (IGKV1-12*01 (90.50%) -IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (231-231":234-234")-bisdisulfure

inmunoglobulina G1-kappa anti-[Homo sapiens IGF1R (receptor del factor de crecimiento 1 análogo a la insulina, IGF1-R, IGF-1R, CD221)], cada cadena pesada estando fusionada con un scFv anti-[Homo sapiens ERBB3 (receptor tirosina-proteína quinasa erbB-3, HER3)], *Homo sapiens* anticuerpo monoclonal, biespecífico tetravalente; cadena pesada gamma1 anti-IGFR1 fusionada con un scFv anti-ERBB3 (1-720) [cadena pesada gamma1 *Homo sapiens* {(Homo sapiens VH (IGHV3-23*01 (90.80%) -(IGHD) -IGHJ4*01 L123>T (117))[8.8.15] (1-122) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (219)(123-220), bisagra (221-235), CH2 (236-345), CH3 E12 (361), M14 (363) (346-450), CHS K2>del (451))(123-451))(1-451) -15-mer tris(tetraglicil-seril) espaciador (452-466)-scFv {(Homo sapiens VH (IGHV3-9*01 (92.90%) -(IGHD) -IGHJ4-01) [8.8.15](467-588) -23-mer alanil-seril-treonil-tetrakis(tetraglicil-seril) espaciador (589-611) -Homo sapiens V-LAMBDA (IGLV3-19*01 (94.80%) -IGLJ3*02 L124>V (716)) [6.3.11] (612-719) -glicil (720))(467-720)), (225-214')-disulfuro con la cadena ligera kappa anti-IGFR1 (1'-214') [Homo sapiens V-KAPPA (IGKV1-12*01 (90.50%) -IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (231-231":234-234")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLQSGGG LVQPGSSRLR SCAASGMFS RYPMHWVRQA PGKLEWVGS 50
ISGSGGATPY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDF 100
YQILTGNADF YWGQGTITVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFFAVLQ SSGLYSLSSV VTFVSSSLGT 200
QTYICNVNHK PSNTKVDKKV EPKSCDKTHT CPFCFAPELL GGPSVFLFPP 250
KPKDTLMISR TPEVTQVVDV VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YNSTYRVVSV LTVLHQDWLN KKEYCKVSN KALPAPIEKT ISKAKQPRE 350
PQVYTLPPSR EEMTKNQVSL TCLVKGFPYS DIAVEWESNG QPENNYKTFP 400
PVLDSGSGFF LYSKLTVDKS RWQQGNVFSV SVMHEALNHN YTKSLSLSP 450
GGGGSGGGGG SGGGSGVQLV VQSGGGLVQP GGSRLSCAA SGFTFDDYAM 500
HWVRQAPGKG LEWVAGISWD SGSTGYADSV KGRFTISRIN AKNSLYLQMN 550
SLRAEDTALY YCARDLQAYQ WVEGFDYNGQ GTLVTVSSAS TGGGGSGGGG 600
SGGGSGGGGG SSYELTQDPA VSVALGQTVR ITCQDGLSLR YYASWYQKPK 650
GQAPVLVIYV KNNRPSGIPD RFGSGTSGNS ASLTITGAQA EDEADYYCNS 700
RDSPGNQWVF GGGTKVTVLG 720
```

Light chain / Chaîne légère / Cadena ligera

```
DIQWTSPPSS LSASLGDRVT ITCRASQGIS SYLAWYQKPK GKAPKLLIYA 50
KSTLQSGVPS RFGSGSGTD FTLTISLQEP EDSATYYCQQ YWTFPLTFGG 100
GTKVEIKRTV AAPSVFIFFP SDEQLKSGTA SVVCLLNNEY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSLSLTIT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEK 214
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 149-205 266-326 372-430 488-562 633-698
 22"-96" 149"-205" 266"-326" 372"-430" 488"-562" 633"-698"
 Intra-L (C23-C104) 23'-88' 134'-194'
 23'''-88''' 134'''-194'''
 Inter-H-L (h 5-CL 126) 225-214' 225"-214"
 Inter-H-H (h 11, h 14) 231-231" 234-234"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4:
 302, 302"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
 complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

ladiratuzumabum #

ladiratuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* SLC39A6 (solute carrier family 39 member 6, solute carrier family 39 (metal ion transporter) member 6, solute carrier family 39 (zinc transporter) member 6, LIV-1)], humanized monoclonal antibody;
 gamma1 heavy chain (1-450) [humanized VH (*Homo sapiens*IGHV1-2*02 (87.60%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) - *Homo sapiens*IGHG1*01, G1m17,1 (CH1 K120 (217) (121-218), hinge (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens*IGKV2-30*02 (89.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (229-229":232-232")-bisdisulfide

ladiratuzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* SLC39A6 (membre 6 de la famille 39 des transporteurs de soluté, membre 6 de la famille 39 (transporteur d'ion métal) des transporteurs de soluté, membre 6 de la famille 39 (transporteur du zinc) des transporteurs de soluté, LIV-1)], anticorps monoclonal humanisé;
 chaîne lourde gamma1 (1-450) [VH humanisé (*Homo sapiens*IGHV1-2*02 (87.60%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) - *Homo sapiens*IGHG1*01, G1m17,1 (CH1 K120 (217) (121-218), charnière (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens*IGKV2-30*02 (89.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimère (229-229":232-232")-bisdisulfure

ladiratuzumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* SLC39A6 (miembro 6 de la familia 39 de los transportadores de soluto, miembro 6 de la familia 39 (transportador del ión metal) de los transportadores de soluto, miembro 6 de la familia 39 (transportador de zinc) de los transportadores de soluto, LIV-1)], anticuerpo monoclonal humanizado;
 cadena pesada gamma1 (1-450) [VH humanizado (*Homo sapiens*IGHV1-2*02 (87.60%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens*IGHG1*01, G1m17,1 (CH1 K120 (217) (121-218), bisagra (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens*IGKV2-30*02 (89.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dímero (229-229":232-232")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGASVKV SCKASGLTIE DYYMHWVRQA PGQGLEWMGW 50
 IDPENGDT EY GPKEFGGRVTM TRDTSINTAY MELSRRLSDD TAVYYCAVHN 100
 AHYGTWFAIW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
 DYFPEPTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
 YICNVNHKPS NTKVDKKVEP KSCDKHTCP PCPAPPELLGG PSVFLFPPKP 250
 KDTLMISRTPEVTCVVVDVSD HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
 STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIK KAKGQPREPQ 350
 VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTFPV 400
 LDSGGSFFLY SKLTVDKSRW QQGNVFCSSV MHEALHNHYT QKSLSLSPGK 450

Light chain / Chaîne légère / Cadena ligera

DVVTQSPPLS LPVTLGQPAS ISCRSSQSLH HSSGNTYLEW YQQRPGQSPR 50
 PLIYKISTRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSHPV 100
 YTFGGGTKE IKRTVAAPSV FIFPPSDEQL KSGTASVCL LNNFYPREAK 150
 VQWVKVDNALQ SGNQSQESVTE QDSKDSYSL SSTLTLSKAD YEKHKVYACE 200
 VTHQGLSSPV TKSFNREGC 219

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 147-203 264-324 370-428
 22"-96" 147"-203" 264"-324" 370"-428"

Intra-L (C23-C104) 23'-93' 139'-199'
 23"'-93"' 139"'-199'"

Inter-H-L (h 5-CL 126) 223-219' 223"-219"

Inter-H-H (h 11, h 14) 229-229" 232-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

300, 300"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
 complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados.

ladiratuzumabum vedotinum #

ladiratuzumab vedotin

immunoglobulin G1-kappa, anti-[*Homo sapiens* SLC39A6 (solute carrier family 39 member 6, solute carrier family 39 (metal ion transporter) member 6, solute carrier family 39 (zinc transporter) member 6, LIV-1)], humanized monoclonal antibody conjugated to auristatin E; gamma1 heavy chain (1-450) [humanized VH (*Homo sapiens*IGHV1-2*02 (87.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens*IGHG1*01, G1m17,1 (CH1 K120 (217) (121-218), hinge (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens*IGKV2-30*02 (89.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (229-229":232-232")-bisdisulfide; conjugated, on an average of 4 cysteinyl, to monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker
 For the vedotin part, please refer to the document "INN for pharmaceutical substances: Names for radicals, groups and others".

ladiratuzumab védotine

immunoglobuline G1-kappa, anti-[*Homo sapiens* SLC39A6 (membre 6 de la famille 39 des transporteurs de soluté, membre 6 de la famille 39 (transporteur d'ion métal) des transporteurs de soluté, membre 6 de la famille 39 (transporteur du zinc) des transporteurs de soluté, LIV-1)], anticorps monoclonal humanisé conjugué à l'auristatine E; chaîne lourde gamma1 (1-450) [VH humanisé (*Homo sapiens*IGHV1-2*02 (87.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens*IGHG1*01, G1m17,1 (CH1 K120 (217) (121-218), charnière (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-219')-disulfure avec la chaîne légère kappa

ladiratuzumab vedotina

(1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-30*02 (89.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimère (229-229":232-232")-bisdisulfure; conjugué, sur 4 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker clivable de type maléimidocaproil-valyl-citrullinyl-p-aminobenziloxycarbonyl (mc-val-cit-PABC)

Pour la partie *vedotina*, veuillez-vous référer au document "INN for pharmaceutical substances: Names for radicals, groups and others".

inmunoglobulina G1-kappa, anti-[*Homo sapiens* SLC39A6 (miembro 6 de la familia 39 de los transportadores de soluto, miembro 6 de la familia 39 (transportador del ión metal) de los transportadores del soluto, miembro 6 de la familia 39 (transportador del zinc) de los transportadores del soluto, LIV-1)], anticuerpo monoclonal humanizado conjugado con la auristatina E; cadena pesada gamma1 (1-450) [VH humanizado (*Homo sapiens* IGHV1-2*02 (87.60%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (217) (121-218), bisagra (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV2-30*02 (89.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dímero (229-229":232-232")-bisdisulfuro; conjugado, con 4 restos cisteinil, por término medio, con monometilauristatina E (MMAE), mediante un enlace de tipo maleimidocaproil-valil-citrulinil-p-aminobenziloxycarbonyl (mc-val-cit-PABC)

Para la fracción *vedotina*, pueden referirse al documento "INN for pharmaceutical substances: Names for radicals, groups and others".

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGASVKV SCKASGLTIE DYYMHWVRQA PGQGLEWMGW 50
IDPENGDEY GPKEFGQVMT TRDTSINTAY MELSRLRSD TAVYYCAVHN 100
AHYCTWFAYW QGGTLVTYSS ASTKGPSVFP LAPSKSTSG TGAALGCLYK 150
DYFPEPTVTS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKVEFP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTPEVTCTVVDVVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPEPV 400
LSDSGSFPLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450

Light chain / Chaîne légère / Cadena ligera

DVYMTQSPLS LPVTLGQPAS ISCRSSQSL L HSSGNTYLEW YQQRPGQSPR 50
PLIYKISTRF SGVPDRFSGS GSGTDFTLKI SRVEADGVV YYCFQGSHPV 100
YTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESYTE QDSKDSYSTL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNREGC 219

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22"-96" 147"-203" 264"-324" 370"-428"
22"-96" 147"-203" 264"-324" 370"-428"

Intra-L (C23-C104) 23"-93" 139"-199"
23"-93" 139"-199"

Inter-H-L (h 5-CL 126) * 223"-219" 223"-219"

Inter-H-H (h 11, h 14) * 229"-229" 232"-232"

*Two or three of the inter-chain disulfide bridges are not present, an average of 4 cysteinyl being conjugated each via a thioether bond to a drug linker.

*Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 4 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.

*Faltan dos o tres puentes disulfuro inter-catenarios, una media de 4 cisteinil está conjugada a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

300, 300"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados.

lanacogenum vosiparvovecum #

lanacogene vosiparvovec

Non-replicating recombinant adeno-associated virus type 5 (AAV5) vector containing a codon-optimised of the wild type human coagulation factor IX (F9, FIX) gene under the control of the liver promoter 1 (LP1).

lanacogène vosiparvovec

vecteur viral adéno-associé recombinant de type 5 (AAV5) non-répliquant contenant une version avec des codons optimisés du gène du facteur IX de coagulation de type sauvage (F9, FIX) humain sous le contrôle du promoteur LP1 des cellules hépatiques.

lanacogén vosiparvovec

Vector del Virus Adeno-asociado de serotipo 5 (AAV5) recombinante, no replicativo, que contiene una versión con codones optimizados del gen del factor de coagulación IX humano (F9, FIX) bajo el control del promotor hepático 1 (LP1).

lazertinibum

lazertinib


N-{5-[(4-{4-[(dimethylamino)methyl]-3-phenyl-1*H*-pyrazol-1-yl}pyrimidin-2-yl)amino]-4-methoxy-2-(morpholin-4-yl)phenyl}prop-2-enamide

lazertinib

N-{5-[(4-{4-[(diméthylamino)méthyl]-3-phényl-1*H*-pyrazol-1-yl}pyrimidin-2-yl)amino]-4-méthoxy-2-(morpholin-4-yl)phényl}prop-2-enamide

lazertinib

N-{5-[(4-{4-[(dimetilamino)metil]-3-fenil-1*H*-pirazol-1-il}pirimidin-2-il)amino]-4-metoxi-2-(morfolin-4-il)fenil}prop-2-enamida
C₃₀H₃₄N₈O₃

**leflutrozolum**

leflutrozole


4,4'-[fluoro(1*H*-1,2,4-triazol-1-yl)methylene]dibenzonitrile

léflutrozole

4,4'-[fluoro(1*H*-1,2,4-triazol-1-yl)méthylène]dibenzonitrile

leflutrozol

4,4'-[fluoro(1*H*-1,2,4-triazol-1-il)metileno]dibenzonitrilo

C₁₇H₁₀FN₅

lifirafenibum

lifirafenib


5-(((1*R*,1*aS*,6*bR*)-1-[5-(trifluoromethyl)-1*H*-benzimidazol-2-yl]-1*a*,6*b*-dihydro-1*H*-cyclopropa[*b*][1]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1*H*)-one

lifirafénib

5-(((1*R*,1*aS*,6*bR*)-1-[5-(trifluorométhyl)-1*H*-benzimidazol-2-yl]-1*a*,6*b*-dihydro-1*H*-cyclopropa[*b*][1]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1*H*)-one

lifirafenib

5-(((1*R*,1*aS*,6*bR*)-1-[5-(trifluorometil)-1*H*-benzimidazol-2-il]-1*a*,6*b*-dihidro-1*H*-ciclopropa[*b*][1]benzofuran-5-il)oxi)-3,4-dihidro-1,8-naftiridin-2(1*H*)-ona

$$\text{C}_{25}\text{H}_{17}\text{F}_3\text{N}_4\text{O}_3$$
**lonapegsomatropinum #**

lonapegsomatropin

human somatotropin (growth hormone, GH) produced in *Escherichia coli*, conjugated to a multi-arm polyethylene glycol carrier molecule;

somatotropin (human), produced by *Escherichia coli*, $N^{6\text{-Lys}}$ -substituted with one (((1*RS*)-5-[bis(6-(((3*RS*)-1-{3-[(2*RS*)-2,3-bis[ω-methoxypoly(oxyethylene)_n-α-yl]propoxy}propyl)amino]-3-oxopropyl)-2,5-dioxopyrrolidin-3-yl)sulfanyl)hexyl)amino]-1-[4-(((3-(dimethylamino)propyl)(methyl)carbamoyl)oxy)phenyl]-5-oxopentyl)oxy)carbonyl group

lonapegsomatropine

somatotropine humaine (hormone de croissance, GH) produite par *Escherichia coli*, conjuguée à une molécule transporteur multi-bras de polyéthylène glycol;

somatotropine (humaine), produite par *Escherichia coli*, substituée en $N^{6\text{-Lys}}$ par un groupe (((1*RS*)-5-[bis(6-(((3*RS*)-1-{3-[(2*RS*)-2,3-bis[ω-méthoxypoly(oxyéthylène)_n-α-yl]propoxy}propyl)amino]-3-oxopropyl)-2,5-dioxopyrrolidin-3-yl)sulfanyl)hexyl)amino]-1-[4-(((3-(diméthylamino)propyl)(méthyl)carbamoyl)oxy)phényl]-5-oxopentyl)oxy)carbonyle

lonapegsomatropina

somatotropina humana (hormona de crecimiento, GH) producida por *Escherichia coli*, conjugada a una molécula transportadora multi-bras de polietileno glicol;

somatotropina (humana), producida por *Escherichia coli*, sustituida en $N^{6\text{-Lys}}$ por un grupo (((1*RS*)-5-[bis(6-(((3*RS*)-1-{3-[(2*RS*)-2,3-bis[ω-metoxipoli(oxietileno)_n-α-il]propoxi}propil)amino]-3-oxopropil)-2,5-dioxopirrolidin-3-il)sulfanil)hexil)amino]-1-[4-(((3-(dimetilamino)propil)(metil)carbamoiil)oxi)fenil]-5-oxopentil)oxi)carbonilo

Sequence / Séquence / Secuencia

FTPTPLSRFL	DNAMLRRAHL	HQLAFDITYQE	FEEAYIPKEQ	KYSFLQNPQT	50
SLCFSESIPV	PSNREETQOK	SNLELLRISL	LIQSWLEPQ	QFRLSVFANS	100
LVYGASDSNV	YDLLKDLLEEG	LQTLMGRLSD	QSPRTGQIFK	QRTYSKFDTNS	150
HNDADLLKNY	GLIYCFKFKDM	DQVTEFLRTV	QCRSPVSGSG	F	191


Disulfide bridges location / Position des ponts disulfure / Posición de los puentes disulfuro
53-165 182-189

Potential modified residues / Résidus modifiés potentiels / Restos modificados potenciales

158 (~50%)

K 38.70.140.145 (~10% each)

41,168,172 (<5% each)



loncastuximabum

loncastuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD19 (B lymphocyte surface antigen B4, Leu-12)], chimeric monoclonal antibody;
gamma1 heavy chain (1-449) [*Mus musculus* VH (IGHV1-69*02 (85.70%) - (IGHD) -IGHJ4*01 [8.8.13] (1-120) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), hinge (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-211')-disulfide with kappa light chain (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70*01 (91.40%) -IGKJ1*01 [5.3.7] (1'-104') -*Homo sapiens* IGKC*01, Km3 A45.1 (150), V101 (188) (105'-211'))]; dimer (229-229':232-232')-bisdisulfide

loncastuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CD19 (antigène de surface B4 des lymphocytes B, Leu-12)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-449) [*Mus musculus* VH (IGHV1-69*02 (85.70%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), charnière (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-211')-disulfure avec la chaîne légère kappa (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70*01 (91.40%) -IGKJ1*01) [5.3.7] (1'-104') -*Homo sapiens* IGKC*01, Km3 A45.1 (150), V101 (188) (105'-211')]; dimère (229-229':232-232')-bisdisulfure

loncastuximab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD19
 (antígeno de superficie B4 de los linfocitos B, Leu-12)],
 anticuerpo monoclonal quimérico;
 cadena pesada gamma1 (1-449) [*Mus musculus* VH (IGHV1-
 69*02 (85.70%) -IGHD) -IGHJ4*01] [8.8.13] (1-120) -*Homo*
sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K
 (217) (121-218), bisagra (219-233), CH2 (234-343), CH3 E12
 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)],
 (223-211')-disulfuro con la cadena ligera kappa (1'-211') [*Mus*
musculus V-KAPPA (IGKV4-70*01 (91.40%) -IGKJ1*01)
 [5.3.7] (1'-104') -*Homo sapiens* IGKC*01, Km3 A45.1 (150),
 V101 (188) (105'-211')]; dímero (229-229':232-232')-
 bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQPGAE VVKPGASVKL SCTSGYFTT SNMHWVKQA PGQGLEWIGE 50
 IDPSDSYTNV NQNFQGKAKL TVDKSTSTAY MEVSSLSRSD TAVVYTCARG 100
 NPYYYAMDYV GQGTSTVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
 DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
 YICNVNHKPS NTKVDKKVEP KSCDKHTCTP PCPAPELLGG PSVFLFPPKP 250
 KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
 STYRVVSVLT VTHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
 VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTTPPV 400
 LDSGDSGFFLY SKLTVDKSRW QQGNVFCV MHEALHNHYT QKSLSLSPG 449

Light chain / Chaîne légère / Cadena ligera

EIVLTQSPAI MSASPGERV MTCSASSGVN YMHVYQQKPG TSPRRWIYDT 50
 SKLASGVPAF FSGSGSGTSY SLTISSMEPE DAATYYCHQR GSYTFGGGTK 100
 LEIKRTVAAP SVFIFPPSDE QLKSGTASVV CLLNFPYPRE AKVQWKVDNA 150
 LQSGNSQESV TEQDSKDSY SLSSTLTLSK ADYKHKVYA CEVTHQGLSS 200
 PVTKSFNRRGE C 211

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 147-203 264-324 370-428
 22"-96" 147"-203" 264"-324" 370"-428"

Intra-L (C23-C104) 23'-87' 131'-191'
 23"'-87'" 131"'-191'"

Inter-H-L (h 5-CL 126) 223-211' 223"-211"

Inter-H-H (h 11, h 14) 229-229" 232-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

300, 300"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados

loncastuximabum tesirinum #

loncastuximab tesirine

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD19 (B lymphocyte surface antigen B4, Leu-12)], chimeric monoclonal antibody conjugated to the pyrrolobenzodiazepine (PBD) dimer SCX; gamma1 heavy chain (1-449) [*Mus musculus* VH (IGHV1-69*02 (85.70%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) - *Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), hinge (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-211')-disulfide with kappa light chain (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70*01 (91.40%) - IGKJ1*01) [5.3.7] (1'-104') - *Homo sapiens* IGKC*01, Km3 A45.1 (150), V101 (188) (105'-211'))]; dimer (229-229":232-232")-bisdisulfide; conjugated, on an average of 2 cysteines, to the pyrrolobenzodiazepine (PBD) dimer SCX, via a cleavable (valine-alanine dipeptide as cathepsin B cleavage site) maleimide type linker containing a spacer PEG (n=8)

For the *tesirine* part, please refer to the prop. INN List 113, published in the *WHO Drug Information*, Vol. 29, No. 2, 2015.

loncastuximab tésirine

immunoglobuline G1-kappa, anti-[*Homo sapiens* CD19 (antigène de surface B4 des lymphocytes B, Leu-12)], anticorps monoclonal chimérique conjugué au dimère de pyrrolobenzodiazépine (PBD) SCX; chaîne lourde gamma1 (1-449) [*Mus musculus* VH (IGHV1-69*02 (85.70%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) - *Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), charnière (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-211')-disulfure avec la

loncastuximab tesirina

chaîne légère kappa (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70*01 (91.40%) -IGKJ1*01) [5.3.7] (1'-104') -*Homo sapiens* IGKC*01, Km3(105'-211')]; dimère (229-229":232-232")-bisdisulfure; conjugué, sur 2 cystéines en moyenne, au dimère de pyrrolobenzodiazépine (PBD) SCX, via un linker clivable (dipeptide valine-alanine clivable par la cathepsine B) de type maléimide et comprenant un espaceur PEG (n=8)
Pour la partie *tesirina*, veuillez-vous référer à la Liste 113 des DCI prop, publiée dans le *WHO Drug Information*, Vol.29, No.2, 2015.

immunoglobulina G1-kappa, anti-[*Homo sapiens* CD19 (antígeno de superficie B4 de los linfocitos B, Leu-12)], anticuerpo monoclonal quimérico conjugado con el dímero de pirrolobenzodiazepina (PDB) SCX;
cadena pesada gamma1 (1-449) [*Mus musculus* VH (IGHV1-69*02 (85.70%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), bisagra (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-211')-disulfuro con la cadena ligera kappa (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70*01 (91.40%) -IGKJ1*01) [5.3.7] (1'-104') -*Homo sapiens* IGKC*01, Km3(105'-211')]; dímero (229-229":232-232")-bisdisulfuro; conjugado, en una media de 2 cisteinil, con el dímero de pirrolobenzodiazepina (PBD) SCX, mediante un conector escindible (dipéptido valina-alanina escindible por la catepsina B) de tipo maleimida y comprende un espaciador PEG (n=8)

Para la fracción *tesirina* se puede referir a la Lista 113 de DCI prop., publicada en el *WHO Drug Information*, Vol.29, No.2, 2015.

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQPGAE VVKPGASVKL SCKTSGYTFT SNMHWVKQA PGQGLEWIGE 50
IDPSDSTNY NQNFQGGKAKL TVDKSTSTAY MEVSSLRSD TAVYYCARGS 100
NPYYAMDMY GQGTSTVTSS ASTKGPVSFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVT VPSSSLGTQT 200
YICNVNHHKS NTKVDKKVEP KSCDKHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTF EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTTPV 400
LSDSGSFFLY SKLTVDKSRW QQGNVFSQSV MHEALHNHYT QKSLSLSPG 449

Light chain / Chaîne légère / Cadena ligera

EIVLTQSPAI MSASPGERV MTCSASSGVN YMHWYQQKPG TSPRRWIYDT 50
SKLASGVPAR FSGSGGTSY SLTISSMEPE DAATYYCHQR GSYTFGGGTK 100
LEIKRTVAAP SVFIPPSDE QLKSGTASVV CLLNFPYRE AKVQWKVDNA 150
LQSGNSQESV TEQDSKDSY SLSTLTLSK ADYERKHKVYA CEVTHQGLSS 200
PVTKSFNRGE C 211

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 147-203 264-324 370-428
22"-96" 147"-203" 264"-324" 370"-428"

Intra-L (C23-C104) 23'-87' 131"-191"
23"-87" 131"-191"

Inter-H-L (h 5-CL 126) * 223-211' 223"-211"
Inter-H-H (h 11, h 14) 229-229" 232-232"

*One or two of the inter-chain disulfide bridges are not present, an average of 2 cysteinyl being conjugated each via a thioether bond to a drug linker.

*Un ou deux des ponts disulfures inter-chaînes ne sont pas présents, 2 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.

*Faltan dos o tres puentes disulfuro inter-catenarios, una media de 2 cisteinil conjugados con sendos enlaces tioéter, a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

300, 300"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

lumasiranum

lumasiran

{(2*S*,4*R*)-1-{1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis-[(3-{3-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy)methyl}-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl)-4-hydroxypyrrolidin-2-yl)methyl hydrogen *all-P-ambo*-2'-O-methyl-*P*-thioguanlyl-(3'→5')-2'-O-methyl-*P*-thioadenyl-(3'→5')-2'-O-methylcytidyl-(3'→5')-2'-O-methyluridyl-(3'→5')-2'-O-methyluridyl-(3'→5')-2'-O-methyluridyl-(3'→5')-2'-O-methyluridyl-(3'→5')-2'-deoxy-2'-fluorocytidyl-(3'→5')-2'-O-methyladenyl-(3'→5')-2'-deoxy-2'-fluorouridyl-(3'→5')-2'-deoxy-2'-fluorocytidyl-(3'→5')-2'-deoxy-2'-fluorocytidyl-(3'→5')-2'-O-methyluridyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyladenyl-(3'→5')-2'-O-methyladenyl-(3'→5')-2'-O-methyluridyl-(3'→5')-2'-O-methyladenyl-(3'→5')-2'-O-methyluridyl-(3'→5')-2'-O-methyl-3'-adenylate duplex with *all-P-ambo*-2'-O-methyl-*P*-thioadenyl-(5'→3')-2'-O-methyl-*P*-thiocytidyl-(5'→3')-2'-O-methylcytidyl-(5'→3')-2'-O-methyluridyl-(5'→3')-2'-O-methylguanylyl-(5'→3')-2'-O-methyladenyl-(5'→3')-2'-O-methyladenyl-(5'→3')-2'-deoxy-2'-fluoroadenyl-(5'→3')-2'-O-methylguanylyl-(5'→3')-2'-deoxy-2'-fluorouridyl-(5'→3')-2'-O-methyladenyl-(5'→3')-2'-O-methylguanylyl-(5'→3')-2'-O-methylguanylyl-(5'→3')-2'-O-methyladenyl-(5'→3')-2'-deoxy-2'-fluorocytidyl-(5'→3')-2'-deoxy-2'-fluorocytidyl-(5'→3')-2'-O-methyluridyl-(5'→3')-2'-deoxy-2'-fluorouridyl-(5'→3')-2'-O-methyluridyl-(5'→3')-2'-O-methyladenyl-(5'→3')-2'-O-methyl-*P*-thiouridyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thioadenyl-(5'→3')-2'-O-methyluridine

lumasiran

hydrogène-*tout-P-ambo*-2'-O-méthyl-*P*-thioguanlyl-(3'→5')-2'-O-méthyl-*P*-thioadényl-(3'→5')-2'-O-méthylcytidyl-(3'→5')-2'-O-méthyluridyl-(3'→5')-2'-O-méthyluridyl-(3'→5')-2'-O-méthyluridyl-(3'→5')-2'-O-méthyluridyl-(3'→5')-2'-désoxy-2'-fluorocytidyl-(3'→5')-2'-O-méthyladényl-(3'→5')-2'-désoxy-2'-fluorouridyl-(3'→5')-2'-désoxy-2'-fluorocytidyl-(3'→5')-2'-désoxy-2'-fluorocytidyl-(3'→5')-2'-O-méthyluridyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-méthyladényl-(3'→5')-2'-O-méthyladényl-(3'→5')-2'-O-méthyluridyl-(3'→5')-2'-O-méthyladényl-(3'→5')-2'-O-méthyluridyl-(3'→5')-2'-O-méthyl-3'-adénylate de {(2*S*,4*R*)-1-{1-[(2-acétamido-2-désoxy-β-D-galactopyranosyl)oxy]-16,16-bis-[(3-{3-[(2-acétamido-2-désoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy)méthyl}-6,10,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl)-4-hydroxypyrrolidin-2-yl)méthyle duplex avec *tout-P-ambo*-2'-O-méthyl-*P*-thioadényl-(5'→3')-2'-O-méthyl-*P*-thiocytidyl-(5'→3')-2'-O-méthylcytidyl-(5'→3')-2'-O-méthyluridyl-(5'→3')-2'-O-méthylguanylyl-(5'→3')-2'-O-méthyladényl-(5'→3')-2'-O-méthyladényl-(5'→3')-2'-désoxy-2'-fluoroadényl-(5'→3')-2'-O-méthylguanylyl-(5'→3')-2'-désoxy-2'-fluorouridyl-(5'→3')-2'-O-méthyladényl-(5'→3')-2'-O-méthylguanylyl-(5'→3')-2'-O-méthylguanylyl-(5'→3')-2'-O-méthyladényl-(5'→3')-2'-désoxy-2'-fluorocytidyl-(5'→3')-2'-désoxy-2'-fluorocytidyl-(5'→3')-2'-O-méthyluridyl-(5'→3')-2'-désoxy-2'-fluorouridyl-(5'→3')-2'-O-méthyluridyl-(5'→3')-2'-O-méthyladényl-(5'→3')-2'-O-méthyl-*P*-thiouridyl-(5'→3')-2'-désoxy-2'-fluoro-*P*-thioadényl-(5'→3')-2'-O-méthyluridine


lumasirán

hidrógeno-*todo-P-ambo*-2'-*O*-metil-*P*-tioguanilil-(3'→5')-2'-*O*-metil-*P*-tioadenilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metil-3'-adenilato de {(2*S*,4*R*)-1-{[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]-16,16-bis-[(3-{3-{[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]pentanamido)propil]amino}-3-oxopropoxi]metil)-6,10,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-ol]-4-hidroxipirrolidin-2-il}metilo dúplex con *todo-P-ambo*-2'-*O*-metil-*P*-tioadenilil-(5'→3')-2'-*O*-metil-*P*-tiocitidilil-(5'→3')-2'-*O*-metilcitidilil-(5'→3')-2'-*O*-metiluridilil-(5'→3')-2'-*O*-metilguanilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-*O*-metilguanilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-*O*-metilguanilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-2'-*O*-metiluridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-*O*-metiluridilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-*O*-metil-*P*-tiouridilil-(5'→3')-2'-desoxi-2'-fluoro-*P*-tioadenilil-(5'→3')-2'-*O*-metiluridina

C₅₃₀H₇₁₂F₁₀N₁₇₃O₃₂₀P₄₃S₆

(3'→5')G = A = C - U - U - C - A - U - C - U - G - G - A - A - U - A - U - A - (R1)
(5'→3')A = C - U - G - A - A - G - U - A - G - A - C - U - U - U - A - U = A = U

X : 2'-deoxy-2'-fluoro-X / X̄ : 2'-desoxy-2'-fluoro-X
X : 2'-*O*-methyl-X / X̄ : 2'-*O*-méthyl-X



mardepodectum

mardepodect


2-({4-[1-methyl-4-(pyridin-4-yl)-1*H*-pyrazol-3-yl]phenoxy)methyl}quinoline

mardépodect

2-({4-[1-méthyl-4-(pyridin-4-yl)-1*H*-pyrazol-3-yl]phénoxy)méthyl}quinoléine

mardepodect

2-({4-[1-metil-4-(piridin-4-il)-1*H*-pirazol-3-il]fenoxi}metil}quinoleína

**milademetanum**

milademetan



(3*R*,4*S*,5*R*)-*N*-[(3*R*,6*S*)-6-carbamoyloxan-3-yl]-6"-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2"-oxo-1",2"-dihydrodispiro[cyclohexane-1,2'-pyrrolidine-3',3"-indole]-5'-carboxamide

miladémétan

(3*R*,4*S*,5*R*)-*N*-[(3*R*,6*S*)-6-carbamoyloxan-3-yl]-6"-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-4,4-diméthyl-2"-oxo-1",2"-dihydrodispiro[cyclohexane-1,2'-pyrrolidine-3',3"-indole]-5'-carboxamide

milademetán

(3*R*,4*S*,5*R*)-*N*-[(3*R*,6*S*)-6-carbamoyloxan-3-il]-6"-cloro-4'-(2-cloro-3-fluoropiridin-4-il)-4,4-dimetil-2"-oxo-1",2"-dihidrodispiro[ciclohexano-1,2'-pirrolidina-3',3"-indol]-5'-carboxamida

**minesapridum**

minesapride



4-amino-5-chloro-*N*-{[(2*S*)-4-{[1-(hydroxyacetyl)piperidin-4-yl]methyl}morpholin-2-yl]methyl}-2-methoxybenzamide

minésapride

4-amino-5-chloro-*N*-{[(2*S*)-4-{[1-(hydroxyacétyl)pipéridin-4-yl]méthyl}morpholin-2-yl]méthyl}-2-méthoxybenzamide

minesaprida

4-amino-5-cloro-*N*-{[(2*S*)-4-{[1-(hidroxiacetil)piperidin-4-il]metil}morfolin-2-il]metil}-2-metoxibenzamida



miralimogenum ensolisbacum #
miralimogene ensolisbac

Recombinant live-attenuated double-deleted (LADD) strain of *Listeria monocytogenes* (*Lm ΔactA/ΔinlB*) expressing a fusion protein comprising the N-terminal 100 amino acids of the *Lm* ActA protein (ActAN100) and amino acids 35-622 of human mesothelin (MSLN) protein, under the control of the *Lm actA* (actin-assembly inducing protein precursor) promoter, and contained within an expression cassette of 2306 bp inserted at the *Lm inlB* (internalin B) locus

miralimogène ensolisbac

souche vivante atténuée recombinante de *Listeria monocytogenes* (*Lm ΔactA/ΔinlB*) avec double deletion, exprimant une protéine de fusion qui consiste en les 100 acides aminés à l'extrémité N-terminale de la protéine *Lm* ActA (ActAN100) et les acides aminés 35-622 de la mésothéline humaine (MSLN), sous le contrôle du promoteur de *Lm actA* (précurseur de la protéine induisant l'assemblage de l'actine), et contenu dans une cassette d'expression de 2306 paires de bases insérée sur le locus de *Lm inlB* (internaline B).

miralimogén ensolisbac

Cepa viva atenuada recombinante, con doble delección, de *Listeria monocytogenes* (*Lm ΔactA/ΔinlB*) que expresa una proteína de fusión consistente en los 100 amino ácidos N-terminales de la proteína *Lm* ActA (ActAN100) y los amino ácidos 35-622 de la mesotelina humana (MSLN), bajo el control del promotor de *Lm actA* (precursor de la proteína inductora del ensamblaje de la actina), y contenido dentro de un casete de expresión de 2306 pares de bases insertado en el locus de *Lm inlB* (internalina B).

mirikizumabum #
mirikizumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* IL23A (interleukin 23 subunit alpha, IL-23A, IL-23 subunit p19, IL23p19)], humanized monoclonal antibody; gamma4 heavy chain (1-441) [humanized VH (*Homo sapiens* IGHV1-2*02 (82.70%) -(IGHD) -IGHJ6*01) [8.8.8] (1-115) -*Homo sapiens* IGHG4*01 (CH1 (116-213), hinge S10>P (223) (214-225), CH2 F1.3>A (229), L1.2>A (230) (226-335), CH3 (336-440), CHS K>del (441)) (116-441)], (129-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (85.30%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (221-221'::224-224')-bisdisulfide

mirikizumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* IL23A (interleukine 23 sous-unité alpha, IL-23A, IL-23 sous-unité p19, IL23p19)], anticorps monoclonal humanisé;

mirikizumab

chaîne lourde gamma4 (1-441) [VH humanisé (*Homo sapiens*IGHV1-2*02 (82.70%) -(IGHD) -IGHJ6*01) [8.8.8] (1-115) -*Homo sapiens*IGHG4*01 (CH1 (116-213), charnière S10>P (223) (214-225), CH2 F1.3>A (229), L1.2>A (230) (226-335), CH3 (336-440), CHS K>del (441)) (116-441)], (129-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens*IGKV1-39*01 (85.30%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (221-221":224-224")-bisdisulfure

inmunoglobulina G4-kappa, anti-[*Homo sapiens* IL23A (interleukina 23 subunidad alfa, IL-23A, IL-23 subunidad p19, IL23p19)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-441) [VH humanizado (*Homo sapiens*IGHV1-2*02 (82.70%) -(IGHD) -IGHJ6*01) [8.8.8] (1-115) -*Homo sapiens*IGHG4*01 (CH1 (116-213), bisagra S10>P (223) (214-225), CH2 F1.3>A (229), L1.2>A (230) (226-335), CH3 (336-440), CHS K>del (441)) (116-441)], (129-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens*IGKV1-39*01 (85.30%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (221-221":224-224")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCRASGYKFT RYVMHWVRQA PGQGLEWMGY 50
INPYNDGTNY NEKFKGRVTI TADKSTSTAY MELSSLSRSED TAVYYCARNW 100
DTGLWGQGT TTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVTVTPSSS LGTKTYTCNV 200
DHKPSNTKVD KRVESKYGPP CPPCPAPEAA GGPSVFLFPP KPKDTLMISR 250
TPEVTICVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTYRVVSV 300
LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGPPE PQVYTLPPSQ 350
EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTT PVLDSGDSFF 400
LYSRLTVDKS RWQEGNVFSC SVMHEALHNH YTKSLSLSL G 441
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVIT TCKASDHIL KFLTWYQQKP GKAPKLLIYG 50
ATSLETGVPS RFGSGSGSTD FTLTISSLQP EDFATYYCQM YWSTPFTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSLSLT LSKADYEKKH VYACEVTHQG 200
LSSPVTKSFN RGECC 214
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 142-198 256-316 362-420
22"-96" 142"-198" 256"-316" 362"-420"

Intra-L (C23-C104) 23'-88" 134'-194"
23'''-88''' 134'''-194'''

Inter-H-L (h 5-CL 126) 129-214' 129"-214'"

Inter-H-H (h 11, h 14) 221-221" 224-224"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4;

292, 292"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados

mosunetuzumabum #
mosunetuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD3E (CD3 epsilon) and *Homo sapiens* MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20)], humanized monoclonal antibody, bispecific;

	gamma1 heavy chain anti-CD3E (1-449) [humanized VH (<i>Homo sapiens</i> IGHV1-3*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -<i>Homo sapiens</i> IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (216) (120-217), hinge (218-232), CH2 N84.4>G (299) (233-342), CH3 E12 (358), M14 (360), T22>S (368) / L24>A (370) / Y86>V (409) (hole) (343-447), CHS (448-449)) (120-449)], (222-219')-disulfide with kappa light chain anti-CD3E (1'-219') [humanized V-KAPPA (<i>Homo sapiens</i> IGKV4-1*01 (91.80%) -IGKJ1*01) [12.3.8] (1'-112') -<i>Homo sapiens</i> IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; gamma1 heavy chain anti-MS4A1 (1-452) [humanized VH (<i>Homo sapiens</i> IGHV3-23*04 (81.60%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -<i>Homo sapiens</i> IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (219) (123-220), hinge (221-235), CH2 N84.4>G (302) (236-345), CH3 E12 (361), M14 (363), T22>W (371) (knob) (346-450), CHS (451-452)) (123-452)], (225-213')-disulfide with kappa light chain anti-MS4A1 (1'-213') [humanized V-KAPPA (<i>Homo sapiens</i> IGKV1-39*01 (86.50%) -IGKJ1*01) [5.3.9] (1'-106') -<i>Homo sapiens</i> IGKC*01, Km3 A45.1 (152), V101 (190) (107'-213')]; dimer (228-231":231-234")-bisdisulfide
mosunétuzumab	immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> CD3E (CD3 epsilon) et <i>Homo sapiens</i> MS4A1 (membre 1 de la sous-famille A à 4 domaines transmembranaires, CD20)], anticorps monoclonal humanisé, bispécifique; chaîne lourde gamma1 anti-CD3E (1-449) [VH humanisé (<i>Homo sapiens</i> IGHV1-3*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -<i>Homo sapiens</i> IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (216) (120-217), charnière (218-232), CH2 N84.4>G (299) (233-342), CH3 E12 (358), M14 (360), T22>S (368) / L24>A (370) / Y86>V (409) (hole) (343-447), CHS (448-449)) (120-449)], (222-219')-disulfure avec la chaîne légère kappa anti-CD3E (1'-219') [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV4-1*01 (91.80%) -IGKJ1*01) [12.3.8] (1'-112') -<i>Homo sapiens</i> IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; chaîne lourde gamma1 anti-MS4A1 (1-452) [VH humanisé (<i>Homo sapiens</i> IGHV3-23*04 (81.60%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -<i>Homo sapiens</i> IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (219) (123-220), charnière (221-235), CH2 N84.4>G (302) (236-345), CH3 E12 (361), M14 (363), T22>W (371) (knob) (346-450), CHS (451-452)) (123-452)], (225-213')-disulfure avec la chaîne légère kappa anti-MS4A1 (1'-213') [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV1-39*01 (86.50%) -IGKJ1*01) [5.3.9] (1'-106') -<i>Homo sapiens</i> IGKC*01, Km3 A45.1 (152), V101 (190) (107'-213')]; dimère (228-231":231-234")-bisdisulfure
mosunetuzumab	inmunoglobulina G1-kappa, anti-[<i>Homo sapiens</i> CD3E (CD3 epsilon) y <i>Homo sapiens</i> MS4A1 (miembro 1 de la subfamilia A con 4 dominios transmembranarios, CD20)], anticuerpo monoclonal humanizado, biespecífico;

cadena pesada gamma1 anti-CD3E (1-449) [VH humanizado (*Homo sapiens* IGHV1-3*01 (82.70%) - (IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (216) (120-217), bisagra (218-232), CH2 N84.4>G (299) (233-342), CH3 E12 (358), M14 (360), T22>S (368) / L24>A (370) / Y86>V (409) (hole) (343-447), CHS (448-449)) (120-449)], (222-219')-disulfuro con la cadena ligera kappa anti-CD3E (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV4-1*01 (91.80%) -IGKJ1*01) [12.3.8] (1'-112') -*Homo sapiens* IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')];

cadena pesada gamma1 anti-MS4A1 (1-452) [VH humanizado (*Homo sapiens* IGHV3-23*04 (81.60%) - (IGHD) -IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (219) (123-220), bisagra (221-235), CH2 N84.4>G (302) (236-345), CH3 E12 (361), M14 (363), T22>W (371) (knob) (346-450), CHS (451-452)) (123-452)], (225-213')-disulfuro con la cadena ligera kappa anti-MS4A1 (1'-213') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (86.50%) -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 A45.1 (152), V101 (190) (107'-213')]; dímero (228-231":231-234")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada (anti-CD3E)

```
EVQLVQSGAE VKKPGASVKV SCKASGYTFT NYIHWVRQA PGQGLEWIGW 50
IYPGNGDNTKY NEKFKGRATL TADTSTSTAY LELSSLSRSED TAVYYCARDS 100
YSNYYFDYWG QGTLVTSSA STKGPSVFPFL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAPLQSSG LYSLSVTVV PSSSLGTQTY 200
ICNVNHHKPSN TKVDKKVEPK SCDKHTCTPP CPAPELLGSP SVFLFPPKPK 250
DTLMISRTPE VTCVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYGS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIETISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLSCA VKGFYPSDIA VEWESNGQPE NNYKTTFPVL 400
DSGGSFFLVS KLTVDKSRWQ QGNVFSQVM HEALHNYTQ KSLSLSPGK 449
```

Light chain / Chaîne légère / Cadena ligera (anti-CD3E)

```
DIVMTQSPDS LAVSLGERAT INCKSSQSLN NSRTRKNYLA WYQKPKGQPP 50
KLLIYWASTR ESGVPDRFSG SGSGLDFTLT ISSLQAEDVA VYCTQSFIL 100
RTFGQGTQVE IKRTVAAPSV FIFPPSDEQL KSGTASVVLCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKSTSYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC 219
```

Heavy chain / Chaîne lourde / Cadena pesada (anti-MS4A1)

```
EVQLVESGGG LVQPGGSLRL SCAASGYTFT SYNHWVRQA PGKGLEWVGA 50
IYPGNGDTSY NQKFKGRFTI SVDKSKNTLY LQMNSLRAED TAVYYCARVV 100
YYSNSYWFYD VWGQGLTVTV SSASTKGPSV FFLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYLSLSS VTPVSSSLGT 200
QTYICNVNHH PSNTKVDKVK EPKSCDKTHT CPCCPAPELL GGPSVFLFPP 250
KPKDITLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YGSTYRVVSV LTVLHQDWLN GKEYCKVSN KALPAPIETK ISKAKGQPRE 350
PQVYTLPPSR EEMTKNQVSL WCLVKGFYPS DIAVEWESNG QPENNYKTTT 400
PVLDSGDSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNN YTKSLSLSP 450
GK 452
```

Light chain / Chaîne légère / Cadena ligera (anti-MS4A1)

```
DIQMTQSPSS LSASVGRVIT ITCRASSSVS YMHYQKPG KAPKPLIYAP 50
SNLQSGVPSR FSGSGSGTDF TLTISLQPE DFATYYCQW SFNPPTFGQG 100
TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTLL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNH GEC 213
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 149'-205" 266"-326" 372"-430"

Intra-L (C23-C104) 23'-94' 139'-199"

23"-87" 133"-193"

Inter-H-L (h 5-CL 126) 222-219' 225"-213"

Inter-H-H (h 11, h 14) 228-231" 231-234"

nadofaragenum firadenovecum #

nadofaragene firadenovec

Replication-deficient adenovirus type 5 (Ad5) vector encoding the human interferon alpha 2 (IFNA2, interferon alpha-2b) gene under the control of the cytomegalovirus (CMV) immediate-early enhancer/promoter.

nadofaragène firadénovec

vecteur adénoviral de type 5 (Ad5) à la réplication déficiente, codant pour le gène de l'interféron alpha 2 (IFNA2, interféron alpha-2b) humain sous le contrôle de l'activateur/promoteur immédiat-précoce du cytomégalovirus (CMV).

nadofaragén firadenovec

Vector de Adenovirus tipo 5 (Ad5) deficiente de replicación, que codifica para el gen del interferón alfa 2 humano (IFNA2, inteferón alfa-2b) bajo el control del promotor/*enhancer* inmediato-temprano del citomegalovirus (CMV).

namodenosonum

namodenoson


1-(2-chloro-6-[[[(3-iodophenyl)methyl]amino]-9*H*-purin-9-yl]-1-deoxy-*N*-methyl-β-D-ribofuranuronamide

namodénoson

1-(2-chloro-6-[[[(3-iodophényl)methyl]amino]-9*H*-purin-9-yl]-1-désoxy-*N*-méthyl-β-D-ribofuranuronamide

namodenosón

1-(2-cloro-6-[[[(3-iodofenil)metil]amino]-9*H*-purin-9-il]-1-desoxi-*N*-metil-β-D-ribofuranuronamida

$$\text{C}_{18}\text{H}_{18}\text{ClIN}_6\text{O}_4$$
**nangibotidum**

nangibotide

human trem-like transcript 1 protein (TLT-1, triggering receptor expressed on myeloid cells-like protein 1) (79-90)-peptide 12-amide:

L-leucyl-L-glutaminy-L-α-glutamyl-L-α-glutamyl-L-α-aspartyl-L-alanylglycyl-L-α-glutamyl-L-tyrosylglycyl-L-cysteinyl-L-methioninamide

nangibotide

protéine transcrit 1 semblable au trem humaine (TLT-1, protéine 1 semblable au récepteur déclenchant exprimé par les cellules myéloïdes) (79-90)-peptide 12-amide: L-leucyl-L-glutaminy-L-α-glutamyl-L-α-glutamyl-L-α-aspartyl-L-alanylglycyl-L-α-glutamyl-L-tyrosylglycyl-L-cystéinyl-L-méthioninamide

nangibotida

proteína transcrito 1 parecido al trem humano (TLT-1, proteína 1 parecida al receptor desencadenante expresado por las células mieloides) (79-90)-péptido 12-amida:

L-leucil-L-glutaminil-L- α -glutamyl-L- α -glutamyl-L- α -aspartil-
L-alanilglycil-L- α -glutamyl-L-tirosilglycil-L-cisteinil-
L-metioninamida

$$\text{C}_{54}\text{H}_{82}\text{N}_{14}\text{O}_{22}\text{S}_2$$

H-Leu-Gln-Glu-Glu-Asp-Ala-Gly-Glu-Tyr-Gly-Cys-Met-NH₂
12

olinciguatum

olinciguat


(2*R*)-3,3,3-trifluoro-2-[[[(5-fluoro-2-{1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)-1*H*-pyrazol-3-yl]pyrimidin-4-yl)amino]methyl]-2-hydroxypropanamide

olinciguat

(2*R*)-3,3,3-trifluoro-2-[[[(5-fluoro-2-{1-[(2-fluorophényl)méthyl]-5-(1,2-oxazol-3-yl)-1*H*-pyrazol-3-yl]pyrimidin-4-yl)amino]méthyl]-2-hydroxypropanamide

olinciguat

(2*R*)-3,3,3-trifluoro-2-[[[(5-fluoro-2-{1-[(2-fluorofenil)metil]-5-(1,2-oxazol-3-il)-1*H*-pirazol-3-il]pirimidin-4-il)amino]metil]-2-hidroxiopropanamida

$$\text{C}_{21}\text{H}_{16}\text{F}_5\text{N}_7\text{O}_3$$


olorofimum

olorofim


2-(1,5-dimethyl-3-phenyl-1*H*-pyrrol-2-yl)-*N*-{4-[4-(5-fluoropyrimidin-2-yl)piperazin-1-yl]phenyl}-2-oxoacetamide

olorofim

2-(1,5-diméthyl-3-phényl-1*H*-pyrrol-2-yl)-*N*-{4-[4-(5-fluoropyrimidin-2-yl)pipérazin-1-yl]phényl}-2-oxoacétamide

olorofim

2-(1,5-dimetil-3-fenil-1*H*-pirrol-2-il)-*N*-{4-[4-(5-fluoropirimidin-2-il)piperazin-1-il]fenil}-2-oxoacetamida

$$\text{C}_{28}\text{H}_{27}\text{FN}_6\text{O}_2$$


omberacetamum

omberacetam


ethyl 1-phenylacetyl-L-prolylglycinate

ombéracétam

1-phénylacétyl-L-prolylglycinate d'éthyle

omberacetam

1-fenilacetil-L-prolilglicinato de etilo

 $C_{17}H_{22}N_2O_4$ **onasemnogenum abeparvovecum #**

onasemnogene abeparvovec

Non-replicating recombinant self-complementary (sc) adeno-associated viral serotype 9 (AAV9) vector containing the cDNA of the survival of motor neuron 2 (SMN2) gene under the control of the hybrid cytomegalovirus (CMV) enhancer/chicken beta-actin promoter (CBA).

onasemnogène abéparvovec

vecteur viral adéno-associé recombinant de sérotype 9 (rAAV9) non-répliquant et auto-complémentaire, contenant l'ADNc du gène de survie des motoneurones 2 (SMN2) sous le contrôle de l'hybride de l'activateur du cytomégalovirus (CMV) et du promoteur de l'actine bêta du poulet (ABP, CBA).

onasemnogén abeparvovec

vector del virus adeno-asociado de serotipo 9 (AAV9) recombinante, no replicativo y auto complementario, que contiene el cDNA del gen de la supervivencia de neuronas motoras 2 (SMN2) bajo el control del híbrido del *enhancer* de citomegalovirus (CMV) y el promotor de la beta-actina de pollo (CBA).

opaganibum

opaganib


3-(4-chlorophenyl)-N-[(pyridin-4-yl)methyl]adamantane-1-carboxamide

opaganib

3-(4-chlorophényl)-N-[(pyridin-4-yl)méthyl]adamantane-1-carboxamide

opaganib

3-(4-clorofenil)-N-[(piridin-4-il)metil]adamantano-1-carboxamida

 $C_{23}H_{25}ClN_2O$ 

opiranserinum


opiranserin

4-butoxy-*N*-[4-(dimethylamino)oxan-4-yl]methyl]-3,5-dimethoxybenzamide

opiransérine

4-butoxy-*N*-[4-(diméthylamino)oxan-4-yl]méthyl]-3,5-diméthoxybenzamide

opiranserina

4-butoxi-*N*-[4-(dimetilamino)oxan-4-il]metil]-3,5-dietoxibenzamida $C_{21}H_{34}N_2O_5$ **opolimogenum capmilibacum #**

opolimogene capmilibac

Recombinant live-attenuated double-deleted (LADD) strain of *Listeria monocytogenes* (*Lm ΔactA/ΔinlB*) expressing three recombinant fusion proteins as follows:

(i) the N-terminal 100 amino acids of the *Lm* ActA (actin-assembly inducing protein precursor) protein (ActAN100), 5 tandem copies of a 21 amino acid fragment of human epidermal growth factor receptor variant III (EGFRvIII) and human protein SSX2 (synovial sarcoma, X breakpoint 2, also known as cancer/testis antigen 5.2 (CT5.2), tumor antigen HOM-MEL-40), under the control of the *Lm actA* promoter, and contained within an expression cassette of 1434 bp inserted at the *actA* locus;

(ii) the N-terminal 100 amino acids of the *Lm* ActA protein (ActAN100), 5 tandem copies of a 21 amino acid fragment of human epidermal growth factor receptor variant III (EGFRvIII) and amino acids 33-386 of human prostatic acid phosphatase (PAP), under the control the *Lm actA* promoter, and contained within an expression cassette of 2057 bp inserted at the *inlB* (internalin B) locus;

(iii) the N-terminal 100 amino acids of the *Lm* ActA protein (ActAN100), 5 tandem copies of a 21 amino acid fragment of human epidermal growth factor receptor variant III (EGFRvIII) and amino acids 11-234 of human homeobox protein Nkx-3.1 (NKX3-1) plus amino acids 1-20, 44-138 and 169-750 of human glutamate carboxypeptidase 2 (also known as folate hydrolase 1 (FOLH1), prostate-specific membrane antigen (PSMA)), under the control the *Lm actA* promoter, and contained within an expression cassette of 4984 bp at the *tRNA^{Arg}* locus.

opolimogène capmilibac

Souche vivante atténuée recombinante de *Listeria monocytogenes* (*Lm ΔactA/ΔinlB*) avec double délétion, exprimant les trois protéines de fusion suivantes:

(i) les 100 acides aminés à l'extrémité N-terminale de la protéine *Lm actA* (précurseur de la protéine induisant l'assemblage de l'actine) (ActAN100), 5 copies en tandem d'un fragment de 21 acides aminés de la variante III du récepteur du facteur de croissance épidermique humain (EGFRvIII) et la protéine humaine SSX2 (sarcome synovial, point de cassure X2, aussi connu comme antigène cancer/testicule 5.2 (CT5.2), antigène tumoral HOM-MEL-40), sous le contrôle du promoteur *Lm actA*, et contenu dans une cassette d'expression de 1434 paires de bases insérée sur le locus de *actA*;

opolimogén capmilibac

(ii) les 100 acides aminés à l'extrémité N-terminale de la protéine *Lm actA* (ActAN100), 5 copies en tandem d'un fragment de 21 acides aminés de la variante III du récepteur du facteur de croissance épidermique humain (EGFRvIII) et les acides aminés 33-386 de la phosphatase acide prostatique (PAP) humaine, sous le contrôle du promoteur *Lm actA*, contenu dans une cassette d'expression de 2057 paires de bases insérée sur le locus de *inlB* (internaline B);

(iii) les 100 acides aminés à l'extrémité N-terminale de la protéine *Lm actA* (ActAN100), 5 copies en tandem d'un fragment de 21 acides aminés de la variante III du récepteur du facteur de croissance épidermique humain (EGFRvIII) et les acides aminés 11-234 de la protéine homéobox humaine Nkx-3.1 (NKX3-1) plus les acides aminés 1-20, 44-138, 169-750 de la glutamate carboxypeptidase 2 humaine (folate hydrolase 1, FOLH1, antigène membranaire spécifique de la prostate, PSMA) sous le contrôle du promoteur *Lm actA*, contenu dans une cassette d'expression de 4984 paires de bases insérée sur le locus de *Lm tRNA^{Arg}*.

Cepa viva atenuada recombinante, con doble delección, de *Listeria monocytogenes* (*Lm ΔactA/ΔinlB*) que expresa las siguientes tres proteínas recombinantes de fusión:

(i) los 100 amino ácidos N-terminales de la proteína *Lm ActA* (precursor de la proteína inductora del ensamblaje de la actina) (ActAN100), 5 copias en tándem de un fragmento de 21 amino ácidos de la variante III del receptor para el factor de crecimiento epidérmico humano (EGFRvIII) y la proteína humana SSX2 (synovial sarcoma, X breakpoint 2, also known as cancer/testis antigen 5.2 (CT5.2), tumor antigen HOM-MEL-40), bajo el control del promotor de *Lm actA*, y contenido dentro de un casete de expresión de 1434 pares de bases insertado en el locus de *actA*;

(ii) los 100 amino ácidos N-terminales de la proteína *Lm ActA* (ActAN100), 5 copias en tándem de un fragmento de 21 amino ácidos de la variante III del receptor para el factor de crecimiento epidérmico humano (EGFRvIII) y los amino ácidos 33-386 de la fosfatasa ácida prostática (PAP) humana, bajo el control del promotor de *Lm actA*, y contenido dentro de un casete de expresión de 2057 pares de bases insertado en el locus de *inlB* (internalina B);

(iii) los 100 amino ácidos N-terminales de la proteína *Lm ActA* (ActAN100), 5 copias en tándem de un fragmento de 21 amino ácidos de la variante III del receptor para el factor de crecimiento epidérmico humano (EGFRvIII) y los amino ácidos 11-234 de la proteína *homeobox* humana Nkx-3.1 (NKX3-1) más los amino ácidos 1-20, 44-138 y 169-750 de la glutamato carboxipeptidasa 2 humana (también conocida como folato hidrolasa 1 (FOLH1), antígeno de membrana específico de próstata (PSMA)), bajo el control del promotor de *Lm actA* y contenido dentro de un casete de expresión de 4984 pares de bases insertado en el locus de *Lm tRNA^{Arg}*.


pamiparibum
pamiparib

(10a*R*)-2-fluoro-10a-methyl-5,8,9,10,10a,11-hexahydro-5,6,7a,11-tetraazacyclohepta[*def*]cyclopenta[*a*]fluoren-4(7*H*)-one

pamiparib (10a*R*)-2-fluoro-10a-méthyl-5,8,9,10,10a,11-hexahydro-5,6,7a,11-tétrazacyclohepta[*def*]cyclopenta[*a*]fluorén-4(7*H*)-one

pamiparib 10a*R*)-2-fluoro-10a-metil-5,8,9,10,10a,11-hexahydro-5,6,7a,11-tetraazacyclohepta[*def*]ciclopenta[*a*]fluoren-4(7*H*)-ona

C₁₆H₁₅FN₄O




parsaclisibum
parsaclisib

(4*R*)-4-{3-[(1*S*)-1-(4-amino-3-méthyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)éthyl]-5-chloro-2-éthoxy-6-fluorophényl}pyrrolidin-2-one

parsaclisib (4*R*)-4-{3-[(1*S*)-1-(4-amino-3-méthyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)éthyl]-5-chloro-2-éthoxy-6-fluorophényl}pyrrolidin-2-one

parsaclisib (4*R*)-4-{3-[(1*S*)-1-(4-amino-3-metil-1*H*-pirazolo[3,4-*d*]pirimidin-1-il)etil]-5-cloro-2-etoxi-6-fluorofenil}pirrolidin-2-ona

C₂₀H₂₂ClFN₆O₂



pegdarbepoetinum beta #
pegdarbepoetin beta

N-terminal pegylated human erythropoietin fragment, mutated, produced in Chinese hamster ovary (CHO) cells, glycoform beta;

[Ala³⁰>Asn, His³²>Thr, Pro⁸⁷>Val, Trp⁸⁸>Asn, Pro⁹⁰>Thr]erythropoietin (human)-(1-165)-peptide, produced in Chinese hamster ovary (CHO) cells, glycoform beta, chemically modified on Ala¹-*N* with a 4-[ω-methoxypoly(oxyethylene)_{*n*}-α-yl]butyl group (*n* ~ 682).

pegdarbépéotine bêta


fragment d'érythropoïétine humaine pégylé à l'extrémité N-terminale, modifié, produit par des cellules ovariennes de hamster chinois (CHO), glycoforme bêta;

pegdarbepoetina beta

[Ala³⁰>Asn,His³²>Thr,Pro⁸⁷>Val,Trp⁸⁸>Asn,Pro⁹⁰>Thr]érythropoïétine (humaine)-(1-165)-peptide, produit par des cellules ovariennes de hamster chinois (CHO), glycoforme bêta, chimiquement modifié sur l'Ala¹-N avec un groupe 4-[ω-méthoxypoly(oxyéthylène)_n-α-yl]butyle (n ~ 682).

fragmente de eritropoyetina humana pegilado en la extremidad N-terminal, modificado, producido por las células ováricas de hamster chino (CHO), glicoforma beta;

[Ala³⁰>Asn,His³²>Thr,Pro⁸⁷>Val,Trp⁸⁸>Asn,Pro⁹⁰>Thr]eritropoyetina (humana)-(1-165)-péptido, producido por las células ováricas de hamster chino (CHO), glicoforma beta, químicamente modificado sobre la Ala¹-N con un grupo 4-[ω-metoxipoli(oxietileno)_n-α-il]butilo (n ~ 682).



Sequence / Séquence / Secuencia

```


APRLICDSR VLERYLLEAK EAENITTCGN ETCSLNENIT VPDTKVNFYA 50
WKRMEVGQQA VEVWQGLALL SEAVLRGQAL LVNSSQVNET LQLHVDKAVS 100
GLRSLTLLR ALGAQKEAIS PPDAASAPL RTITADTERK LFRVYSNFLR 150
GKLKLYTGEA CRTGD 165

```

Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro
7-161 29-33

Modified residue / Résidu modifié / Resto modificado

Δ (1) = N-pegAla



Glycosylation site (N, S) / Site de glycosylation (N, S) / Posición de glicosilación (N, S)
Asn-24 Asn-30 Asn-38 Asn-88 Asn-80 Ser-126

pegilodecakinum #
pegilodecakin

N-terminal pegylated human interleukin 10 (IL10) analogue, with an added methionine at the N-terminus, dimer, produced in recombinant *Escherichia coli*; N-{3-[ω-methoxypoly(oxyethylene)-α-yl]propyl}-L-methionyl-interleukin 10 (human), homodimer (non-covalent), produced in recombinant *Escherichia coli*

pégilodécakine

analogue de l'interleukine 10 humaine, pégylé en position N-terminale, avec l'ajout d'une méthionine en position N-terminale, dimère, produit par *Escherichia coli*; N-{3-[ω-méthoxypoly(oxyéthylène)-α-yl]propyl}-L-méthionyl-interleukine 10 (humaine), homodimère (non covalent), produit par *Escherichia coli*

pegilodecakina


análogo de la interleukina 10 humano, pegilado en posición N-terminal, con la ayuda de una metionina en posición N-terminal, dímero, producido por *Escherichia coli*; N-{3-[ω-metoxipoli(oxietileno)-α-il]propil}-L-metionil-interleukina 10 (humano), homodímero (no covalente), producido por *Escherichia coli*

Monomer sequence / Séquence du monomère / Secuencia del monómero

SPGQGTQSEN	SCTHFPGNLP	NMLRDLRDAF	SRVKTFFQMK	DQLDNLLKE	50
SLEEDFKGYL	GCQALSEMIQ	FYLEEVMPQA	ENQDPDIKAH	VNSLGENLKT	100
LRRLRRCHR	FLPCENKSKA	VEQVKNAFNK	LQEKGIYKAM	SEFDIFINYI	150
EAYMTMKIRN					160

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
12-108 62-114

Modified residues / Résidus modifiés / Restos modificados



pegzilarginasum #
pegzilarginase

pegylated human arginine amidinase (arginase I, EC=3.5.3.1), mutated, cobalt ions replacing native manganese ions, trimer, produced in *Escherichia coli*;

des-Met¹-arginase-1 (human) dicobalt(II) complex, trimer, produced by *Escherichia coli*, substituted on an average of 8 to 16 primary amino groups of each protein monomer with [ω -methoxypoly(oxyethylene)_n- α -yl]acetyl groups (n ~ 120)

pegzilarginase

arginine amidinase humaine pégylée (arginase I, EC=3.5.3.1), modifiée, dans laquelle le manganèse est remplacé par du cobalt, trimère, produit par *Escherichia coli*;

dès-Mét¹-arginase-1 (humaine) dicobalt(II) complexe, trimère, produit par *Escherichia coli*, substituée sur une moyenne de 8 sur 16 groupes amines primaires de chaque monomère de la protéine avec des groupes [ω -méthoxypoly(oxyéthylène)_n- α -yl]acétyles (n ~ 120)

pegzilarginasa


arginina amidinasa humana pegilada (arginasa I, EC=3.5.3.1), modificada, iones de cobalto que reemplazan iones de manganeso nativos, trímero, producido por *Escherichia coli*;

des-Met¹-arginasa-1 (humana) dicobalto(II) complejo, trímero, producido por *Escherichia coli*, sustituida por una media de 8 a 16 grupos aminas primarias de cada monómero de la proteína con los grupos [ω -metoxipoli(oxiétileno)_n- α -il]acetilos (n ~ 120)

Monomer sequence / Séquence du monomère / Secuencia del monómero

SAKSRTIGII	GAPFSKGQPR	GGVEEGPTVL	RKAGLLEKLK	EQECDEVKDYG	50
DLFFADIPND	SPFQIVKNPR	SVGKASEQLA	GKVAEVKKNK	RISLVLGGDH	100
SLAIGSISGH	ARVHPDLGVI	WVDAHTDINT	PLTTSGNLH	GQPVSFLLKE	150
LKGIKIPDVPG	FSWVTPCISA	KDIVYIGLRD	VDPGEHYILK	TLGIKYFSMT	200
EVDRLGIGKV	MEETLSYLLG	RKKRPIHLSF	DVDGLDPSFT	PATGTPVVG	250
LTYREGLYIT	EETIKTGLLS	GLDIMEVNP	LGKTPEEVTR	TVNTAVAITL	300
ACFLAREGN	HKPIDYLNPP	K			321

Potential modified residues / Résidus modifiés potentiels / Restos modificados potenciales



pemlimogenum merolisbacum #
pemlimogene merolisbac

Recombinant live-attenuated double-deleted (LADD) strain of *Listeria monocytogenes* (*Lm ΔactA/ΔinlB*) expressing a fusion protein comprising the N-terminal 100 amino acids of the *Lm* ActA protein (ActAN100), 5 tandem copies of a 21 amino acid fragment of human epidermal growth factor receptor variant III (EGFRvIII) and amino acids 35-622 of human mesothelin (MSLN), under the control the *Lm actA* (actin-assembly inducing protein precursor) promoter, and contained within an expression cassette of 3874 bp inserted at the *Lm tRNA^{Arg}* locus.

pemlimogène mérolisbac

Souche vivante atténuée recombinante de *Listeria monocytogenes* (*Lm ΔactA/ΔinlB*) avec double délétion, exprimant une protéine de fusion qui consiste en les 100 acides aminés à l'extrémité N-terminale de la protéine *Lm* ActA (ActAN100), 5 copies en tandem d'un fragment de 21 acides aminés de la variante III du récepteur du facteur de croissance épidermique humain (EGFRvIII) et les acides aminés 35-622 de la mésothéline humaine (MSLN), sous le contrôle du promoteur de *Lm actA* (précurseur de la protéine induisant l'assemblage de l'actine), et contenu dans une cassette d'expression de 3874 paires de bases insérée sur le locus de *Lm tRNA^{Arg}*.

pemlimogén merolisbac

Cepa viva atenuada recombinante, con doble deleción, de *Listeria monocytogenes* (*Lm ΔactA/ΔinlB*) que expresa una proteína de fusión consistente en los 100 amino ácidos N-terminales de la proteína *Lm* ActA (ActAN100), 5 copias en tándem de un fragmento de 21 amino ácidos de la variante III del receptor para el factor de crecimiento epidérmico humano (EGFRvIII) y los amino ácidos 35-622 de la mesotelina humana (MSLN), bajo el control del promotor de *Lm actA* (precursor de la proteína inductora del ensamblaje de la actina), y contenido dentro de un casete de expresión de 3874 pares de bases insertado en el locus de *Lm tRNA^{Arg}*.

petesicatibum
petesicatib



(2*S*,4*R*)-*N*-(1-cyanocyclopropyl)-4-[4-(1-methyl-1*H*-pyrazol-4-yl)-2-(trifluoromethyl)benzenesulfonyl]-1-[1-(trifluoromethyl)cyclopropane-1-carbonyl]pyrrolidine-2-carboxamide

pétésicatib

(2*S*,4*R*)-*N*-(1-cyanocyclopropyl)-4-[4-(1-méthyl-1*H*-pyrazol-4-yl)-2-(trifluorométhyl)benzènesulfonyl]-1-[1-(trifluorométhyl)cyclopropane-1-carbonyl]pyrrolidine-2-carboxamide

petesicatib

2*S*,4*R*)-*N*-(1-cianociclopropil)-4-[4-(1-metil-1*H*-pirazol-4-il)-2-(trifluorometil)bencenosulfonil]-1-[1-(trifluorometil)ciclopropano-1-carbonil]pirrolidina-2-carboxamida

**pixatimodum**

pixatimod



5α-cholestan-3β-yl 2,3,4,6-tetra-O-sulfo-α-D-glucopyranosyl-(1→4)-2,3,6-tri-O-sulfo-α-D-glucopyranosyl-(1→4)-2,3,6-tri-O-sulfo-α-D-glucopyranosyl-(1→4)-2,3,6-tri-O-sulfo-β-D-glucopyranoside

pixatimod

2,3,4,6-tétra-O-sulfo-α-D-glucopyranosyl-(1→4)-2,3,6-tri-O-sulfo-α-D-glucopyranosyl-(1→4)-2,3,6-tri-O-sulfo-α-D-glucopyranosyl-(1→4)-2,3,6-tri-O-sulfo-β-D-glucopyranoside de 5α-cholestan-3β-yle

pixatimod

2,3,4,6-tetra-O-sulfo-α-D-glucopiranosil-(1→4)-2,3,6-tri-O-sulfo-α-D-glucopi-ranosil-(1→4)-2,3,6-tri-O-sulfo-α-D-glucopiranosil-(1→4)-2,3,6-tri-O-sulfo-β-D-glucopiranosída de 5α-colestan-3β-ilo

**plocabulinum**

plocabulin



(1Z,4S,6Z)-1-[(2S)-2-[(2Z,4Z,6E,8S)-8-[(2S)-5-methoxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-6-methylnona-2,4,6-trienamido]-3,3-dimethylbutanamido]octa-1,6-dien-4-yl carbamate

plocabuline

carbamate de (1Z,4S,6Z)-1-[(2S)-2-[(2Z,4Z,6E,8S)-8-[(2S)-5-méthoxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-6-méthylnona-2,4,6-triénamido]-3,3-diméthylbutanamido]octa-1,6-dien-4-yle

plocabulina

carbamato de (1Z,4S,6Z)-1-[(2S)-2-[(2Z,4Z,6E,8S)-8-[(2S)-5-metoxi-6-oxo-3,6-dihidro-2H-piran-2-il]-6-metilnona-2,4,6-trienamido]-3,3-dimetilbutanamido]octa-1,6-dien-4-ilo



prasinezumabum #
prasinezumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* SNCA (synuclein alpha, PARK1, PARK4, Parkinson disease (autosomal dominant, Lewy body) 4, alpha-synuclein, aSyn, non A4 component of amyloid precursor, NACP)], humanized monoclonal antibody;
gamma1 heavy chain (1-446) [humanized VH (*Homo sapiens* IGHV3-7*01 (87.80%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120(213) (117-214), hinge (215-229), CH2 (230-339), CH3 E12 (355), M14(357) (340-444), CHS (445-446)) (117-446)], (219-220')-disulfide with kappa light chain (1'-220') [humanized V-KAPPA (*Homo sapiens* IGKV1-16*01 (81.20%) -IGKJ4*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dimer (225-225'':228-228'')-bisdisulfide

prasinezumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* SNCA (synucléine alpha, PARK1, PARK4, maladie de Parkinson (autosomique dominante, corps de Lewy) 4, synucléine-alpha, aSyn, composant non A4 du précurseur amyloïde, NACP)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-446) [VH humanisé (*Homo sapiens* IGHV3-7*01 (87.80%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120(213) (117-214), charnière (215-229), CH2 (230-339), CH3 E12 (355), M14(357) (340-444), CHS (445-446)) (117-446)], (219-220')-disulfure avec la chaîne légère (1'-220') [V-KAPPA humanisé (*Homo sapiens* IGKV1-16*01 (81.20%) -IGKJ4*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dimère (225-225'':228-228'')-bisdisulfure

prasinezumab

immunoglobulina G1-kappa, anti-[*Homo sapiens* SNCA (sinucleína alfa, PARK1, PARK4, enfermedad de Parkinson (autosómica dominante, cuerpos de Lewy) 4, sinucleína-alfa, aSyn, componente no A4 del precursor amiloide, NACP)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-446) [VH humanizado (*Homo sapiens* IGHV3-7*01 (87.80%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120(213) (117-214), bisagra (215-229), CH2 (230-339), CH3 E12 (355), M14(357) (340-444), CHS (445-446)) (117-446)], (219-220')-disulfuro con la cadena ligera (1'-220') [V-KAPPA humanizado (*Homo sapiens* IGKV1-16*01 (81.20%) -IGKJ4*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dímero (225-225'':228-228'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLVESGGG LVQPGGSLRL SCAASGFTFS NYGMSWVRQA PGKGLEWVAS 50
 ISSGGGSTYY PDNVKGRFTI SRDDAKNSLY LQMNSLRAED TAVYYCARGG 100
 AGIDYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
 EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
 VNHKPSNTKV DKRVEPKSCD KHTTCPPCPA PELLGGPSVF LFPKPKDTL 250
 MISRTPEVTC VVVVDSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
 VVSVLTVLHQ DWLNGKEYKC KVSNAKLPAP TEKTISKAKG QPREPQVYTL 350
 PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNQGPENNY KTTTPVLDSD 400
 GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK 446

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS LSASVGRVIT ITCKSIQTLT YSSNQKNYLA WFQQKPGKAP 50
 KLLIYWASIR KSGVPSRFSG SGSSTDFTLT ISSLQPEDLA TYQCQYYYS 100
 PLTFGGGKTL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNMFYPREA 150
 KVQWKVDNAL QSGNSQESVT EQDSKDYTS LSSTLTLSKA DYEKHKVYAC 200
 EVTHQGLSSP VTKSFNRGEC 220

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 143-199 260-320 366-424
 22"-96" 143"-199" 260"-320" 366"-424"

Intra-L (C23-C104) 23'-94' 140'-200'
 23'''-94''' 140'''-200'''

Inter-H-L (h 5-CL 126) 219-220' 219"-220"

Inter-H-H (h 11, h 14) 225-225" 228-228"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

296, 296"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados

ralanitenum

ralaniten


(2R)-3-[4-(2-{4-[(2S)-3-chloro-2-hydroxypropoxy]phenyl}propan-2-yl)phenoxy]propane-1,2-diol

ralaniten

(2R)-3-[4-(2-{4-[(2S)-3-chloro-2-hydroxypropoxy]phényl}propan-2-yl)phénoxy]propane-1,2-diol

ralaniten

(2R)-3-[4-(2-{4-[(2S)-3-cloro-2-hidroxiopropoxi]fenil}propan-2-il)fenoxi]propano-1,2-diol

C₂₁H₂₇ClO₅**ravulizumabum #**

ravulizumab

immunoglobulin G2-4-kappa, anti-[*Homo sapiens* C5 (complement 5)], humanized monoclonal antibody; gamma2-4 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV1-46*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG2*01 (CH1 (123-220), hinge (221-232), CH2 1.6-1.1 (233-237)) (123-237) - *Homo sapiens* IGHG4*01 (CH2 1-125 (238-341), CH3 M107>L (429), N114>S (435) (342-446), CHS (447-448)) (238-448)], (146-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (84.20%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214'')]; dimer (224-224":225-225":228-228":231-231")-tetrakisdisulfide

ravulizumab

immunoglobuline G2-4-kappa, anti-[*Homo sapiens* C5 (complément 5)], anticorps monoclonal humanisé; chaîne lourde gamma2-4 (1-448) [VH humanisé (*Homo sapiens* IGHV1-46*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG2*01 (CH1 (123-220), charnière (221-232), CH2 1.6-1.1 (233-237)) (123-237) -*Homo sapiens* IGHG4*01 (CH2 1-125 (240-341), CH3 M107>L (429), N114>S (435) (342-446), CHS (447-448)) (240-448)], (146-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (84.20%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*0, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (224-224":225-225":228-228":231-231")-tétrakisdisulfure

ravulizumab

immunoglobulina G2-4-kappa, anti-[*Homo sapiens* C5 (complemento 5)], anticuerpo monoclonal humanizado; cadena pesada gamma2-4 (1-448) [VH humanizado (*Homo sapiens* IGHV1-46*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG2*01 (CH1 (123-220), bis (221-232), CH2 1.6-1.1 (233-237)) (123-237) -*Homo sapiens* IGHG4*01 (CH2 1-125 (240-341), CH3 M107>L (429), N114>S (435) (342-446), CHS (447-448)) (240-448)], (146-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (84.20%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*0, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (224-224":225-225":228-228":231-231")-tetraakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```

QVQLVQSGAE VKKPGASVKV SKASGHIFS NYWIQWVRQA PGQGLEWMGE 50
ILPGSGHTEY TENFKDRVTM TRDTSSTVY MELSSLRSED TAVYYCARYF 100
FGSSPNWYFD VWGQGTLLVT SSASTKGPSV FPLAPCSRST SESTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTPVSSNFGT 200
QTYTCNVDHK PSNTKVDKTV ERKCCVECPF CPAPPVAGPS VFLEPPKPKD 250
TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST 300
YRVVSVLTVL HQDWLNGKEY CKVSNKGLP SSIEKTISKA KGQPREPQVY 350
TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQFEN NYKTTTPPVL 400
SDGSFFLYSR LTVDKSRWQE GNVFSCSVLH EALHSHYTQK SLSLSLGK 448

```

Light chain / Chaîne légère / Cadena ligera

```

DIQMTQSPSS LSASVGRVIT ITCGASENIY GALNWYQQKP GKAPKLLIYG 50
ATNLADGVPS RFGSGSGGTD FTLTISSLPQ EDFATYYCQN VLNTPLTFGQ 100
GTKVEIKRTV AAPSVFIFFP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEK 214

```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22"-96" 149"-205" 262"-322" 368"-426"

22"-96" 149"-205" 262"-322" 368"-426"

Intra-L (C23-C104) 23"-88" 134"-194"

23"-88" 134"-194"

Inter-H-L (CH1 10-CL 126) 136"-214" 136"-214"

Inter-H-H (h 4, h 5, h 8, h 11) 224-224" 225-225" 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

298, 298"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

redasemtium


redasemtide

human high mobility group protein B1 (HMG-1)-(1-44)-peptide (including Met¹), chemically synthesized (without any modified residues)

rédiaseptide

protéine B1 du groupe à haute mobilité humaine (HMGB1)-(1-44)- peptide (incluant Met¹), synthétisé chimiquement (sans aucun résidu modifié)

redasemtida

proteína B1 del grupo de alta movilidad humana (HMGB1)-(1-44)-péptido (incluyendo Met¹), sintetizado químicamente (sin restos modificados)

Sequence / Séquence / Secuencia

MGKGDPPKPR GKSSSYAFFV QTCREEHKKK HPDASVNFSE FSKK 44

relmapirazinum



relmapirazin

N,N-(3,6-diaminopyrazine-2,5-dicarbonyl)di-D-serine

relmapirazine

N,N-(3,6-diaminopyrazine-2,5-dicarbonyl)di-D-sérine

relmapirazina

N,N-(3,6-diaminopirazina-2,5-dicarbonil)di-D-serina**reloxaliasum #**


reloxaliase

oxalate decarboxylase (OxdC, EC=4.1.1.2, *Bacillus subtilis* gene yvrK), hexamer, produced in *Escherichia coli*

réloxiase

oxalate décarboxylase (OxdC, EC=4.1.1.2, gène yvrK de *Bacillus subtilis*), hexamère, produit par *Escherichia coli*

reloxaliasa

oxalate decarboxilasa (OxdC, EC=4.1.1.2, gén yvrK de *Bacillus subtilis*), hexámero, producido por *Escherichia coli*

Monomer sequence / Séquence du monomère / Secuencia del monómero

```

MKKQNDIPQP IRGDKGATVK IPRNIERDRQ NPDMLVPPET DHGTVSNMKF 50
SFSDTHNRLE KGGYAREVTV RELPISENLA SVNMLKPGA IRELHWHKEA 100
EWAYMIYGSA RVTIVDEKGR SFIDDVGEED LWYFPSGLPH SIQALEEGAE 150
FLLVFDDGSF SENSTFQLTD WLAHTPKEVI AANFGVTKEE ISNLPGKEKY 200
IFENQLPGSL KDDIVEGPNG EVPYPTTYRL LEQEPISSEG GKVIADSTN 250
FKVSKTIASA LVTVEPGAMR ELHWHPNTHE WQYIISGKAR MTVFASDGHA 300
RTFNYQAGDV GYVPFAMGHY VENIGDEPLV FLEIFKDDHY ADVSLNQWLA 350
MLPETFVQAH LDLGKDFTDV LSKEKHPVVK KKCSK 385

```

remlarsenum

remlarsen





(2*RS*)-3-[[6-(cholest-5-en-3 β -yloxy)hexyl]oxy]-2-hydroxypropyl hydrogen 2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-adenylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-guanylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-adenylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-3'-adenylate duplex with *all-P-ambo-P*-thiouridylyl-(5'→3')-*P*-thiouridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-guanylyl-(5'→3')-adenylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-adenylyl-(5'→3')-guanylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-adenylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-guanylyl-(5'→3')-adenylyl-(5'→3')-2'-deoxy-2'-fluorouridine

remlarsen

hydrogéno-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-adénylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-guanylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-3'-adénylate de (2*RS*)-3-[[6-(cholest-5-én-3 β -yloxy)hexyl]oxy]-2-hydroxypropyle duplex avec *tout-P-ambo-P*-thiouridylyl-(5'→3')-*P*-thiouridylyl-(5'→3')-2'-désoxy-2'-fluorouridylyl-(5'→3')-2'-désoxy-2'-fluorouridylyl-(5'→3')-guanylyl-(5'→3')-adénylyl-(5'→3')-2'-désoxy-2'-fluorocytidylyl-(5'→3')-2'-désoxy-2'-adénylyl-(3'→5')-adénylyl-(5'→3')-adénylyl-(5'→3')-adénylyl-(5'→3')-guanylyl-(5'→3')-2'-désoxy-2'-fluorouridylyl-(5'→3')-2'-désoxy-2'-fluorouridylyl-(5'→3')-2'-désoxy-2'-fluorocytidylyl-(5'→3')-2'-désoxy-2'-fluorocytidylyl-(5'→3')-adénylyl-(5'→3')-2'-désoxy-2'-fluorocytidylyl-(5'→3')-guanylyl-(5'→3')-adénylyl-(5'→3')-2'-désoxy-2'-fluorouridine

remlarsén

hidrógeno-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-adenilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-guanylyl-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-adenilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-adenilil-(3'→5')-adenilil-(3'→5')-adenilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-guanilil-(3'→5')-guanilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-3'-adenilato de (2*RS*)-3-[[6-(colest-5-en-3 β -iloxi)hexil]oxi]-2-hidroxi-propilo dúplex con *todo-P-ambo-P*-tiouridilil-(5'→3')-*P*-tiouridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-guanilil-(5'→3')-adénylyl-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-adenilil-(5'→3')-adenilil-(5'→3')-adenilil-(5'→3')-guanilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-adenilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-guanilil-(5'→3')-adenilil-(5'→3')-2'-desoxi-2'-fluorouridina



rezafungini acetat
rezafungin acetate



$N^{5,1},6$ -anhydro[(4*R*,5*R*)-4-hydroxy-2-[3⁴-(pentyloxy)[1¹,2¹:2⁴,3¹-terphenyl]-1⁴-carboxamido]-5-[2-(trimethylazaniumyl)ethyl]-L-ornithyl-L-threonyl-*trans*-4-hydroxy-L-prolyl-(4*S*)-4-hydroxy-4-(4-hydroxyphenyl)-L-threonyl-L-threonyl-(3*S*,4*S*)-3-hydroxy-4-methyl-L-proline]acetate

acétate de rézafungine

acétate de $N^{5,1},6$ -anhydro[(4*R*,5*R*)-4-hydroxy-2-[3⁴-(pentyloxy)[1¹,2¹:2⁴,3¹-terphényl]-1⁴-carboxamido]-5-[2-(triméthylazaniumyl)éthyl]-L-ornithyl-L-thréonyl-*trans*-4-hydroxy-L-prolyl-(4*S*)-4-hydroxy-4-(4-hydroxyphényl)-L-thréonyl-L-thréonyl-(3*S*,4*S*)-3-hydroxy-4-méthyl-L-proline]

acetato de rezafungina

acetato de $N^{5,1},6$ -anhidro[(4*R*,5*R*)-4-hidroxi-2-[3⁴-(pentiloxi)[1¹,2¹:2⁴,3¹-terfenil]-1⁴-carboxamido]-5-[2-(trimetilazaniumil)etil]-L-ornitil-L-treonil-*trans*-4-hidroxi-L-proli-(4*S*)-4-hidroxi-4-(4-hidroxiifenil)-L-treonil-L-treonil-(3*S*,4*S*)-3-hidroxi-4-metil-L-prolina]




riamilovirum
riamilovir

7-(methylsulfonyl)-3-nitro[1,2,4]triazolo[5,1-*c*][1,2,4]triazin-4(1*H*)-one

riamilovir 7-(méthylsulfanyl)-3-nitro[1,2,4]triazolo[5,1-c][1,2,4]triazin-4(1*H*)-one

riamilovir 7-(metilsulfanil)-3-nitro[1,2,4]triazolo[5,1-c][1,2,4]triazin-4(1*H*)-ona

$C_5H_4N_6O_3S$




rivoceranibum

rivoceranib *N*-[4-(1-cyanocyclopentyl)phenyl]-2-[[pyridin-4-yl)méthyl]amino}pyridine-3-carboxamide

rivocéranib *N*-[4-(1-cyanocyclopentyl)phényl]-2-[[pyridin-4-yl)méthyl]amino}pyridine-3-carboxamide

rivoceranib *N*-[4-(1-cianociclopentil)fénil]-2-[[piridin-4-il]metil]amino}pidina-3-carboxamida

$C_{24}H_{23}N_5O$




rivogenlecleucelum #

rivogenlecleucel

Human culture expanded genetically modified allogenic T cells for cell-based therapy. Cells are derived from isolated blood of a healthy human donor chosen by available HLA match (haploidentical up to fully matched) and are transduced with a Gibbon ape leukemia virus (GaV) pseudotyped gammaretroviral vector carrying an inducible caspase 9 suicide transgene and a truncated CD19 marker gene allowing selection, and a drug binding domain consisting of human FK506 (tacrolimus)-binding protein (FKBP12) with an F36V mutation. Cells exhibit anti-infective activity as adjunctive T-cell therapy in combination with allogenic hematopoietic stem cell transplantation, in combination with an inducible suicide mechanism in the event of donor T-cell induced graft versus host disease (GvHD).

rivogenlecleucel

Lymphocytes T humains allogéniques, en culture d'expansion et modifiés génétiquement en vue d'une thérapie cellulaire. Les cellules sont dérivées du sang prélevé chez un donneur sain choisi pour sa compatibilité HLA (de haploidentique à correspondant totalement) et sont transduites avec un vecteur rétroviral gamma


	pseudotypé virus de la leucémie du singe Gibbon (GalV) transportant un transgène suicide inducible de la caspase 9 et un gène CD19 tronqué comme marqueur permettant la sélection, ainsi qu'un domaine de liaison médicamenteuse consistant en la protéine humaine (FKBP12) se liant au tacrolimus (FK506) avec une mutation F36V. Les cellules montrent une activité anti-infectieuse comme thérapie adjuvante de lymphocytes T en association avec la transplantation de cellules souches hématopoïétiques allogéniques, en association aussi avec un mécanisme suicide inducible en cas de réaction du greffon contre l'hôte (GVH) induit par les lymphocytes T du donneur.
rivogenlecleucel	Linfocitos T alogénicos, humanos, expandidos en cultivo y modificados genéticamente para terapia celular. Las células se derivan a partir de sangre aislada de un donante humano sano elegido por su compatibilidad HLA (desde haploidentico hasta totalmente coincidente) y están transducidas con un vector gamma-retroviral seudotipado del virus de la leucemia de monos Gibbon (GalV) que porta un transgen inducible suicida de caspasa 9 y un gen CD19 truncado como marcador que permite la selección, y un dominio de unión a drogas consistente en la proteína de unión al tacrólimus (FK506) humana (FKBP12) con una mutación F36V. Las células muestran actividad anti-infecciosa en terapia adyuvante de linfocitos T en combinación con trasplante alogénico de células madre hematopoyéticas, en combinación con un mecanismo suicida inducible en caso de enfermedad injerto contra huésped (EICH) inducida por los linfocitos T del donante.
rovazolacum	
rovazolac	ethyl {5-[3'-(methanesulfonyl)[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1 <i>H</i> -pyrazol-1-yl}acetate
rovazolac	{5-[3'-(méthanesulfonyl)[1,1'-biphényl]-4-yl]-3-(trifluorométhyl)-1 <i>H</i> -pyrazol-1-yl}acétate d'éthyle
rovazolac	{5-[3'-(metanosulfonyl)[1,1'-bifenil]-4-il]-3-(trifluorometil)-1 <i>H</i> -pirazol-1-il}acetato de etilo
	$C_{21}H_{19}F_3N_2O_4S$ 
seliforantum	
seliforant	6-[3-(methylamino)azetidin-1-yl]-2-(2-methylpropyl)pyrimidin-4-amine

séliforant

6-[3-(méthylamino)azétidin-1-yl]-2-(2-méthylpropyl)pyrimidin-4-amine

seliforant

6-[3-(metilamino)azetidin-1-il]-2-(2-metilpropil)pirimidin-4-amina

 $C_{12}H_{21}N_5$ setrusumabum #
setrusumab

immunoglobulin G2-lambda, anti-[*Homo sapiens* SOST (sclerostin)], *Homo sapiens* monoclonal antibody; gamma2 heavy chain (1-443) [*Homo sapiens* VH (IGHV3-66*01 (89.80%) -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -IGHG2*01, G2m.. (CH1 (118-215), hinge (216-227), CH2 V45.1 (278) (228-336), CH3 (337-441), CHS (442-443)) (118-443)], (131-216')-disulfide with lambda light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV2-23*02 (92.60%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimer (219-219":220-220":223-223":226-226")-tetrakisdisulfide

sétrusumab

immunoglobuline G2-lambda, anti-[*Homo sapiens* SOST (sclérostine)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma2 (1-443) [*Homo sapiens* VH (IGHV3-66*01 (89.80%) -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -IGHG2*01, G2m.. (CH1 (118-215), charnière (216-227), CH2 V45.1 (278) (228-336), CH3 (337-441), CHS (442-443)) (118-443)], (131-216')-disulfure avec la chaîne légère lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV2-23*02 (92.60%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimère (219-219":220-220":223-223":226-226")-tétrakisdisulfure

setrusumab

immunoglobulina G2-lambda, anti-[*Homo sapiens* SOST (esclerostina)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma2 (1-443) [*Homo sapiens* VH (IGHV3-66*01 (89.80%) -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -IGHG2*01, G2m.. (CH1 (118-215), bisagra (216-227), CH2 V45.1 (278) (228-336), CH3 (337-441), CHS (442-443)) (118-443)], (131-216')-disulfuro con la cadena ligera lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV2-23*02 (92.60%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dímero (219-219":220-220":223-223":226-226")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVESGGG LVQPFGSLRL SCAASGFTFR SHWLSWRQA PGKGLEWVSN 50
 INYDGSSTYY ADSVKGRFTI SRDNSKNITLY LQMNSLRAED TAVYYCARDT 100
 YLHFDYWGQG TLVTVSSAST KGPSVFPLAP CSRSTSESTA ALGCLVKDYF 150
 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVTVTPS SNFGTQTYTC 200
 NVDHKPSNTK VDKTVERKCC VECPPCPAPP VAGPSVFLFP PKPKDTLMIS 250
 RTPEVTCVVV DVSHEDEPEVQ FNWYVDGVEV HNAKTKPREE QFNSTFRVVS 300
 VLTVVHQDWL NGKEYCKVVS NKGLPAPIEK TISKTKGQPR EPQVYTLPPS 350
 REEMTKNQVS LTCLVKGFPY SDIAVEWESN GQPENNYKTT PPMLESDGSF 400
 FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSL PGK 443

Light chain / Chaîne légère / Cadena ligera

DIALTQPASV SGSPGQSITI SCTGTSSDVG DINDVSWYQQ HPGKAPKLM 50
 YDVNNRPSGV SNRFGSGKSG NTASLTISGL QAEDEADYYC QSYAGSYLSE 100
 VFGGGTKLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150
 VAWKADSSPV KAGVETTPS KQSNKNYAAS SYLSLTPEQW KSHRSYSCQV 200
 TLEGSTVEKT VAPTECS 217

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 144-200 257-317 363-421
 22"-96" 144"-200" 257"-317" 363"-421"

Intra-L (C23-C104) 22'-90' 139'-198"
 22"-90" 139"-198"

Inter-H-L (CH1 10-CL 126) 131-216 131"-216"

Inter-H-H (h 4, h 5, h 8, h 11) 219-219" 220-220" 223-223" 226-226"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

293, 293"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados

spartalizumabum #
 spartalizumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], humanized monoclonal antibody;
 gamma4 heavy chain (1-443) [humanized VH (*Homo sapiens* IGHV1-69-2*01 (75.00%) -(IGHD) -IGHJ6*01) [8.8.10] (1-117) -*Homo sapiens* IGHG4*01 (CH1 (118-215), hinge S10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS K2>del (443)) (118-443)], (131-220')-disulfide with kappa light chain (1'-220') [humanized V-KAPPA (*Homo sapiens* IGKV3D-11*03 (75.80%) -IGKJ1*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (114'-220')]; dimer (223-223":226-226")-bisdisulfide

spartalizumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps monoclonal humanisé;
 chaîne lourde gamma4 (1-443) [VH humanisé (*Homo sapiens* IGHV1-69-2*01 (75.00%) -(IGHD) -IGHJ6*01) [8.8.10] (1-117) -*Homo sapiens* IGHG4*01 (CH1 (118-215), charnière S10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS K2>del (443)) (118-443)], (131-220')-disulfure avec la chaîne légère kappa (1'-220') [V-KAPPA humanisé (*Homo sapiens* IGKV3D-11*03 (75.80%) -IGKJ1*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (114'-220')]; dimère (223-223":226-226")-bisdisulfure

espartalizumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal humanizado;

cadena pesada gamma4 (1-443) [VH humanizado (*Homo sapiens* IGHV1-69-2*01 (75.00%) -(IGHD) -IGHJ6*01) [8.8.10] (1-117) -*Homo sapiens* IGHG4*01 (CH1 (118-215), bisagra S10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS K2>del (443)) (118-443)], (131-220')-disulfuro con la cadena ligera kappa (1'-220') [V-KAPPA humanizado (*Homo sapiens* IGKV3D-11*03 (75.80%) -IGKJ1*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (114'-220')]; dímero (223-223":226-226")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 EVQLVQSGAE VKKPGESLRI SCKGSGYTFT TYWMHWVRQA TGQGLEWMGN 50
 IYPGTGGSNF DEKFKNRVTI TADKSTSTAY MELSSLRSED TAVYYCTRTW 100
 TGTGAYWGQG TTVTVSSAST KGPSVFPLAP CSRSTSESTA ALGCLVKDYF 150
 PEPVTVSNNS GALTSGVHTF PAVLQSSGLY SLSSVTVTPS SSLGKTKYTC 200
 NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGSPSVFLF PPKPKDTLMI 250
 SRTPEVTCVV VDVQSQEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTYRVV 300
 SVLTIVLHQDW LNKKEYKCKV SNKGLPSSIE KTISKAKGQP REPQVYTLPP 350
 SQEEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TTPVLDSDGS 400
 FFLYSRLTVD KSRWQEGNVF SCSVMHEALH NHYTKSLSL SLG 443

Light chain / Chaîne légère / Cadena ligera
 EIVLTQSPAT LSLSPGERAT LSKSSQSL DSGNQKNFLT WYQKPGQAP 50
 RLLIYWASTR ESGVPSRFSG SGSGTDFTFI ISSLEAEDAA TYQCNDYSY 100
 PYTFGQGTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
 KVQWKVDNAL QSGNSQESVT EQDSKDSYS LSSTLTLSKA DYKHKVYAC 200
 EVTHQGLSP VTKSFNRGEC 220

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 144-200 258-318 364-422

22"-96" 144"-200" 258"-318" 364"-422"

Intra-L (C23-C104) 23'-94' 140'-200'

23'''-94''' 140'''-200'''

Inter-H-L (h 5-CL 126) 131-220' 131"-220"

Inter-H-H (h 11, h 14) 223-223" 226-226"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

294, 294"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados.

sultimotidum alfa

sultimotide alfa

a fusion protein consisting of fragments of hepatitis B virus transcription factor X, large S-protein antigen (envelope antigen), B antigen (core antigen) and of a C-terminal six-histidine tag, expressed by engineered whole heat-killed *Saccharomyces cerevisiae*, glycoform alfa;

Met-Ala-Asp-Glu-Ala-Pro-Thr-Ser-[des-(69-83)-[P⁵⁹>F]pro-tein X (hepatitis B virus)-(52-127)-peptide (9-69)]-[{[M¹>E, G³>Q, Q¹⁰>K, P¹⁹S, G³⁵>R, N³⁹>A, H⁵¹>T, P⁶⁵>L, T⁸⁶>Q, A⁹¹>N]large S protein (hepatitis B virus) (70-243)]-[{[T⁴>I, V²⁵>I, N²⁰⁷>S, L²⁰⁹>V, L²¹³>I]small S protein (hepatitis B virus) (244-469)]-[des-Met¹-[S¹²>T]capsid protein (hepatitis B virus) (470-651)]-His₆ (652-657) fusion protein, produced in *Saccharomyces cerevisiae*, glycoform alfa

sultimotide alfa

protéine de fusion consistant en des fragments du facteur X de transcription du virus de l'hépatite B, de l'antigène de la grande protéine S (antigène de l'enveloppe), antigène B (antigène core) et d'un fragment de 6 histidines, produite par une souche de *Saccharomyces cerevisiae* inactivée par la chaleur, glycoforme alfa:

sultimotida alfa

Met-Ala-Asp-Glu-Ala-Pro-Thr-Ser-(dès-(69-83)-
[P⁵⁹>F]pro-téine X (virus de l'hépatite B)-(52-127)-peptide
(9-69))-
{[M¹>E,G³>Q,Q¹⁰>K,P¹⁹S,G³⁵>R,N³⁹>A,H⁵¹>T,P⁶⁵>L,T⁸⁶>Q,
A⁹¹>N]grande protéine S (virus de l'hépatite B) (70-243))-
{[T⁴>I,V²⁵>I,N²⁰⁷>S,L²⁰⁹>V,L²¹³>I]petite protéine S (virus de
l'hépatite B) (244-469))-(dès-Mét¹-[S¹²>T]protéine de la
capside (virus de l'hépatite B) (470-651))-His₆ (652-657)
protéine de fusion, produite par *Saccharomyces
cerevisiae*, glycoforme alfa

proteína de fusión consistente en los fragmentos del factor
X de transcripción del virus de la hepatitis B, del antígeno
de la proteína S grande (antígeno de la envoltura),
antígeno B (antígeno nuclear) y de un fragmento de 6
histidinas, producida por una cepa de *Saccharomyces
cerevisiae* inactivada por el calor, glicofoma alfa:

Met-Ala-Asp-Glu-Ala-Pro-Thr-Ser-(des-(69-83)-
[P⁵⁹>F]proteína X (virus de la hepatitis B)-(52-127)-
péptido)-
{[M¹>E,G³>Q,Q¹⁰>K,P¹⁹S,G³⁵>R,N³⁹>A,H⁵¹>T,P⁶⁵>L,T⁸⁶>Q,
A⁹¹>N]proteína S grande (virus de la hepatitis B))-
{[T⁴>I,V²⁵>I,N²⁰⁷>S,L²⁰⁹>V,L²¹³>I]proteína S pequeña (virus
de la hepatitis B))-(des-Met¹-[S¹²>T]proteína de la cápside
(virus de la hepatitis B))-His₆ proteína de fusión, producida
por *Saccharomyces cerevisiae*, glicofoma alfa

Sequence / Séquence / Secuencia

```
MADEAPTSHL SLRGLFVCAF SSAGPNAHQF LPKVLHKRTL GLSAMSTTDL 50
EAYFKDCLEK DWEELEGELE GQWSSKPRKG MGTNLVSNP LGFFPDHQLD 100
PAFRANSANP DWDFNPKNKT WPEANQGVVG AFGLGFTPPH GLLGWSPQA 150
QGILQTVPAN PPPASTNRQS GRQPTPISTP LRDSHPQAMQ WNSTTFHQAL 200
LDPVRVGLYF PAGGSSSGTV NPVPTTASPI SSIFSRGTGP ALNMENTISG 250
FLGPLLVLQA GFLLLRILT IPQSLDSWWT SLNFLGGTTT CPGQNSQSPT 300
SNHSPTSCPP ICPGYRWML RRFIFLFLIL LLCLIFLLVL LDYQGMPLVC 350
PLLPGTSTTS TGPKCTCTIP AQGTSMFPSC CTKPDSGNC TCIPIPSSWA 400
FARFLWEWAS VRFWSLSLLV PFVQWVGLS PTVWLSVIWM MWYWGSPSLYS 450
IVSPFIPLLP IFFCLWVYID IDPYKEFGAT VELLSEFLPSD FFPSVRDLDS 500
TASALYREAL ESPEHCSPHH TALRQAILCW GELMNLATWV GSNLEDPASR 550
ELVVSYNVNV MGLKIRQLLW FHISCLTFGR ETVLEYLVSF GVWIRTPPAY 600
RPPNAPILST LPETTVVRRR GRSPRRRTPS PRRRRSQSPR RRRSQSRESQ 650
CHHHHHH 657
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
18-350 57-308 291-319 312-529 333-380
364-367 381-390 382-392 464-651 516-575

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-84 Asn-192 Asn-246 Asn-302 Asn-389

tabelecleucelum
tabelecleucel

Human culture enriched allogenic Epstein-Barr virus-
specific cytotoxic T cells (EBV-CTL) for cell-based therapy.
Cells are isolated from blood of EBV seropositive healthy
human donors. EBV-CTLs exhibit human leukocyte
antigen (HLA)-restricted cytotoxic activity against EBV+
cells in allogeneic hematopoietic cell transplant patients
with EBV associated post-transplant lymphoproliferative
disease.

tabécleleucel	Lymphocytes T cytotoxiques spécifiques du virus d'Epstein-Barr (EBV-CTL), allogéniques, humains, enrichis en culture pour thérapie cellulaire. Les cellules sont isolées à partir du sang de donneurs humains sains séropositifs à l'EBV. Les EBV-CTL montrent une activité cytotoxique restreinte à l'antigène leucocytaire humain (HLA) contre les cellules EBV+ chez des patients transplantés avec des cellules hématopoïétiques allogéniques souffrants d'un syndrome lymphoprolifératif associé à l'EBV post-transplantation.
tabelecleucel	Linfocitos T citotóxicos específicos del virus de Epstein-Barr (EBV-CTL), alogénicos, humanos, enriquecidos en cultivo para terapia celular. Las células están aisladas a partir de sangre de donantes humanos sanos seropositivo para EBV. Los EBV-CTLs muestran actividad citotóxica restringida por HLA contra células EBV+ in pacientes trasplantados con células hematopoyéticas alogénicas con enfermedad linfoproliferativa post-trasplante asociada a EBV.
talacotuzumabum # talacotuzumab	immunoglobulin G1-2-kappa, anti-[<i>Homo sapiens</i> IL3RA (interleukin 3 receptor subunit alpha, interleukin 3 receptor alpha (low affinity), CD123)], humanized monoclonal antibody; gamma1-2 heavy chain (1-450) [humanized VH (<i>Homo sapiens</i> IGHV5-51*01 (82.70%) -(IGHD) -IGHJ3*01) [8.8.13] (1-120) - <i>Homo sapiens</i> IGHG1*01 (CH1 G1m17, K120 (217) (121-218) -hinge (219-233) -CH2 1.6-1.1 (234-239)) (121-239) - <i>Homo sapiens</i> IGHG2*01 (CH2 1-125, S3>D (242), G2m.. V45.1 (285), G110>A (330), I117>E (335) (240-343) -CH3 nG1m1 E12 (359), M14 (361) (344-448), CHS (449-450)) (240-450)], (223-220')-disulfide with kappa light chain (1'-220') [humanized V-KAPPA (<i>Homo sapiens</i> IGKV4-1*01 (90.10%) -IGKJ2*01) [12.3.9] (1'-113') - <i>Homo sapiens</i> IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dimer (229-229":232-232")-bisdisulfide
talacotuzumab	immunoglobuline G1-2-kappa, anti-[<i>Homo sapiens</i> IL3RA (sous-unité alpha du récepteur de l'interleukine 3, récepteur alpha (faible affinité) de l'interleukine 3, CD123)], anticorps monoclonal humanisé; chaîne lourde gamma1-2 (1-450) [VH humanisé (<i>Homo sapiens</i> IGHV5-51*01 (82.70%) -(IGHD) -IGHJ3*01) [8.8.13] (1-120) - <i>Homo sapiens</i> IGHG1*01 (CH1 G1m17, K120 (217) (121-218) -charnière (219-233) -CH2 1.6-1.1 (234-239)) (121-239) - <i>Homo sapiens</i> IGHG2*01 (CH2 1-125, S3>D (242), G2m.. V45.1 (285), G110>A (330), I117>E (335) (240-343) -CH3 nG1m1 E12 (359), M14 (361) (344-448), CHS (449-450)) (240-450)], (223-220')-disulfure avec la chaîne légère kappa (1'-220') [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV4-1*01 (90.10%) -IGKJ2*01) [12.3.9] (1'-113') - <i>Homo sapiens</i> IGKC*01, Km3 A45.1, V101 (114'-220')]; dimère (229-229":232-232")-bisdisulfure

talacotuzumab

inmunoglobulina G1-2-kappa, anti-[*Homo sapiens* IL3RA (subunidad alfa del receptor de la interleukina 3, receptor alfa (baja afinidad) de la interleukina 3, CD123)], anticuerpo monoclonal humanizado; cadena pesada gamma1-2 (1-450) [VH humanizado (*Homo sapiens*IGHV5-51*01 (82.70%) -(IGHD) -IGHJ3*01) [8.8.13] (1-120) -*Homo sapiens*IGHG1*01 (CH1 G1m17, K120 (217) (121-218) -bisagra (219-233) -CH2 1.6-1.1 (234-239)) (121-239) -*Homo sapiens*IGHG2*01 (CH2 1-125, S3>D (242), G2m.. V45.1 (285), G110>A (330), I117>E (335) (240-343) -CH3 nG1m1 E12 (359), M14 (361) (344-448), CHS (449-450)) (240-450)], (223-220')-disulfuro con la cadena ligera kappa (1'-220') [V-KAPPA humanizado (*Homo sapiens*IGKV4-1*01 (90.10%) -IGKJ2*01) [12.3.9] (1'-113') -*Homo sapiens*IGKC*01, Km3 A45.1, V101 (114'-220')]; dímero (229-229":232-232")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGESLKI SCKGSGYSFT DYYMKWARQM PGKGLEWMD 50
IIPSNQATFY NQKFKGQVTI SADKSISTTY LQWSSLKASD TAMYCARSH 100
LLRASWFAYW GQGTMTVTSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTYS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPPELLGG PDVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVQFNW YVDGVEVHNA KTKPREEQFN 300
STFRVSVLT VVHGDWLNKG EYKCKVSNKA LPAPEEKTI S KTKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTTFFM 400
LDSGGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPDS LAVSLGERAT INCESSQSLL NSGNQKNYLT WYQKPGQPP 50
KPLIYWASTR ESGVPRDFSG SGSGTDFTLT ISSLQAEDVA VYYCQNDYSY 100
PYTFGQGTKL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKSTYS LSSTLTLSKA DYKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC 220
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22"-96" 147"-203" 264"-324" 370"-428"

22"-96" 147"-203" 264"-324" 370"-428"

Intra-L (C23-C104) 23'-94" 140"-200"

23"-94" 140"-200"

Inter-H-L (h 5-CL 126) 223"-220" 223"-220"

Inter-H-H (h 11, h 14) 229"-229" 232"-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

300, 300"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados.

tasadenoturevum #
tasadenoturev

Conditionally replicating adenovirus (CRAd) serotype 5 carrying a 24-bp deletion in early E1A gene and insertion of an integrin-binding motif (Arg-Gly-Asp) (RGD) motif into the H1 loop of the fiber knob.

tasadénoturev

adénovirus de sérotype 5 dont la réplication est conditionnelle et portant une délétion de 24 paires de bases sur le gène précoce E1A et l'insertion d'un motif d'union à l'intégrine dans la boucle H1 du *knob* de la fibre

tasadenoturev

Adenovirus de serotipo 5, con replicación condicionada, portando una delección de 24 pares de bases en el gen temprano E1A y la inserción de un motivo de unión a integrina (Arg-Gly-Asp) (RGD) en el bucle H1 del *knob* de fibra

tasipimidinum

tasipimidine


rac-2-[(1*R*)-5-methoxy-3,4-dihydro-1*H*-2-benzopyran-1-yl]-4,5-dihydro-1*H*-imidazole

tasipimidine

rac-2-[(1*R*)-5-méthoxy-3,4-dihydro-1*H*-2-benzopyran-1-yl]-4,5-dihydro-1*H*-imidazole

tasipimidina

rac-2-[(1*R*)-5-metoxi-3,4-dihidro-1*H*-2-benzopiran-1-il]-4,5-dihidro-1*H*-imidazol

C₁₃H₁₆N₂O₂**telacebecum**

telacebec


6-chloro-2-ethyl-*N*-[(4-{4-(trifluoromethoxy)phenyl}piperidin-1-yl)phenyl)methyl]imidazo[1,2-*a*]pyridine-3-carboxamide

télacébec

6-chloro-2-éthyl-*N*-[(4-{4-(trifluorométhoxy)phényl}pipéridin-1-yl)phényl)méthyl]imidazo[1,2-*a*]pyridine-3-carboxamide

telacebec













6-cloro-2-etil-*N*-[(4-{4-(trifluorometoxi)fenil}piperidin-1-il)fenil)metil]imidazo[1,2-*a*]piridina-3-carboxamida

C₂₉H₂₈ClF₃N₄O₂**temavirsenum**

temavirsén

[(2*S*,4*R*)-1-{1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis[{3-[(3-{5-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy)methyl]-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin-2-yl)methyl hydrogen *all*-*P*-ambo-2'-*O*-(2-methoxyethyl)-*P*-thioadenylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl

	-(3'→5')-2'-O-(2-methoxyethyl)-<i>P</i>-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-<i>P</i>-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-<i>P</i>-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-<i>P</i>-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-<i>P</i>-thiouridylyl-(3'→5')-<i>P</i>-thiothymidylyl-(3'→5')-2'-deoxy-<i>P</i>-thioguanilyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-ethane-1,1-diyl]-<i>P</i>-thiouridylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-ethane-1,1-diyl]-<i>P</i>-thiocytidylyl-(3'→5')-2'-deoxy-<i>P</i>-thioadenylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-ethane-1,1-diyl]-<i>P</i>-thiocytidylyl-(3'→5')-2'-deoxy-<i>P</i>-thioadenylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-ethane-1,1-diyl]-<i>P</i>-thiocytidylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-ethane-1,1-diyl]-<i>P</i>-thiothymidylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-ethane-1,1-diyl]-<i>P</i>-thiocytidylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-ethane-1,1-diyl]cytidylyl-(3'→5')-2'-deoxy-3'-adenylate
témavirsen	hidrogéno-<i>tout-P-ambo</i>-2'-O-(2-méthoxyéthyl)-<i>P</i>-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-<i>P</i>-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-<i>P</i>-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-<i>P</i>-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-<i>P</i>-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-<i>P</i>-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-<i>P</i>-thiouridylyl-(3'→5')-<i>P</i>-thiothymidylyl-(3'→5')-2'-désoxy-<i>P</i>-thioguanilyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-éthane-1,1-diyl]-<i>P</i>-thiouridylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-éthane-1,1-diyl]-<i>P</i>-thiocytidylyl-(3'→5')-2'-désoxy-<i>P</i>-thioadénylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-éthane-1,1-diyl]-<i>P</i>-thiocytidylyl-(3'→5')-2'-désoxy-<i>P</i>-thioadénylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-éthane-1,1-diyl]-<i>P</i>-thiocytidylyl-(3'→5')-2'-désoxy-<i>P</i>-thioadénylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-éthane-1,1-diyl]-<i>P</i>-thiothymidylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-éthane-1,1-diyl]-<i>P</i>-thiocytidylyl-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-éthane-1,1-diyl]cytidylyl-(3'→5')-2'-désoxy-3'-adénylate de [(2<i>S</i>,4<i>R</i>)-1-{1-[(2-acétamido-2-désoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acétamido-2-désoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy)méthyl)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin-2-yl)méthyle
temavirsén	hidrógeno-<i>todo-P-ambo</i>-2'-O-(2-metoxietil)-<i>P</i>-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-<i>P</i>-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-<i>P</i>-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-<i>P</i>-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-<i>P</i>-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-<i>P</i>-tiouridilil-(3'→5')-<i>P</i>-tiotimidilil-(3'→5')-2'-desoxi-<i>P</i>-tioguanilil-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-etano-1,1-diil]-<i>P</i>-tiouridilil-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-etano-1,1-diil]-<i>P</i>-tiocitidilil-(3'→5')-2'-desoxi-<i>P</i>-tioadenilil-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-etano-1,1-diil]-<i>P</i>-tiocitidilil-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-etano-1,1-diil]-<i>P</i>-tiocitidilil-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-etano-1,1-diil]-<i>P</i>-tiotimidilil-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-etano-1,1-diil]-<i>P</i>-tiocitidilil-(3'→5')-2'-O,4'-C-[(1<i>S</i>)-etano-1,1-diil]citidilil-(3'→5')-2'-desoxi-3'-adenilato de [(2<i>S</i>,4<i>R</i>)-1-{1-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]-16,16-bis({3-[(3-{5-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]pentanamido}propil)amino]-3-oxopropoxi)metil)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oil}-4-hidroxiipirrolidin-2-il]metilo



tibilizumabum # tibilizumab

immunoglobulin G4-kappa anti-[*Homo sapiens* TNFSF13B (tumor necrosis factor (TNF) superfamily member 13B, BAFF, THANK, TALL1, TALL-1, BLYS, BLYS, B cell activating factor, B lymphocyte activator, CD257)], each heavy chain being fused to a scFv anti-[*Homo sapiens* IL17A (interleukin 17A, IL-17A)], humanized monoclonal antibody, bispecific tetravalent; gamma4 heavy chain anti-TNFSF13B fused to a scFv anti-IL17A (1-714) [gamma4 heavy chain {(*Homo sapiens* VH (IGHV4-34*01 (100.00%) - (IGHD) -IGHJ4*01) [8.7.17] (1-123) -*Homo sapiens* IGHG4*01 (CH1 (124-221), hinge S10>P (231) (222-233), CH2 (234-343), CH3L125>del (344-447), CHS G1>del, K2>del) (124-447))} (1-447) -16-mer linker (448-463) -scFv {(humanized VH (*Homo sapiens* IGHV1-69*01 (83.70%) - (IGHD) -IGHJ4*01) [8.8.12] (464-582) -20-mer tetra(tetraglycyl-seryl) linker (583-602) -humanized V-KAPPA (*Homo sapiens* IGKV2D-29*02 (89.00%) -IGKJ2*02) [11.3.9] (603-714))} (464-714)], (137-214')-disulfide with kappa light chain anti-TNFSF13B (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*05, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229":232-232")-bisdissulfide

tibilizumab

immunoglobuline G4-kappa anti-[*Homo sapiens* TNFSF13B (membre 13B de la superfamille des facteurs de nécrose tumorale (TNF), BAFF, THANK, TALL1, TALL-1, BLYS, BLYS, facteur d'activation des lymphocytes B, activateur des lymphocytes B, CD257)], chaque chaîne lourde étant fusionnée à un scFv anti-[*Homo sapiens* IL17A (interleukine 17A, IL-17A)], anticorps monoclonal humanisé, bispécifique tétravalent;

chaîne lourde gamma4 anti-TNFSF13B fusionnée à un scFv anti-IL17A (1-714) [chaîne lourde gamma4 {(Homo sapiens VH (IGHV4-34*01 (100.00%) (IGHD) -IGHJ4*01) [8.7.17] (1-123) -Homo sapiens IGHG4*01 (CH1 (124-221), charnière S10>P (231) (222-233), CH2 (234-343), CH3 L125>del (344-447), CHS G1>del, K2>del) (124-447)} (1-447) -16-mer linker (448-463) -scFv {(VH humanisé (Homo sapiens IGHV1-69*01 (83.70%) (IGHD) -IGHJ4*01) [8.8.12] (464-582) -20-mer tétra(tétraglycyl-séryl) linker (583-602) -V-KAPPA humanisé (Homo sapiens IGKV2D-29*02 (89.00%) -IGKJ2*02) [11.3.9] (603-714)} (464-714)], (137-214')-disulfure avec la chaîne légère anti-TNFSF13B (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*05, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (229-229'':232-232'')-bisdisulfure

tibulizumab

inmunoglobulina G4-kappa anti-[Homo sapiens TNFSF13B (miembro 13B de la superfamilia de los factores de necrosis tumoral (TNF), BAFF, THANK, TALL1, TALL-1, BLYS, BLyS, factor de activación de linfocitos B, activador de linfocitos B, CD257)], cada cadena pesada estando fusionada con un scFv anti-[Homo sapiens IL17A (interleukina 17A, IL-17A)], anticuerpo monoclonal humanizado, biespecífico tetravalente; cadena pesada gamma4 anti-TNFSF13B fusionada con un scFv anti-IL17A (1-714) [cadena pesada gamma4 {(Homo sapiens VH (IGHV4-34*01 (100.00%) (IGHD) -IGHJ4*01) [8.7.17] (1-123) -Homo sapiens IGHG4*01 (CH1 (124-221), bisagra S10>P (231) (222-233), CH2 (234-343), CH3 L125>del (344-447), CHS G1>del, K2>del) (124-447)} (1-447) -16-mer de conexión (448-463) -scFv {(VH humanizado (Homo sapiens IGHV1-69*01 (83.70%) (IGHD) -IGHJ4*01) [8.8.12] (464-582) -20-mer tetra(tetraglicil-seril) linker (583-602) -V-KAPPA humanizado (Homo sapiens IGKV2D-29*02 (89.00%) -IGKJ2*02) [11.3.9] (603-714)} (464-714)], (137-214')-disulfuro con la cadena ligera anti-TNFSF13B (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*05, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (229-229'':232-232'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```

OVQLQGWGAG LLKPSETLSL TCAVYGGSF S GYVSWIRQP PGKGLEWIGE 50
INHSGSTNYN PSLKSRVTIS VDTSKNQFSL KLSVTAADT AVYYCARGYY 100
DILTGYYF DYWGQGLT VSSASTKGPS VFPLAPCSRS TSESTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFFAVL QSSGLYSLS VVTVPSSSLG 200
TKTYTCNVDP KPSNTKVDKR VESKYGFPCP PCPAEFLGG PSVFLFFPKP 250
KDTLMISRTPT EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN 300
STYRVSVLT VLHQDWLNGK EYCKCKVSKG LPSSIEKTI KAKGQPREPQ 350
VYTLPPSQEE MTRKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTTPV 400
LDSGGSEFLY SRLTVKRSRW QEGNVFSCSV MHEALNHYT QKSLSLSPGG 450
GGSGGGGTGG GGSQVQLVDS GAIVKRPFGS VVYCKRAGY KFTDYHIHWV 500
RQAPQCLEW MGVIINPTGT TDYKQKFRG VTIADSTST TAMELSSLR 550
SEDTAVYICA RYDYETGETV YWGGTGLTVV SSGGGSGSG GSGGGSGGG 600
GSDIVMTQTP LSLSVTPGQP ASISCRSSRS LVHSRGETYL HWVLQPKQGS 650
PQLLYKVN RFIQVDPDRFS GSGSGDTFTL KISRVEADV GVYYCSQSTH 700
LPFTFGCGTK LEIK 714

```

Light chain / Chaîne légère / Cadena ligera

```

EIVLTQSPAT LSLSPGERAT LSCRASQSVS RYLAWYQQKP GPAPRLLIYD 50
ASNRATGIPA RFGSGSGSDT SLTISSLEP EDFAVYYCQ RSNWPRTFGQ 100
GTKVEIKRTV AAPSVFIIPP SDEQLKSGTA SVVCLLNFFY BREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSLNTL LSKADYEKHK VYACEVTHG 200
LSSPVTKSFN RGE 214

```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104, except for *) 22-95 150-206 264-324 370-428
 485-559 507-707 * 625-695
 22'-95" 150"-206" 264"-324" 370"-428"
 485"-559" 507"-707" * 625"-695"

Intra-L (C23-C104) 23'-88" 134'-194'
 23"-88" 134"-194"

Inter-H-L (CH1 10-CL 126) 137'-214' 137"-214"

Inter-H-H (h 8, h 11) 229-229" 232-232"

*Disulfide bridge between the scFv VHC49 (507, 507") and V-KAPPA C120(707, 707")

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

HCH2 N84.4:

300, 300"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

tigilanoli tiglas

tigilanol tiglate


(1*aR*,1*bR*,1*cS*,2*aR*,3*S*,3*aS*,6*aS*,6*bR*,7*R*,8*R*,8*aS*)-3,3*a*,6*b*-trihydroxy-2*a*-(hydroxymethyl)-1,1,5,7-tetramethyl-4-oxo-1,1*a*,1*b*,1*c*,2*a*,3,3*a*,4,6*a*,6*b*,7,8-dodecahydro-8*aH*-cyclopropa[5',6']benzo[1',2':-7,8]azuleno[5,6-*b*]oxirene-8,8*a*-diyl 8*a*-[(2*S*)-2-methylbutanoate] 8-[(2*E*)-2-methylbut-2-enoate]

tiglate de tigilanol

8*a*-[(2*S*)-2-méthylbutanoate] et 8-[(2*E*)-2-méthylbut-2-énoate] de
(1*aR*,1*bR*,1*cS*,2*aR*,3*S*,3*aS*,6*aS*,6*bR*,7*R*,8*R*,8*aS*)-3,3*a*,6*b*-trihydroxy-2*a*-(hydroxyméthyl)-1,1,5,7-tétraméthyl-4-oxo-1,1*a*,1*b*,1*c*,2*a*,3,3*a*,4,6*a*,6*b*,7,8-dodécahydro-8*aH*-cyclopropa[5',6']benzo[1',2':7,8]azuléno[5,6-*b*]oxirène-8,8*a*-diyle

toglato de tigilanol

8*a*-[(2*S*)-2-metilbutanoato] y 8-[(2*E*)-2-metilbut-2-enoato] de (1*aR*,1*bR*,1*cS*,2*aR*,3*S*,3*aS*,6*aS*,6*bR*,7*R*,8*R*,8*aS*)-3,3*a*,6*b*-trihidroxi-2*a*-(hidroximetil)-1,1,5,7-tetrametil-4-oxo-1,1*a*,1*b*,1*c*,2*a*,3,3*a*,4,6*a*,6*b*,7,8-dodécahidro-8*aH*-ciclopropa[5',6']benzo[1',2':7,8]azuleno[5,6-*b*]oxireno-8,8*a*-diilo

C₃₀H₄₂O₁₀**tigolanerum**

tigolaner


2-chloro-*N*-(1-cyanocyclopropyl)-5-[2'-methyl-5'-(pentafluoroethyl)-4'-(trifluoromethyl)-2'-*H*-[1,3'-bipyrazol]-4-yl]benzamide

tigolaner

2-chloro-*N*-(1-cyanocyclopropyl)-5-[2'-méthyl-5'-(pentafluoroéthyl)-4'-(trifluorométhyl)-2'-*H*-[1,3'-bipyrázol]-4-yl]benzamide

tigolaner

2-cloro-*N*-(1-cianociclopropil)-5-[2'-metil-5'-(pentafluoroetil)-4'-(trifluorometil)-2'-*H*-[1,3'-bipirázol]-4-il]benzamida

C₂₁H₁₃ClF₈N₆O

tilsotolimodum

tilsotolimod


O,O'-(2-hydroxypropane-1,3-diyl) bis(hydrogen all-P-ambo-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-7-carba-P-thioguanilyl-(3'→5')-2'-deoxy-P-thioadenilyl-(3'→5')-2'-deoxy-P-thioadenilyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-7-carba-P-thioguanilyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-7-carba-P-thio-3'-guanylate)

tilsotolimod

bis(hydrog no-tout-P-ambo-P-thiothymidylyl-(3'→5')-2'-d soxy-P-thiocytidylyl-(3'→5')-2'-d soxy-7-carba-P-thioguanilyl-(3'→5')-2'-d soxy-P-thioad nylyl-(3'→5')-2'-d soxy-P-thioad nylyl-(3'→5')-2'-d soxy-P-thiocytidylyl-(3'→5')-2'-d soxy-7-carba-P-thioguanilyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-d soxy-P-thiocytidylyl-(3'→5')-2'-d soxy-7-carba-P-thio-3'-guanylate) de O,O'-(2-hydroxypropane-1,3-diyle)

tilsotolimod

bis(hidr geno-todo-P-ambo-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-7-carba-P-tioguanilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-7-carba-P-tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-7-carba-P-tio-3'-guanilato) de O,O'-(2-hidroxiopropano-1,3-diilo)

C₂₂₃H₂₈₄N₇₄O₁₁₅P₂₂S₂₂**timrepigenum emparvovecum #**

timrepig ne emparvovec

Non-replicating recombinant adeno-associated virus serotype 2 (rAAV2) vector encoding the cDNA of human Rab escort protein 1 (CHM, REP-1), driven by the hybrid cytomegalovirus (CMV) enhancer/chicken beta-actin promoter (CBA).

timr pig ne emparvovec

Vecteur viral ad no-associ  recombinant de s rotype 2 (rAAV2) non-r pliquant codant pour l'ADN cyclique (ADNc) de la prot ine escorte Rab 1 (CHM, REP-1) humaine sous

	le contrôle de l'hybride de l'activateur du cytomégalovirus (CMV) et du promoteur de l'actine bêta du poulet (ABP, CBA).
timrepigén emparovect	Vector no replicativo del Virus Adeno-asociado de serotipo 2 (rAAV2) que codifica el cDNA de la proteína escolta Rab 1 (CHM, REP-1) humana, impulsado por el híbrido del <i>enhancer</i> de citomegalovirus (CMV) y el promotor de la beta-actina de pollo (CBA).
tiragolumabum # tiragolumab	immunoglobulin G1-kappa, anti-[<i>Homo sapiens</i> TIGIT (T-cell immunoreceptor with Ig domain and ITIM, V-set Ig member 9, VSIG9, V-set and transmembrane member 3, VSTM3)], <i>Homo sapiens</i> monoclonal antibody; gamma1 heavy chain (1-456) [<i>Homo sapiens</i> VH (IGHV6-1*01 (93.10%) -(IGHD) -IGHJ4*01) [10.9.16] (1-126) - <i>Homo sapiens</i> IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (223) (127-224), hinge (225-239), CH2 (240-349), CH3 E12 (365), M14 (367) (350-454), CHS (455-456)) (127-456)], (229-220')-disulfide with kappa light chain (1'-220') [<i>Homo sapiens</i> V-KAPPA (IGKV4-1*01 (97.00%) - IGKJ3*01) [12.3.9] (1'-113') - <i>Homo sapiens</i> IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dimer (235-235":238-238")-bisdisulfide
tiragolumab	immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> TIGIT (immunorécepteur des lymphocytes T avec domaine Ig et ITIM, membre 9 de l'Ig V-set, VSIG9, membre 3 de l'Ig V-set et région transmembrane, VSTM3)], <i>Homo sapiens</i> anticorps monoclonal; chaîne lourde gamma1 (1-456) [<i>Homo sapiens</i> VH (IGHV6-1*01 (93.10%) -(IGHD) -IGHJ4*01) [10.9.16] (1-126) - <i>Homo sapiens</i> IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (223) (127-224), charnière (225-239), CH2 (240-349), CH3 E12 (365), M14 (367) (350-454), CHS (455-456)) (127-456)], (229-220')-disulfure avec la chaîne légère (1'-220') [<i>Homo sapiens</i> V-KAPPA (IGKV4-1*01 (97.00%) -IGKJ3*01) [12.3.9] (1'-113') - <i>Homo sapiens</i> IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dimère (235-235":238-238")-bisdisulfure
tiragolumab	immunoglobulina G1-kappa, anti-[<i>Homo sapiens</i> TIGIT (inmunoreceptor de linfocitos T con dominio Ig e ITIM, miembro 9 de la Ig V-set, VSIG9, miembro 3 de la Ig V-set y región transmembrana, VSTM3)], <i>Homo sapiens</i> anticuerpo monoclonal; cadena pesada gamma1 (1-456) [<i>Homo sapiens</i> VH (IGHV6-1*01 (93.10%) -(IGHD) -IGHJ4*01) [10.9.16] (1-126) - <i>Homo sapiens</i> IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (223) (127-224), bisagra (225-239), CH2 (240-349), CH3 E12 (365), M14 (367) (350-454), CHS (455-456)) (127-456)], (229-220')-disulfuro con la cadena ligera (1'-220') [<i>Homo sapiens</i> V-KAPPA (IGKV4-1*01 (97.00%) -IGKJ3*01) [12.3.9] (1'-113') - <i>Homo sapiens</i> IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dímero (235-235":238-238")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLQQSGPG LVKPSQTLSTL TCAISGDSVS SNSAANNWIR QSPSRGLEWL 50
 GKTYYRFKMY SDYAVSVKGR ITINPDTSKN QFSLQLNSVT PEDTAVFYCT 100
 RESTTYDLA GPFDYWGQGT LVTSSASTK GPSVFPLAPS SKSTSGGTAA 150
 LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS 200
 SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KHTTCPPCPA PELLGGPSVF 250
 LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP 300
 REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNNKALPAP IEKTISKAKG 350
 QPREPQVYTL PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNQGPENNY 400
 KTTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMEHA LHNHYTQKSL 450
 SLSPGK 456

Light chain / Chaîne légère / Cadena ligera

DIVMTQSPDS LAVSLGERAT INCKSSQTVL YSSNNKKYLA WYQKPGQPP 50
 NLLIYWASTR ESGVPDRFSG SGSSTDFTLT ISSLQAEDVA VYYCQYYST 100
 PFTFGPGTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
 KVQWKVDNAL QSGNSQESVT EQDSKDSSTYS LSSTLTLSKA DYEKKHYVAC 200
 EVTHQGLSSP VTKSFNRGEC 220

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-99 153-209 270-330 376-434
 22"-99" 153"-209" 270"-330" 376"-434"

Intra-L (C23-C104) 23'-94' 140"-200"
 23'"-94'" 140'"-200'"

Inter-H-L (h 5-CL 126) 229-220" 229"-220"

Inter-H-H (h 11, h 14) 235-235" 238-238"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

306, 306"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
 complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

tirvalimogenum teraplasmidum #

tirvalimogene teraplasmid

plasmid DNA vector encoding E6 and E7 antigens of human papillomavirus types 16 and 18 (HPV 16/18), the extracellular domain of *fms*-like tyrosine kinase-3 ligand (FLT3L) and signal sequences of tissue plasminogen activator (tpa) driven by a cytomegalovirus promoter.

tirvalimogène téraplasme

vecteur constitué d'ADN plasmidique codant pour les antigènes E6 et E7 des papillomavirus humains de types 16 et 18 (VPH 16/18), le domaine extracellulaire du ligand de la tyrosine kinase 3 semblable au *fms* (FLT3L) et les séquences signal de l'activateur tissulaire du plasmogène (tpa) sous le contrôle d'un promoteur de cytomégalovirus.

tirvalimogén teraplásmido

Vector de DNA plasmídico que codifica los antígenos E6 y E7 de los tipos 16 y 18 del virus del papiloma humano (VPH 16/18), el dominio extracelular del ligando de la tirosina quinasa-3 similar a *fms* (FLT3L) y secuencias señal del activador de plasminógeno tisular (tpa) impulsado por un promotor de citomegalovirus.

tisagenlecleucelum #

tisagenlecleucel

human culture expanded genetically modified autologous T cells for cell-based gene therapy. Cells are derived from isolated blood of the patient and are transduced with non-replicative lentiviral vector encoding an FMC63 anti-CD19 single chain variable fragment (scFv) 4-1BB/CD3zeta chimeric antigen receptor (CAR) under the control of the EF-1 alpha promoter. Cells exhibit anti-tumoral activity in patients with CD19-expressing B cell malignancies.

tisagenlecleucel	Lymphocytes T autologues humains en culture d'expansion, modifiés génétiquement en vue d'une thérapie génique avec cellules. Les cellules sont isolées à partir du sang prélevé chez le patient et sont transduites avec un vecteur lentiviral non-répliquant codant pour le récepteur de l'antigène chimérique (CAR) FMC63 anti-CD-19 fragment de la chaîne simple de la région variable de l'anticorps (scFv) 4-1BB/CD3zêta (SFG-1928z CAR) sous le contrôle du promoteur EF-1 alpha. Les cellules montrent une activité anti-tumorale chez les patients présentant des lymphocytes B malins exprimant le CD19.
tisagenlecleucel	Linfocitos T autólogos, humanos, expandidos en cultivo y modificados genéticamente, para terapia génica con células. Las células se derivan a partir de sangre aislada del paciente y están transducidas con un vector lentiviral no replicativo que codifica para el receptor de antígenos quimérico (CAR) FMC63 anti-CD19 fragmento de cadena simple de la región variable del anticuerpo (scFv) 4-1BB/CD3zeta bajo el control del promotor EF-1 alfa. Las células muestran actividad anti-tumoral en pacientes con malignidades de linfocitos B que expresan CD19.
tislelizumabum # tislelizumab	immunoglobulin G4-kappa, anti-[<i>Homo sapiens</i> PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], humanized monoclonal antibody; gamma4 heavy chain (1-445) [humanized VH (<i>Homo sapiens</i> IGHV4-59*01 (88.70%) -(IGHD) -IGHJ3*01 M123>T (113)) [8.7.12] (1-118) - <i>Homo sapiens</i> IGHG4*01 (CH1 (119-216), hinge S10>P (226) (217-228), CH2 E1.4>P (231), F1.3>V (232), L1.2>A (233), D27>A (263) (229-338), CH3 R88>K (407) (339-443), CHS (444-445)) (119-445)], (132-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (<i>Homo sapiens</i> IGKV4-1*01 (81.20%) -IGKJ2*01) [6.3.9] (1'-107') - <i>Homo sapiens</i> IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (224-224":227-227")-bisdisulfide
tislélizumab	immunoglobuline G4-kappa, anti-[<i>Homo sapiens</i> PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-445) [VH humanisé (<i>Homo sapiens</i> IGHV4-59*01 (88.70%) -(IGHD) -IGHJ3*01 M123>T (113)) [8.7.12] (1-118) - <i>Homo sapiens</i> IGHG4*01 (CH1 (119-216), charnière S10>P (226) (217-228), CH2 E1.4>P (231), F1.3>V (232), L1.2>A (233), D27>A (263) (229-338), CH3 R88>K (407) (339-443), CHS (444-445)) (119-445)], (132-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV4-1*01 (81.20%) -IGKJ2*01) [6.3.9] (1'-107') - <i>Homo sapiens</i> IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (224-224":227-227")-bisdisulfure

tislelizumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-445) [VH humanizado (*Homo sapiens* IGHV4-59*01 (88.70%) -(IGHD) -IGHJ3*01 M123>T (113)) [8.7.12] (1-118) -*Homo sapiens* IGHG4*01 (CH1 (119-216), bisagra S10>P (226) (217-228), CH2 E1.4>P (231), F1.3>V (232), L1.2>A (233), D27>A (263) (229-338), CH3 R88>K (407) (339-443), CHS (444-445)) (119-445)], (132-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV4-1*01 (81.20%) -IGKJ2*01 [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]]; dímero (224-224':227-227')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLQESGPG LVKPSSETLSL TCTVSGFSLT SYGVHWIRQP PGKGLEWIGV 50
 IYADGSTNYN PSLKSRVTIS KDTSKNQVSL KLSSTAAAD AVYYCARAYG 100
 NYWYIDVWGQ GTTVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
 FPEFVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVTVTP SSSLGTTKTYT 200
 CNVDHKPSNT KVDKRVESKY GPPCPPCPAP PVAGGPSVFL FPPKPKDTLM 250
 ISRTPEVTCV VVAVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTYRV 300
 VSVLTIVVHGD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYITLP 350
 PSQEEMTKNQ VSLTCLVKGF YPSDIAVEWE NNGQPENNYK TTPPVLDSDG 400
 SFFLYSKLTV DKSRWQEGNV FSCSVMEAL HNHYTQKSLS LSLGK 445

Light chain / Chaîne légère / Cadena ligera

DIVMTQSPDS LAVSLGERAT INCKSSESVS NDVAWYQQKQ GQPPKLLINY 50
 AFHRTGVPD RFSGSGYGT DFTLTISLQA EDVAVYYCHQ AYSSPYTFGQ 100
 GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNFEY PREAKVQWKV 150
 DNALQSGNSQ ESVTEQDSKD STYSLSSLT LSKADYERHK VYACEVTHQG 200
 LSSPVTKSFN RGEK 214

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-95 145-201 259-319 365-423
 22"-95" 145"-201" 259"-319" 365"-423"

Intra-L (C23-C104) 23'-88" 134'-194"
 23'''-88''' 134'''-194'''

Inter-H-L (CH1 10-CL 126) 132-214' 132"-214"

Inter-H-H (h 8, h 11) 224-224" 227-227"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

295, 295"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados.

tralesinidasum alfa #
tralesinidase alfa

human α -N-acetylglucosaminidase fused to truncated human insulin-like growth factor II (IGF2) via a peptide linker, produced in Chinese hamster ovary (CHO) cells, glycoform alfa;

human α -N-acetylglucosaminidase (NAG, EC=3.2.1.50) (1-720) fusion protein with glycyl-L-alanyl-L-prolyl triglycyl-L-seryl-bis(L-prolyl-L-alanyl-L-prolyl-L-alanyl-L-prolyl-L-threonyl)-bis(L-prolyl-L-alanyl)-triglycyl-L-prolyl-L-seryl-glycyl-L-alanyl-L-prolyl-[37-L-alanine(R³⁷>A₍₇₈₁₎)]human insulin-like growth factor II (somatomedin-A, T3M-11-derived growth factor, IGF-II) (8-67)-peptide (752-811), produced in Chinese hamster ovary (CHO) cells, glycoform alfa

tralésinidase alfa

alpha-*N*-acétylglucosaminidase humaine fusionnée au facteur II de croissance humain analogue à l'insuline (IGF2) tronqué, via un peptide de liaison, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa;

alpha-*N*-acétylglucosaminidase humaine (NAG, EC=3.2.1.50) (1-720) protéine de fusion avec glycyL-L-alanyl-L-prolyl(triglycyl-L-séryl-bis(L-prolyl-L-alanyl-L-prolyl-L-alanyl-L-prolyl-L-thréonyl)-bis(L-prolyl-L-alanyl)-triglycyl-L-prolyl-L-sérylglycyl-L-alanyl-L-prolyl-[37-L-alanine(R³⁷>A₍₇₈₁₎)]facteur II de croissance analogue à l'insuline humain (somatomédine-A, T3M-11-facteur de croissance dérivé, IGF-II) (8-67)-peptide (752-811), produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

tralesinidasa alfa

alfa-*N*-acetilglucosaminidasa humana fusionada con el factor II de crecimiento humano análogo a la insulina (IGF2) truncada, vía un péptido de unión, producida en las células ováricas de hamster chino (CHO), glicoforma alfa;

alfa-*N*-acetilglucosaminidasa humana (NAG, EC=3.2.1.50) (1-720) proteína de fusión con glicil-L-alanil-L-prolil(triglicil-L-seril-bis(L-prolil-L-alanil-L-prolil-L-alanil-L-prolil-L-treonil-bis(L-prolil-L-alanil)-triglicil-L-prolil-L-serilglicil-L-alanil-L-prolil-[37-L-alanina(R³⁷>A₍₇₈₁₎)]factor II de crecimiento análogo a la insulina humano (somatomedina-A, T3M-11-factor de crecimiento derivado, IGF-II) (8-67)-péptido (752-811), producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Sequence / Séquence / Secuencia

```
DEAREAAAVR ALVARLLGPG PAADFSVSVE RALAAKPGLD TYSLGGGGAA 50
RVRVRGSGTV AAAAGLHRYL RDFCGCHVAV SGSQRLRPRP LPAVPGELTE 100
ATPNRYRYQQ NVCTQSYSEFV WWDWARWERE IDWMALNGIN LALAWSGQEA 150
IWQRVYLALG LTQAEINEFF TGPAFLAWGR MGNLHTWDGP LPPSWHIKQL 200
YLQHRVLDQM RSFGMTPLVP AFAGHVPEAV TRVFPQNVNT KMGSWGHNFC 250
SYSCSFLLAP EDPIFFPIGS LFLRELIKEF GTDHIYGADT FNEMQPPSSE 300
PSYLAATAA VYEAMTAVDT EAVWLLQGWL FQHQPQFWGP AQIRAVLGAV 350
PRGRLLVLDL FAESQPVYTR TASFGQGPFI WCMLHNFEGN HGLFGALEAV 400
NGGPEAARLF PNSTMVGTGM APEGISQNEV VYSLMAELGW RKDPVPDLAA 450
WVTSFAARRY GVSHPDAGAA WRLLRSVYN CSGEACRGNH RSPLVRRPSL 500
QMNTSIWYNR SDVFEAWRL LTSAPLSATS PAFRYDLDDL TRQAVQELVS 550
LYYEEARSAY LSKELASLLR AGGVLYELL PALDEVASD SRFLGSWLE 600
QARAAAVSEA EADFYEQNSR YQTLWGPPEG NILDYANKQL AGLVANYTTP 650
RWRLFLEALV DSAVQGIFFQ QHQFDKNVFO LEQAFVLSKQ RYPSQPRGDT 700
VDLAKKIFLK YIPRWVAGSW GAPGGGSPAP APTAPAPTP APAGGGPSGA 750
PLCGGELVDT LQFVCGDRGF YFSRPASRVS ARSRGIVEEC CFRSCDLALL 800
ETYCATAKKS E 811
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
74-76 250-254 481-486 753-791 765-804 790-795

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-238 Asn-249 Asn-412 Asn-480 Asn-490 Asn-503 Asn-509

Glycosylation sites (O) / Sites de glycosylation (O) / Posiciones de glicosilación (O)
Ser-727 Thr-733 Thr-739 Ser-748

trilaciclibum
trilaciclib


2'-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]-7',8'-dihydro-6'*H*-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-*d*]pyrimidin]-6'-one

trilaciclib

2'-[5-(4-méthylpipérazin-1-yl)pyridin-2-yl]amino]-7',8'-dihydro-6'*H*-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-*d*]pyrimidin]-6'-one

trilaciclib

2'-[5-(4-méthylpipérazin-1-il)pyridin-2-il]amino]-7',8'-dihydro-6'*H*-spiro[cyclohexano-1,9'-pirazino[1',2':1,5]pirrolo[2,3-*d*]pirimidin]-6'-ona

C₂₄H₃₀N₈O**vactosertibum**

vactosertib


2-fluoro-*N*-{[4-(6-méthylpyridin-2-yl)-5-([1,2,4]triazolo[1,5-*a*]pyridin-6-yl)-1*H*-imidazol-2-yl]méthyl}aniline

vactosertib

2-fluoro-*N*-{[4-(6-méthylpyridin-2-yl)-5-([1,2,4]triazolo[1,5-*a*]pyridin-6-yl)-1*H*-imidazol-2-yl]méthyl}aniline

vactosertib

2-fluoro-*N*-{[4-(6-méthylpyridin-2-il)-5-([1,2,4]triazolo[1,5-*a*]pyridin-6-il)-1*H*-imidazol-2-il]méthyl}anilina

C₂₂H₁₈FN₇**vadacabtagenum leraleucelum #**



vadacabtagene leraleucel



human culture expanded genetically modified autologous T cells for cell-based gene therapy. Cells are derived from isolated blood of the patient and are transduced with non-replicative retroviral vector encoding the SJ25C1 anti-CD19 single chain variable fragment (scFv) CD28/CD3zeta chimeric antigen receptor (SFG-1928z CAR). Cells exhibit anti-tumoral activity in patients with CD19-expressing B cell malignancies.

vadacabtagène léraleucel

Lymphocytes T humains autologues en culture d'expansion et modifiés génétiquement pour thérapie génique avec cellules. Les cellules sont dérivées du sang prélevé chez le patient et sont transduites avec un vecteur rétroviral non-répliquant codant pour le récepteur de

	l'antigène chimérique SJ25C1 anti-CD-19 fragment de la chaîne simple de la région variable de l'anticorps (scFv) CD28/CD3zêta (SFG-1928z CAR). Les cellules montrent une activité anti-tumorale chez les patients présentant des lymphocytes B malins exprimant le CD19.
vadacabtagén leraleucel	Linfocitos T autólogos, humanos, expandidos en cultivo y modificados genéticamente, para terapia génica con células. Las células se derivan a partir de sangre aislada del paciente y están transducidas con un vector retroviral no replicativo que codifica para el receptor de antígenos quimérico SJ25C1 anti-CD19 fragmento de cadena simple de la región variable del anticuerpo (scFv) CD28/CD3zeta (SFG-1928z CAR). Las células muestran actividad anti-tumoral en pacientes con malignidades de linfocitos B que expresan CD19.
valzifloceptum # valziflocept	human immunoglobulin gamma Fc region receptor II-b (FcγRII-b), extracellular N-terminal fragment, produced in <i>Escherichia coli</i> ; human low affinity immunoglobulin gamma Fc region receptor II-b (IgG Fc receptor II-b, CDw32, Fc-gamma RII-b, FcRII-b, antigen CD32)-(4-179) peptide (N-terminal extracellular portion), produced in <i>Escherichia coli</i>
valziflocept	récepteur II-b de la région Fc de l'immunoglobuline gamma humaine (FcγRII-b), fragment extracellulaire N-terminal, produit par <i>Escherichia coli</i> ; récepteur II-b de faible affinité pour la région Fc de l'immunoglobuline gamma humaine (IgG Fc récepteur II-b, CDw32, Fc-gamma RII-b, FcRII-b, antigène CD32)-(4-179) peptide (partie extracellulaire)
valziflocept	receptor II-b de la región Fc de la inmunoglobulina gamma humana (FcγRII-b), fragmento extracelular N-terminal, producido por <i>Escherichia coli</i> ; receptor II-b de baja afinidad para la región Fc de la inmunoglobulina gamma humana (IgG Fc receptor II-b, CDw32, Fc-gamma RII-b, FcRII-b, antígeno CD32)-(4-179) péptido (parte extracelular N-terminal), producido por <i>Escherichia coli</i>
Sequence / Séquence / Secuencia APPKAVLKLE PQWINVLQED SVILTCRGTH SPESDSIQWF HNGNLIPHT 50 QPSYRFKANN NDSGEYTCQT GQTSLSDPVH LTVLSEWLVL QTPHLEFQEG 100 ETIVLRCHSW KDKPLVKVTF FQNGKSKKFS RSDPNFSIPQ ANHSHSGDYH 150 CTGNIGYTLY SSKPVTITVQ APSSP 176	
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 26-68 107-151	
vatinoxanum vatinoxan	<i>N</i> -{2-[(2 <i>R</i> ,12 <i>bS</i>)-2'-oxo-1,3,4,6,7,12 <i>b</i> -hexahydrospiro[[1]benzofuro[2,3- <i>a</i>]quinolizine-2,4'-imidazolidin]-3'-yl]ethyl}methanesulfonamide

vatinoxan	<i>N</i> -{2-[(2 <i>R</i> ,12 <i>bS</i>)-2'-oxo-1,3,4,6,7,12 <i>b</i> -hexahydrospiro[[1]benzofuro[2,3- <i>a</i>]quinolizine-2,4'-imidazolidin]-3'-yl]ethyl)méthanesulfonamide
vatinoxán	<i>N</i> -{2-[(2 <i>R</i> ,12 <i>bS</i>)-2'-oxo-1,3,4,6,7,12 <i>b</i> -hexahidrospiro[[1]benzofuro[2,3- <i>a</i>]quinolizina-2,4'-imidazolidin]-3'-il]etil}metanosulfonamida
	$C_{20}H_{26}N_4O_4S$
	
vecabrutinibum	
vecabrutinib	(3 <i>R</i> ,3' <i>R</i> ,4' <i>S</i>)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-[3-chloro-5-(trifluoromethyl)anilino]-2-oxo[1,3'-bipiperidine]-4'-carboxamide
vécabrutinib	(3 <i>R</i> ,3' <i>R</i> ,4' <i>S</i>)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-[[3-chloro-5-(trifluorométhyl)phényl]amino]-2-oxo-[1,3'-bipéridine]-4'-carboxamide
vecabrutinib	(3 <i>R</i> ,3' <i>R</i> ,4' <i>S</i>)-1'-(6-amino-5-fluoropirimidin-4-il)-3-[[3-cloro-5-(trifluorometil)fenil]amino]-2-oxo-[1,3'-bipiperidina]-4'-carboxamida
	$C_{22}H_{24}ClF_3N_7O_2$
	
veldoreotidum	
veldoreotide	<i>N</i> ^{4.1} , <i>C</i> ^{α.8} -anhydro[<i>N</i> -(2-amino-2-oxoethyl)-4-aminobutanoyl-4-aminobutanoyl-L-phenylalanyl-L-tryptophyl-D-tryptophyl-L-lysyl-L-threonyl-L-phenylalanine]
veldoréotide	<i>N</i> ^{4.1} , <i>C</i> ^{α.8} -anhydro[<i>N</i> -(2-amino-2-oxoéthyl)-4-aminobutanoyl-4-aminobutanoyl-L-phénylalanyl-L-tryptophyl-D-tryptophyl-L-lysyl-L-thréonyl-L-phénylalanine]
veldoreotida	<i>N</i> ^{4.1} , <i>C</i> ^{α.8} -anhidro[<i>N</i> -(2-amino-2-oxoetil)-4-aminobutanoil-4-aminobutanoil-L-fenilalanil-L-triptofil-D-triptofil-L-lisil-L-treonil-L-fenilalanina]

**vorasidenibum**



vorasidenib

6-(6-chloropyridin-2-yl)-*N*²,*N*⁴-bis[(2*R*)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine

vorasidénib

6-(6-chloropyridin-2-yl)-*N*²,*N*⁴-bis[(2*R*)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine

vorasidenib

6-(6-cloropiridin-2-il)-*N*²,*N*⁴-bis[(2*R*)-1,1,1-trifluoropropan-2-il]-1,3,5-triazina-2,4-diamina**zanubrutinibum**



zanubrutinib

(7*S*)-2-(4-phenoxyphenyl)-7-[1-(prop-2-enoyl)piperidin-4-yl]-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyrimidine-3-carboxamide

zanubrutinib

(7*S*)-2-(4-phénoxyphényl)-7-[1-(prop-2-enoyl)pipéridin-4-yl]-4,5,6,7-tétrahidropirazolo[1,5-*a*]pyrimidine-3-carboxamide

zanubrutinib

(7*S*)-2-(4-fenoxifenil)-7-[1-(prop-2-enoyl)piperidin-4-il]-4,5,6,7-tetrahidropirazolo[1,5-*a*]pirimidina-3-carboxamida**zenocutuzumabum #**

zenocutuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* ERBB3 (receptor tyrosine-protein kinase erbB-3, HER3) and *Homo sapiens* ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody, bispecific;

	gamma1 heavy chain anti-ERBB3 (1-453) [<i>Homo sapiens</i> VH (IGHV1-2*02 (100.00%) -(IGHD) -IGHJ4*01) [8.8.17] (1-124) -<i>Homo sapiens</i> IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), hinge (223-237), CH2 (238-347), CH3 L7>K (358), E12 (363), M14 (365), T22>K (373) (348-452), CHS K>del (453)) (125-453)], (227-214')-disulfide with kappa light chain (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -<i>Homo sapiens</i> IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; gamma1 heavy chain anti-ERBB2 (1-450) [humanized VH (<i>Homo sapiens</i> IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.14] (1-121) -<i>Homo sapiens</i> IGHG1*03, G1m3, nG1m1 (CH1 R120 (218) (122-219), hinge (220-234), CH2 (235-344), CH3 L7>D (355), E12 (360), M14 (362), L24>E (372) (345-449), CHS K>del (450)) (122-450)] (224-214')-disulfide with kappa light chain (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -<i>Homo sapiens</i> IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (233-230":236-233")-bisdisulfide
zénocutuzumab	immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> ERBB3 (récepteur à activité tyrosine kinase erbB-3, HER3) et <i>Homo sapiens</i> ERBB2 (récepteur 2 du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], anticorps monoclonal humanisé, bispécifique; chaîne lourde gamma1 anti-ERBB3 (1-453) [<i>Homo sapiens</i> VH (IGHV1-2*02 (100.00%) -(IGHD) -IGHJ4*01) [8.8.17] (1-124) -<i>Homo sapiens</i> IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), charnière (223-237), CH2 (238-347), CH3 L7>K (358), E12 (363), M14 (365), T22>K (373) (348-452), CHS K>del (453)) (125-453)], (227-214')-disulfure avec la chaîne légère kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -<i>Homo sapiens</i> IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; chaîne lourde gamma1 anti-ERBB2 (1-450) [VH humanisé (<i>Homo sapiens</i> IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.14] (1-121) -<i>Homo sapiens</i> IGHG1*03, G1m3, nG1m1 (CH1 R120 (218) (122-219), charnière (220-234), CH2 (235-344), CH3 L7>D (355), E12 (360), M14 (362), L24>E (372) (345-449), CHS K>del (450)) (122-450)] (224-214')-disulfure avec la chaîne légère kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -<i>Homo sapiens</i> IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (233-230":236-233")-bisdisulfure
zenocutuzumab	inmunoglobulina G1-kappa, anti-[<i>Homo sapiens</i> ERBB3 (receptor de la actividad tirosina kinasa erbB-3, HER3) y <i>Homo sapiens</i> ERBB2 (receptor 2 del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], anticuerpo monoclonal humanizado, biespecífico; cadena pesada gamma1 anti-ERBB3 (1-453) [<i>Homo sapiens</i> VH (IGHV1-2*02 (100.00%) -(IGHD) -IGHJ4*01) [8.8.17] (1-124) -<i>Homo sapiens</i> IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), bisagra (223-237), CH2 (238-347), CH3 L7>K (358), E12 (363), M14 (365), T22>K (373) (348-452), CHS K>del (453)) (125-453)], (227-214')-disulfuro con la cadena ligera kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -<i>Homo sapiens</i> IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; cadena pesada gamma1 anti-ERBB2 (1-450) [VH humanizado (<i>Homo sapiens</i> IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.14] (1-121) -<i>Homo sapiens</i> IGHG1*03, G1m3, nG1m1 (CH1 R120 (218) (122-219), bisagra (220-234), CH2 (235-344), CH3 L7>D (355), E12 (360), M14 (362), L24>E (372) (345-449), CHS K>del (450)) (122-450)] (224-214')-disulfuro con la cadena ligera kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -<i>Homo sapiens</i> IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (233-230":236-233")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada (anti-ERBB3)

QVQLVQSGAE VKKPGASVKV SCKASGYTFT GYYMHWVRQA PGQGLEWMGW 50
 INPNSGGTNY AQKFQGRVTM TRDTSISTAY MELSLRLSDD TAVYYCARDH 100
 GSRHFWSYWG FDYWGQGLTV TVSSASTKGF SVFPLAPSSK STSGGTAALG 150
 CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVTVFSSSL 200
 GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HTCPPCPAPE LGGPSVFLF 250
 PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKFRE 300
 EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350
 REPQVYTKPP SREEMTKNQV SLKCLVKGFY PSDIAVEWES NGQPENNYKT 400
 TPPVLDSGGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTKQKSLSL 450
 SPG 453

Heavy chain / Chaîne lourde / Cadena pesada (anti-ERBB2)

QVQLVQSGAE VKKPGASVKL SCKASGYTFT AYYINWVRQA PGQGLEWIGR 50
 IYPSGYSYTSY AQKFQGRATL TADESTSTAY MELSSLRSED TAVYFCARPP 100
 VYDSSAWFAY WGQGLTVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
 KDYFPEFPTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
 TYICNVNHPK SNTKVDKRVK PKSCDKTHTC PPCPAPELLG GPSVFLFPFK 250
 PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
 NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
 QVYTDPPSRE EMTKNQVSLT CEVKGIFYPSD IAVEWESNGQ PENNYKTTTP 400
 VLDSGGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNNHY TQKSLSLSPG 450

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS LSASVGDRVT ITCRASQGIS SYLNWYQQKP GKAPKLLIYA 50
 ASSLSQGVPS RFGSGSGSGTD FTLTISSLQF EDFATYYCQQ SYSTPPTFGQ 100
 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLNNFY PREAKVQWKV 150
 DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYEEKH VYACEVTHQG 200
 LSSPVTKSFN RGEK 214

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 151-207 268-328 374-432
 22"-96" 148"-204" 265"-325" 371"-429"

Intra-L (C23-C104) 23'-88' 134'-194'
 23'''-88''' 134'''-194'''

Inter-H-L (h 5-CL 126) 227-214' 224"-214"

Inter-H-H (h 11, h 14) 233-230" 236-233"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

304, 301"

Defucosylated ($\geq 90\%$) complex bi-antennary CHO-type glycans / glycanes de type CHO

bi-antennaires complexes défucosylés ($\geq 90\%$) / glicanos de tipo CHO biantenaríos

complejos defucosilados ($\geq 90\%$)

zolbetuximabum #

zolbetuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CLDN18 (claudin 18, claudin-18, SFTPJ, surfactant associated protein J) isoform 2, extracellular domain 1 (EC1)], chimeric monoclonal antibody;
 gamma1 heavy chain (1-448) [*Mus musculus* VH (IGHV1-61*01 (92.90%) - (IGHD) -IGHJ2*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (215) (119-216), hinge (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfide with kappa light chain (1'-220') [*Mus musculus* V-KAPPA (IGKV8-19*01 (100.00%) -IGKJ4*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dimer (227-227":230-230")-bisdisulfide

zolbétuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CLDN18 (claudine 18, claudine-18, SFTPJ, surfactant associé à la protéine J) isoforme 2, domaine extracellulaire 1 (EC1)], anticorps monoclonal chimérique;
 chaîne lourde gamma1 (1-448) [*Mus musculus* VH (IGHV1-61*01 (92.90%) - (IGHD) -IGHJ2*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (215) (119-216), charnière (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfure avec la chaîne légère kappa (1'-220') [*Mus musculus* V-KAPPA (IGKV8-19*01 (100.00%) -IGKJ4*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dimère (227-227":230-230")-bisdisulfure

zolbetuximab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CLDN18 (claudina 18, claudina-18, SFTPJ, surfactante asociado a la proteína J) isoforma 2, dominio extracelular 1 (EC1)], anticuerpo monoclonal quimérico; cadena pesada gamma1 (1-448) [*Mus musculus* VH (IGHV1-61*01 (92.90%) -(IGHD) -IGHJ2*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (215) (119-216), bisagra (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfuro con la cadena ligera kappa (1'-220') [*Mus musculus* V-KAPPA (IGKV8-19*01 (100.00%) -IGKJ4*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dímero (227-227":230-230")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLQQPGAE	LVRPGASVKL	SCKASGYTFT	SYWINWVKQR	PGQGLEWIGN	50
IYPSDSYTN	NQKFKDKATL	TVDKSSSTAY	MLSSPTSED	SAVYYCTRSW	100
RGNSTFYWGQ	GTTLTVSSAS	TKGPSVFPLA	PSSKSTSGGT	AALGCLVKDY	150
FPEPVTVSWN	SGALTSGVHT	FPAVLQSSGL	YSLSSVTVTP	SSSLGTQTYI	200
CNVNHKPSNT	KVDKRVPEPKS	CDKTHTCPPC	PAPELLGGPS	VFLFPPKPKD	250
TLMISRTPEV	TCVVVDVSHE	DPEVKFNWYV	DGVEVHNAKT	KPREEQYNST	300
YRVVSVLTVL	HQDWLNGKEY	KCKVSNKALP	APIEKTISKA	KGQPREPQVY	350
TLFPSREEMT	KNQVSLTCLV	KGFYPSTIAV	EWESNGQPEN	NYKTTFPVLD	400
SDGSFFLYSK	LTVDKSRWQQ	GNVFSCSVMH	EALHNHYTQK	SLSLSPGK	448

Light chain / Chaîne légère / Cadena ligera

DIVMTQSPSS	LTVTAGEKVT	MSCKSSQSL	NSGNQKNYLT	WYQQKPGQPP	50
KLLIYWASTR	ESGVPRDFTG	SGSGTDFTLT	ISVQAEDLA	VYYCQNDYSY	100
PFTFGSGTKL	EIKRTVAAPS	VFIFFPSDEQ	LKSGTASVVC	LLNMFYPREA	150
KVQWKVDNAL	QSGNSQESVT	EQDSKSDSTYS	LSSTLTLSKA	DYEKHKVYAC	200
EVTHQGLSSP	VTKSFNRGEC				220

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	145-201	262-322	368-426
	22"-96"	145"-201"	262"-322"	368"-426"

Intra-L (C23-C104)	23'-94'	140'-200'
	23"-94"	140"-200"

Inter-H-L (h 5-CL 126)	221-220'	221"-220"
------------------------	----------	-----------

Inter-H-H (h 11, h 14)	227-227"	230-230"
------------------------	----------	----------

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

298, 298"


Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaire complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados

Electronic structure available on Mednet: <http://mednet.who.int/># Structure électronique disponible sur Mednet: <http://mednet.who.int/># Estructura electrónica disponible en Mednet: <http://mednet.who.int/>* <http://www.who.int/medicines/services/inn/publication/en/>

**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Recommended International Nonproprietary Names (Rec. INN): List 47
Dénominations communes internationales recommandées (DCI Rec.): Liste 47
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 47
(WHO Drug Information, Vol. 16, No 1, 2002)

- p. 84 **alicaforsenum**
alicaforsen *replace the chemical name and the molecular formula by the following ones*
alicaforsen *remplacer le nom chimique et la formule moléculaire brute par les suivants*
alicaforsén *sustitúyase el nombre químico y la fórmula molecular por los siguientes*
- all-P-(R)-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxyadenosine*
- tout-P-(R)-2'-désoxy-P-thioguanylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-2'-désoxy-P-thioguanylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-désoxy-P-thioguanylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-2'-désoxy-P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-2'-désoxyadénosine*
- todo-P-(R)-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxiadenosina*



Recommended International Nonproprietary Names (Rec. INN): List 71
Dénominations communes internationales recommandées (DCI Rec.): Liste 71
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 71
(WHO Drug Information, Vol. 28, No 1, 2014)


p. 101 **patisiranum**

patisiran

patisiran

patisirán

replace the molecular formula by the following one
remplacer la formule moléculaire brute par la suivante
sustitúyase la fórmula molecular por la siguiente



Recommended International Nonproprietary Names (Rec. INN): List 75
Dénominations communes internationales recommandées (DCI Rec.): Liste 75
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 75
(WHO Drug Information, Vol. 30, No 1, 2016)


p. 105 **cenerimodum #**

cenerimod

cénérimod

cenerimod

replace the structure by the following one
remplacer la structure par la suivante
sustitúyase la estructura por la siguiente



Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.